Nitrogen-containing heterocyclic compound and use thereof

Abstract

27077616_1 (GHMatters) P124432.AU.1 Abstract The present invention relates to a nitrogen-containing heterocyclic compound and the use thereof. Specifically, provided is a compound of formula I or an optical isomer thereof, or a racemate 5 thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof. The compound has excellent and precise therapeutic effects on tumors with low expression or non-expression of the NNMT gene, high expression of DNA methylase, high expression of UHRFl, a high methylation level of nucleotide sites of the NNMT gene, and / or a high methylation level of DNA CpG site in a NNMT gene region. 10 I 15 Abstract 5 R R R RR R N R R R R RR R R R I 15 20 26 24 22 60 02 O ct 2 02 6 0 2 O c t 2 0 2 6 5 2 0 2 6 2 4 2 2 6 0 R R R R R R N R R R R R R R 1 5

Description

FIELD OF THE INVENTION The present invention relates to the field of medicine. Specifically, the present invention relates 5 to nitrogen-containing heterocyclic compound and use thereof. The entire disclosure in the complete specification of our Australian Patent Application No. 2023233624 is by this cross-reference incorporated into the present specification. BACKGROUND TECHNOLOGY 10        Tumor is a common disease that seriously endangers human health, and the mortality rate of malignant tumors is rising. Due to the heterogeneity of tumor, simply using the same treatment method or medication based on source or pathological characteristic of tumors can easily lead to improper treatment, which can delay valuable treatment time and opportunities for patient. Therefore, it is very necessary to take precision treatment according to the different features of tumor. With the 15 development of biological technology, tumors are typed at the molecular level such as gene and protein level, etc, and more and more changes in tumor-related gene and the expression and activity of protein have been discovered, changes in tumor-related gene and the expression and activity of protein play an important role in the development of malignant tumors, the discovery and application of biomarkers can provide precise guidance for the application of related drug and make precision 20 treatment of tumor possible, thereby achieving targeted administration of drug, significantly improving treatment effect, reducing the dose of drug and reducing toxic side effects. Therefore, there is an urgent need in the art to develop a drug that can achieve precision treatment on tumor. 25     SUMMARY OF THE INVENTION It is an object of the present invention to provide a compound, the compound has excellent precision treatment effect on tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene. 30 In the first aspect of the present invention, it provides a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof; 35                                                       I wherein, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted -1- 2026242260   02 Oct 2026 C1-C16 alkyl, substituted or unsubstituted C3-C16 cycloalkyl, substituted or unsubstituted 3-12 membered heterocycloalkyl, substituted or unsubstituted C1-C16 haloalkyl, substituted or unsubstituted C3-C16 halocycloalkyl, substituted or unsubstituted C6-C16 aryl, substituted or unsubstituted 5-12 membered heteroaryl; 5       R3, R4 and R5 are each independently hydrogen, halogen, R17-O-, R17-S-, (R18R19) N-; or R3 and R4, or R4 and R5 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkane ring; R6, R8, R11, R12, R13, R14 and R15 are each independently hydrogen, substituted or unsubstituted C1-C8 alkyl, halogen; 10       R7 is hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C1-C12 haloalkyl, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted 5-16 membered heteroaryl-substituted or unsubstituted C1-C12 alkyl-; R9 and R10 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkane ring; I D 15       R17 is hydrogen, substituted or unsubstituted C1-C16 alkyl, D , substituted or unsubstituted C3-C16 cycloalkyl, substituted or unsubstituted 3-12 membered heterocycloalkyl, substituted or unsubstituted C3-C16 cycloalkyl-substituted or unsubstituted C2-C10 acyl-, substituted or unsubstituted C3-C16 cycloalkyl-C(O)-, substituted or unsubstituted C1-C16 haloalkyl, substituted or unsubstituted C3-C16 halocycloalkyl, substituted or unsubstituted 3-12 membered 20 heterocycloalkyl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted 5-16 membered heteroaryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted C6-C16 aryl-O-substituted or  unsubstituted C1-C12 alkyl-, substituted  or 25 unsubstituted C6-C16 aryl-S-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted 5-16 membered heteroaryl-O-substituted or  unsubstituted C1-C12 alkyl-, substituted  or unsubstituted 5-16 membered heteroaryl-S-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted C2-C8 alkenyl-substituted  or unsubstituted C1-C8 alkyl-substituted  or unsubstituted C2-C8 alkenyl-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted 30 C2-C8 alkenyl-substituted or unsubstituted C1-C8 alkyl-, (R20R21) N-substituted or unsubstituted C1-C12 alkyl-; R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 35   3-12 membered heterocycloalkane ring; R20 and R21 are each independently hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C2-C10 ester group; or R20 and R21 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkyl. In another preferred embodiment, the heterocyclic ring of the heterocycloalkyl, heteroaryl and 40 heterocycloalkane ring has 1-4 (preferably 1, 2, 3 or 4) heteroatoms independently selected from the group consisting of N, O and S. In another preferred embodiment, the heterocyclic ring of the heterocycloalkyl has 1-4 (preferably 1, 2, 3 or 4) heteroatoms independently selected from the group consisting of N, O and S. 45       In another preferred embodiment, the heterocyclic ring of the heteroaryl has 1-4 (preferably 1, 2, 3 or 4) heteroatoms independently selected from the group consisting of N, O and S. In another preferred embodiment, the heterocyclic ring of the heterocycloalkane ring has 1-4 (preferably 1, 2, 3 or 4) heteroatoms independently selected from the group consisting of N, O and S. -2- 2026242260   02 Oct 2026 In another preferred embodiment, the heterocycloalkyl has 0, 1, or 2 C=C ring double bonds. In another preferred embodiment, the heterocycloalkane ring has 0, 1, or 2 C=C ring double bonds. In another preferred embodiment, each "substituted" means that one or more (preferably 1, 2, 5   3, 4, 5, 6, 7, or 8) hydrogen atoms on the ring or group are independently substituted by substituent selected from the group consisting of C1-C10 alkyl, C2-C6 alkenyl, C3-C12 cycloalkyl, C1-C10 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, carbonyl (=O), hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C8 ester group, C2-C4 amide group, C2-C6 acyl, C1-C10 10 alkoxyl, C1-C10 alkylthio, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl, (R20R21) N-. In another preferred embodiment, each "substituted" means that one or more (preferably 1, 2, 3, 4, 5, 6, 7, or 8) hydrogen atoms on the ring or group are independently substituted by substituent 15 selected from the group consisting of C1-C8 alkyl, C2-C6 alkenyl, C3-C12 cycloalkyl, C1-C8 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, carbonyl (=O), hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C8 ester group, C2-C4 amide group, C2-C4 acyl, C1-C8 alkoxyl, C1-C8 alkylthio, C1-C8 haloalkoxyl, C1-C8 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 20   5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl, (R20R21) N-. In another preferred embodiment, each "substituted" means that one or more (preferably 1, 2, 3, 4, 5, 6, 7, or 8) hydrogen atoms on the ring or group are independently substituted by substituent selected from the group consisting of C1-C6 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C1-C6 25 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, carbonyl (=O), hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C6 ester group, C2-C4 amide group, C2-C4 acyl, C1-C6 alkoxyl, C1-C6 alkylthio, C1-C6 haloalkoxyl, C1-C6 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl, (R20R21) 30   N-. In another preferred embodiment, each "substituted" means that one or more (preferably 1, 2, 3, 4, 5, 6, 7, or 8) hydrogen atoms on the ring or group are independently substituted by substituent selected from the group consisting of C1-C4 alkyl, C2-C4 alkenyl, C3-C10 cycloalkyl, C1-C4 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 35 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, carbonyl (=O), hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C2-C4 acyl, C1-C4 alkoxyl, C1-C4 alkylthio, C1-C4 haloalkoxyl, C1-C4 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl, (R20R21) N-. 40       In another preferred embodiment, each "substituted" means that one or more (preferably 1, 2, 3, 4, 5, 6, 7 or 8) hydrogen atoms on the ring or group are each independently substituted by a substituent. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, 45 substituted or unsubstituted 3-12 membered heterocycloalkyl, substituted or unsubstituted C1-C12 haloalkyl, substituted or unsubstituted C3-C12 halocycloalkyl, substituted or unsubstituted C6-C12 aryl, substituted or unsubstituted 5-12 membered heteroaryl. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, 50 substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C1-C10 haloalkyl, substituted or unsubstituted C3-C10 halocycloalkyl, substituted or unsubstituted C6-C10 2026242260   02 Oct 2026 10 15 20 25 30 35 40 45 aryl, substituted or unsubstituted 5-10 membered heteroaryl. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C1-C6 haloalkyl, substituted or unsubstituted C3-C10 halocycloalkyl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-8 membered heteroaryl. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C3-C10 halocycloalkyl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-8 membered heteroaryl. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted C6-C8 aryl, substituted or unsubstituted 5-8 membered heteroaryl. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C1-C6 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted C6-C8 aryl, substituted or unsubstituted 5-8 membered heteroaryl. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C1-C4 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted C6-C8 aryl, substituted or unsubstituted 5-8 membered heteroaryl. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C1-C2 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted C6-C8 aryl, substituted or unsubstituted 5-8 membered heteroaryl. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted butyl, substituted or unsubstituted pentyl, substituted or unsubstituted hexyl, substituted or unsubstituted heptyl, substituted or unsubstituted octyl, substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted cycloheptyl, substituted or unsubstituted cyclooctyl, substituted or unsubstituted halomethyl, substituted or unsubstituted haloethyl, substituted or unsubstituted halopropyl, substituted or unsubstituted halobutyl substituted or unsubstituted halopentyl, substituted or unsubstituted halohexyl, substituted or unsubstituted phenyl, acetyl-methyl-, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrrolyl, cyclohexanone group. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, halogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, halomethyl, haloethyl, halopropyl, halobutyl halopentyl, halohexyl, phenyl, acetyl-methyl-, pyridinyl, pyrrolyl, cyclohexanone group. In another preferred embodiment, the pyridinyl is -4- 2026242260   02 Oct 2026 10 15 20 25 30 In another preferred embodiment, the acetyl-methyl- is In another preferred embodiment, the pyrrolyl is In another preferred embodiment, the cyclohexanone group is In another preferred embodiment, R1 and R2 are hydrogen or deuterium. In another preferred embodiment, at least one of R1 and R2 is not hydrogen or deuterium. In another preferred embodiment, R1 is hydrogen or deuterium, and R2 is not hydrogen or deuterium. In another preferred embodiment, R1 is not hydrogen or deuterium, and R2 is hydrogen or deuterium. In another preferred embodiment, both R1 and R2 are not hydrogen or deuterium. In another preferred embodiment, R1 is not hydrogen or deuterium. In another preferred embodiment, R2 is not hydrogen or deuterium. In another preferred embodiment, R1 and R2 are the same or different functional groups. In another preferred embodiment, the halogen is fluorine, chlorine, bromine or iodine. In another preferred embodiment, the halo is mono-halo, di-halo, tri-halo or full-halo. In another preferred embodiment, halo is fluoro, chloro, bromo, iodo. In another preferred embodiment, the halomethyl is trichloromethyl. In another preferred embodiment, the deuterated is mono-deuterated, di-deuterated, trideuterated or fully-deuterated. In another preferred embodiment, R1 and R2 are each independently hydrogen, deuterium, trichloromethyl, methyl, cyclobutyl, cyclopentyl, butyl, hexyl, phenyl. In another preferred embodiment, the propyl is n-propyl. In another preferred embodiment, the propyl is In another preferred embodiment, the butyl is n-butyl. In another preferred embodiment, the butyl is In another preferred embodiment, the pentyl is n-pentyl. . In another preferred embodiment, the pentyl is In another preferred embodiment, the hexyl is n-hexyl. In another preferred embodiment, the hexyl is . In another preferred embodiment, the cyclobutyl is In another preferred embodiment, the cyclohexyl is . . . In another preferred embodiment, R3, R4 and R5 are each independently hydrogen, halogen, R17- -5- 2026242260   02 Oct 2026 O-, R17-S-, (R18R19) N-; or R3 and R4, or R4 and R5 are connected to form a substituted or unsubstituted 3-10 membered heterocycloalkane ring. In another preferred embodiment, R3, R4 and R5 are each independently hydrogen, halogen, R17-O-, R17-S-, (R18R19) N-; or R3 and R4, or R4 and R5 are connected to form a substituted or 5 unsubstituted 3-8 membered heterocycloalkane ring. In another preferred embodiment, R3, R4 and R5 are each independently hydrogen, halogen, R17-O-, R17-S-, (R18R19) N-; or R3 and R4, or R4 and R5 are connected to form a substituted or unsubstituted 3 membered heterocycloalkane ring, substituted or unsubstituted 4 membered heterocycloalkane ring, substituted or unsubstituted 5 membered heterocycloalkane ring, substituted 10 or unsubstituted 6 membered heterocycloalkane ring, substituted or unsubstituted 7 membered heterocycloalkane ring, substituted or unsubstituted 8 membered heterocycloalkane ring, substituted or unsubstituted 9 membered heterocycloalkane ring, substituted or unsubstituted 10 membered heterocycloalkane ring. In another preferred embodiment, R3, R4 and R5 are each independently hydrogen, halogen (e.g, 15 Cl, Br), R17-O-, R17-S-, (R18R19) N-; or R3 and R4, or R4 and R5 are connected to form a substituted or unsubstituted 5 membered heterocycloalkane ring. In another preferred embodiment, R3, R4 and R5 are each independently hydrogen, halogen (e.g, Cl, Br), R17-O-, R17-S-, (R18R19) N-; or R3 and R4, or R4 and R5 are connected to form a substituted or unsubstituted dioxolene ring. 20       In another preferred embodiment, R3, R4 and R5 are each independently hydrogen, halogen (e.g, Cl, Br), R17-O-, R17-S-, (R18R19) N-; or R3 and R4, or R4 and R5 are connected to form if  )—R41 >4 W;      . ; W1 and W2 are each independently O or S; R41 is hydrogen, substituted or unsubstituted C1-C8 alkyl. 25       In another preferred embodiment, W1 is O or S. In another preferred embodiment, W2 is O or S. In another preferred embodiment, R3 is hydrogen. In another preferred embodiment, R5 is hydrogen. If  )—r41 In another preferred embodiment, R3 and R4 are connected to form                  . |£  )---R41 30       In another preferred embodiment, R4 and R5 are connected to form      w2        . In another preferred embodiment, R6, R8, R11, R12, R13, R14 and R15 are each independently hydrogen, substituted or unsubstituted C1-C8 alkyl, halogen (e.g, Br). In another preferred embodiment, R6, R8, R11, R12, R13, R14 and R15 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, halogen (e.g, Br). 35        In another preferred embodiment, R6, R8, R11, R12, R13, R14 and R15 are each independently hydrogen, substituted or unsubstituted C1-C4 alkyl, halogen (e.g, Br). In another preferred embodiment, R6, R8, R11, R12, R13, R14 and R15 are each independently hydroge, halogen (e.g, Br). In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C10 alkyl, 40 substituted or unsubstituted C1-C10 haloalkyl, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted 5-16 membered heteroaryl-substituted -6- 2026242260   02 Oct 2026 or unsubstituted C1-C12 alkyl-. In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted 5-16 membered heteroaryl-substituted 5 or unsubstituted C1-C12 alkyl-. In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C1-C10 haloalkyl, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C10 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-substituted or unsubstituted C1-C10 alkyl-. 10       In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C1-C10 haloalkyl, substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-substituted or unsubstituted C1-C10 alkyl-. In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C8 alkyl, 15 substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C10 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-substituted or unsubstituted C1-C12 alkyl-. In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C6-C12 aryl-substituted 20 or unsubstituted C1-C10 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-substituted or unsubstituted C1-C10 alkyl-. In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-substituted or 25 unsubstituted C1-C8 alkyl-. In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-substituted or unsubstituted C1-C6 alkyl-. 30       In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C5 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-substituted or unsubstituted C1-C5 alkyl-. In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C8 alkyl, 35 substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted 5-8 membered heteroaryl- R25 R2^ substituted or unsubstituted C1-C4 alkyl-, Z1 and Z2 are each independently substituted or unsubstituted C1-C8 alkylidene; R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently hydrogen, C1-C8 alkyl, C3- C12 cycloalkyl, C1-C8 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, 40 C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C6 ester group, C2-C4 amide group, C1-C8 alkoxyl, C1-C8 alkylthio, C1-C8 haloalkoxyl, C1-C8 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl. In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted C1-C6 alkyl, -7- 2026242260   02 Oct 2026 substituted or unsubstituted C1-C8 10 15 haloalkyl, pyridinyl-methyl-, R26 In another preferred embodiment, R7 is hydrogen, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted butyl, substituted or unsubstituted pentyl, substituted or unsubstituted hexyl, substituted or unsubstituted heptyl, substituted or unsubstituted octyl, halohexyl, pyridinyl-methyl-, In another preferred embodiment, R7 is hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, halohexyl, pyridinyl-methyl-, In another preferred embodiment, the pentyl is n- pentyl. In another preferred embodiment, the pentyl is Xy    / X.     . In another preferred embodiment, the octyl is R30 , In another preferred embodiment, the halohexyl is monohalohexyl. In another preferred embodiment, the halohexyl is Cl or Br . 20 25 In another preferred embodiment, R9 and R10 are connected to form a substituted or unsubstituted 3-10 membered heterocycloalkane ring. In another preferred embodiment, R9 and R10 are connected to form a substituted or unsubstituted 3-8 membered heterocycloalkane ring. In another preferred embodiment, R9 and R10 are connected to form a substituted or unsubstituted 5-8 membered heterocycloalkane ring. In another preferred embodiment, R9 and R10 are connected to form a substituted or unsubstituted 5-7 membered heterocycloalkane ring. In another preferred embodiment, R9 and R10 are connected to form a substituted or unsubstituted 3 membered heterocycloalkane ring, substituted or unsubstituted 4 membered heterocycloalkane 2026242260   02 Oct 2026 ring, substituted or unsubstituted 5 membered heterocycloalkane ring, substituted or unsubstituted 6 membered heterocycloalkane ring, substituted or unsubstituted 7 membered heterocycloalkane ring, substituted or unsubstituted 8 membered heterocycloalkane ring, substituted or unsubstituted 9 membered heterocycloalkane ring, substituted or unsubstituted 10 membered heterocycloalkane ring, 5 substituted or unsubstituted 11 membered heterocycloalkane ring, substituted or unsubstituted 12 membered heterocycloalkane ring. 10 In another preferred embodiment, R9 and R10 are connected to form a substituted or unsubstituted substituted or unsubstituted 15 W3, W4, W5 and W6 are each independently O or S; R31, R32, R33, R34 and R35 are each independently hydrogen, C1-C8 alkyl, C3-C12 cycloalkyl, C1-C8 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C8 alkoxyl, C1-C8 alkylthio, C1-C8 haloalkoxyl, C1-C8 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl. w3~rV R3'--( X / In another preferred embodiment, R9 and R10 are connected to form        w-*     or R32 R35 20 25 30 In another preferred embodiment, W3 is O or S. In another preferred embodiment, W4 is O or S. In another preferred embodiment, W5 is O or S. In another preferred embodiment, W6 is O or S. In another preferred embodiment, the propyl-phenyl-methy- is      . In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C12 alkyl, y^D Id D , substituted or unsubstituted C3-C14 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C3-C14 cycloalkyl-substituted or unsubstituted C2-C8 acyl-, substituted or unsubstituted C3-C14 cycloalkyl-C(O)-, substituted or unsubstituted C1-C12 haloalkyl, substituted or unsubstituted C3-C12 halocycloalkyl, substituted or unsubstituted 310 membered heterocycloalkyl-substituted or unsubstituted C1-C10 alkyl-, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C10 alkyl-, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C10 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-substituted or unsubstituted C1-C10 alkyl-, 2026242260   02 Oct 2026 substituted or unsubstituted C6-C12 aryl-O-substituted or unsubstituted C1-C10 alkyl-, substituted or unsubstituted C6-C12 aryl-S-substituted or unsubstituted C1-C10 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-O-substituted or unsubstituted C1-C10 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-S-substituted or unsubstituted C1-C10 alkyl-, substituted 5 or unsubstituted C2-C6 alkenyl-substituted or unsubstituted C1-C6 alkyl-substituted or unsubstituted C2-C6 alkenyl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted C2-C6 alkenyl-substituted or unsubstituted C1-C6 alkyl-, (R20R21) N-substituted or unsubstituted C1-C10 alkyl-. In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C10 alkyl, I D 10     D , substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C3-C12 cycloalkyl-substituted or unsubstituted C2-C6 acyl-, substituted or unsubstituted C3-C12 cycloalkyl-C(O)-, substituted or unsubstituted C1-C10 haloalkyl, substituted or unsubstituted C3-C10 halocycloalkyl, substituted or unsubstituted 310 membered heterocycloalkyl-substituted or unsubstituted C1-C8 alkyl-, substituted or 15 unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted C6-C12 aryl-O-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted C6-C12 aryl-S-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted 20   5-12 membered heteroaryl-O-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-S-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-, (R20R21) N-substituted or unsubstituted C1-C10 alkyl-. 25       In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C8 alkyl, I D D , substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C3-C12 cycloalkyl-substituted or unsubstituted C2-C4 acyl-, substituted or unsubstituted C3-C12 cycloalkyl-C(O)-, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted 3-10 30 membered heterocycloalkyl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted C6-C12 arylsubstituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted C6-C12 aryl-O-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted 35 C6-C12 aryl-S-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-O-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-S-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or 40 unsubstituted C1-C4 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C8 alkyl, I D D , substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C3-C12 cycloalkyl-substituted or unsubstituted C2-C4 acyl-, substituted or unsubstituted C3-C12 cycloalkyl-C(O)-, substituted or unsubstituted C1-C8 45 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl--10- 2026242260   02 Oct 2026 substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 5 membered heteroaryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. 10       In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C6 alkyl, I D D , substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C5-C12 cycloalkyl-substituted or unsubstituted C2-C4 acyl-, substituted or unsubstituted C5-C12 cycloalkyl-C(O)-, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted 3-10 15 membered heterocycloalkyl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 arylsubstituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 20   C6-C10 aryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or 25 unsubstituted C1-C4 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C6 alkyl, I D D , substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C6-C12 cycloalkyl-substituted or unsubstituted C2 acyl-, substituted or unsubstituted C6-C12 cycloalkyl-C(O)-, substituted or unsubstituted C1-C6 30 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C8 arylsubstituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-substituted or unsubstituted C1-C2 alkyl-, substituted or 35 unsubstituted C6-C8 aryl-O-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-S-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-O-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-S-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C4 alkyl-substituted or unsubstituted C2-C4 alkenyl-substituted or 40 unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C6 alkyl, I D D , substituted or unsubstituted C6-C12 cycloalkyl-substituted or unsubstituted C2-C4 acyl-, substituted or unsubstituted C6-C12 cycloalkyl-C(O)-, substituted or unsubstituted 3-10 membered 45 heterocycloalkyl, substituted or unsubstituted C1-C6 haloalkyl, substituted or unsubstituted 5-7 membered heterocycloalkyl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl--11- 2026242260   02 Oct 2026 substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 5 membered heteroaryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. 10       In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C6 alkyl, I D D , substituted or unsubstituted C8-C10 cycloalkyl-substituted or unsubstituted C2 acyl-, substituted or unsubstituted C8-C10 cycloalkyl-C(O)-, substituted or unsubstituted 5-7 membered heterocycloalkyl, substituted or unsubstituted C1-C6 haloalkyl, substituted or unsubstituted 5-7 membered heterocycloalkyl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 15 C6-C8 aryl-O-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-S-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-8 membered 20 heteroaryl-O-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-S-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C2 alkyl-substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. 25 In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C4 alkyl, I D D , substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C6-C12 cycloalkyl-substituted or unsubstituted C2 30 acyl-, substituted or unsubstituted C6-C12 cycloalkyl-C(O)-, substituted or unsubstituted C1-C6 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 arylsubstituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C2 alkyl-, substituted or 35 unsubstituted 5-8 membered heteroaryl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-O-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-S-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-O-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-S-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenyl-40 substituted or unsubstituted C1-C4 alkyl-substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C4 alkyl, I D D , substituted or unsubstituted C6-C12 cycloalkyl-substituted or unsubstituted C2-C4 acyl-, 45 substituted or unsubstituted C6-C12 cycloalkyl-C(O)-, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C1-C6 haloalkyl, substituted or unsubstituted 5-7 membered heterocycloalkyl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted -12- 2026242260   02 Oct 2026 C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 arylsubstituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5 C6-C10 aryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or 10 unsubstituted C1-C2 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted C1-C2 alkyl, I D D , substituted or unsubstituted C8-C10 cycloalkyl-substituted or unsubstituted C2 acyl-, substituted or unsubstituted C8-C10 cycloalkyl-C(O)-, substituted or unsubstituted 5-7 membered heterocycloalkyl, substituted or unsubstituted C3-C6 haloalkyl, substituted or unsubstituted 5-7 15 membered heterocycloalkyl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-O-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-S-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered 20 heteroaryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-O-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted 5-8 membered heteroaryl-S-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenylsubstituted or unsubstituted C1-C2 alkyl-substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C2 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted 25 C1-C2 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-. I D In another preferred embodiment, R17 is hydrogen, substituted or unsubstituted methyl, D , substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted pentyl, substituted or unsubstituted hexyl, substituted or unsubstituted phenyl-O-substituted or unsubstituted butyl-, haloethyl, halopropyl, halobutyl, halohexyl, substituted or unsubstituted 30 phenyl-substituted or unsubstituted ethyl-, substituted or unsubstituted phenyl-substituted or unsubstituted propyl-, substituted or unsubstituted phenyl-substituted or unsubstituted butyl-, substituted or unsubstituted cyclodecyl-substituted or unsubstituted acetyl-, substituted or unsubstituted butenyl-substituted or unsubstituted ethyl-substituted or unsubstituted propenylsubstituted or unsubstituted methyl-, (R20R21)N-substituted or unsubstituted hexyl-, (R20R21)N-35 substituted or unsubstituted butyl-, (R20R21)N-substituted or unsubstituted ethyl-, substituted or unsubstituted piperidinyl-substituted or unsubstituted ethyl-, substituted or unsubstituted butylsubstituted or unsubstituted piperazine ring-, substituted or unsubstituted methyl-substituted or unsubstituted piperidinyl-, substituted or unsubstituted phenyl-substituted or unsubstituted phenylsubstituted or unsubstituted methyl-, substituted or unsubstituted ethylenyl-substituted or 40 unsubstituted methyl-, substituted or unsubstituted piperidinyl-substituted or unsubstituted propyl-, substituted or unsubstituted piperidinyl-substituted or unsubstituted ethyl-, dimethylamino-ethyl-. I D In another preferred embodiment, R17 is hydrogen, methyl, D , ethyl, propyl, pentyl, hexyl, phenyl-O-butyl-, haloethyl, halopropyl, halobutyl, halohexyl, phenyl-ethyl-, phenyl-propyl-, phenylbutyl-, cyclodecyl-acetyl-, butenyl-ethyl-propenyl-methyl-, (R20R21)N-hexyl-, (R20R21)N-butyl-, 45   (R20R21)N-ethyl-, piperidinyl-ethyl-, butyl-piperazinyl-, methyl-piperidinyl-, phenyl-phenyl- methyl-, ethylenyl-methyl-, piperidinyl-propyl-, piperidinyl-ethyl-, dimethylamino-ethyl-. In another preferred embodiment, the butyl is n-butyl. 2026242260   02 Oct 2026 In another preferred embodiment, the butyl is In another preferred embodiment, the hexyl is In another preferred embodiment, the pentyl is n-pentyl. In another preferred embodiment, the pentyl is In another preferred embodiment, the cyclopentyl is In another preferred embodiment, the phenyl-propyl- is In another preferred embodiment, the phenyl-butyl- is In another preferred embodiment, the phenyl-O-butyl- is 10 In another preferred embodiment, haloethyl is monobromoethyl, monochloroethyl or monofluoroethyl. In another preferred embodiment, the haloethyl is or 15 In another preferred embodiment, the propyl is n- propyl. In another preferred embodiment, the propyl is               . In another preferred embodiment, the halopropyl is n-halopropyl. In another preferred embodiment, the halopropyl is monobromopropyl, monochloropropyl or monofluoropropyl. In another preferred embodiment, the halopropyl is 20       In another preferred embodiment, the butyl is n-butyl. In another preferred embodiment, the halobutyl is n- halobutyl. In another preferred embodiment, the halobutyl is monobromobutyl, monochlorobutyl or monofluorobutyl. In another preferred embodiment, the halobutyl is                     . 25       In another preferred embodiment, the hexyl is n-hexyl. In another preferred embodiment, the halohexyl is n-halohexyl. In another preferred embodiment, the halohexyl is monochlorohexyl or monobromohexyl. In another preferred embodiment, the halohexyl is                   ,                    . 2026242260   02 Oct 2026 10 15 20 25 In another preferred embodiment, the cyclodecyl-acetyl- is 0 . . N . In another preferred embodiment, the butenyl-ethyl-propenyl-methyl- is In another preferred embodiment, the piperidinyl-ethyl- is In another preferred embodiment, the phenyl-phenyl-methyl- is In another preferred embodiment, the ethylenyl-methyl- is In another preferred embodiment, the piperidinyl-propyl- is In another preferred embodiment, the piperidinyl-ethyl- is In another preferred embodiment, the dimethylamino-ethyl- is In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C10 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C8 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C6 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 3-10 membered heterocycloalkane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C12 aryl-substituted or unsubstituted C1-C4 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 3-8 membered heterocycloalkane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 3-8 membered heterocycloalkane ring. 2026242260   02 Oct 2026 10 15 20 25 30 35 40 In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C4 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 5-8 membered heterocycloalkane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C4 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 5 membered heterocycloalkane ring, substituted or unsubstituted 6 membered heterocycloalkane ring, substituted or unsubstituted 7 membered heterocycloalkane ring, substituted or unsubstituted 8 membered heterocycloalkane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted phenyl-substituted or unsubstituted ethyl-; or R18 and R19 are connected to form a substituted or unsubstituted piperazine ring, substituted or unsubstituted piperidine ring, substituted or unsubstituted azacycloheptane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or or or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C4 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted piperazine ring, substituted or unsubstituted piperidine ring, or substituted or unsubstituted azacycloheptane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted phenyl-substituted or unsubstituted ethyl-; or R18 and R19 are connected to form a substituted or unsubstituted methyl-substituted or unsubstituted piperazine ring, substituted or unsubstituted butyl-substituted or unsubstituted piperazine ring, substituted or unsubstituted methylsubstituted or unsubstituted piperidine ring, trifluoromethyl-piperidine ring, halopiperidine ring, or substituted or unsubstituted azacycloheptane ring. In another preferred embodiment, R18 and R19 are each independently hydrogen, phenyl-ethyl-; or R18 and R19 are connected to form a methyl-piperazine ring, butyl-piperazine ring, trifluoromethyl-piperazine ring, trifluoromethoxyl-piperazine ring, halopiperazine ring, methylpiperidine ring, trifluoromethyl-piperidine ring, trifluoromethoxyl-piperidine ring, halopiperidine ring, azacycloheptane ring, (R20R21)N-piperidine ring. In another preferred embodiment, R3 is hydrogen, hydroxyl, sulfhydryl, amino, methyl-O-, . / ° D D , ethyl-O-, propyl-O-, pentyl-O-, hexyl-O-, phenyl-O-butyl-O-O-, haloethyl-O-, halopropyl-O-, halobutyl-O-, halohexyl-O-, phenyl-ethyl-O-, phenyl-propyl-O-, phenyl-butyl-O-, cyclodecyl-acetyl-O-, butenyl-ethyl-propenyl-methyl-O-, (R20R21)N-hexyl-O-, (R20R21)N-butyl-O-, (R20R21)N-ethyl-O-, piperidinyl-ethyl-O-, butyl-piperazinyl-O-, methyl-piperidinyl-O-, phenyl- phenyl-methyl-O-,     ethylenyl-methyl-O-, dimethylamino-ethyl-O-,     phenyl-ethyl-NH-, piperidinyl-propyl-O-,     piperidinyl-ethyl-O-, butyl-piperazinyl-,     methyl-piperazinyl-, trifluoromethyl-piperazinyl-, trifluoromethoxyl-piperazinyl-, halopiperazinyl, methyl-piperidinyl-, trifluoromethyl-piperidinyl-, trifluoromethoxyl-piperidinyl-, group, (R20R21) N- piperazinyl-. halopiperidinyl, azacycloheptane In another preferred embodiment, the phenyl-ethyl- is In another preferred embodiment, the methyl-piperazine ring is In another preferred embodiment, the methyl-piperazinyl- is . 2026242260   02 Oct 2026 I      N HN   J In another preferred embodiment, the butyl-piperazine ring is I N In another preferred embodiment, the butyl-piperazinyl- is F IT ^"N^F H N / In another preferred embodiment, the trifluoromethyl-piperidine ring is F it [^^N^F In another preferred embodiment, the trifluoromethyl-piperazinyl- is .O^T t'j ^F In another preferred embodiment, the trifluoromethoxyl-piperazine ring is .o I N In another preferred embodiment, the trifluoromethoxyl-piperazinyl- is In another preferred embodiment, the halopiperazine ring is chloropiperazine ring. ,F It F .Cl \ N HN J In another preferred embodiment, the halopiperazine ring is In another preferred embodiment, the halopiperazinyl is chloropiperazinyl. Cl 10 In another preferred embodiment, the halopiperazinyl is F F . . In another preferred embodiment, the methyl-piperidiny-l is In another preferred embodiment, the methyl-piperidine ring is In another preferred embodiment, the trifluoromethyl-piperidiny- is In another preferred embodiment, the trifluoromethoxyl-piperidine ring is In another preferred embodiment, the trifluoromethoxyl-piperidinyl- is 2026242260   02 Oct 2026 F F . In another preferred embodiment, the trifluoromethyl-piperidine ring is In another preferred embodiment, the halopiperidine ring is chloropiperidine ring. Cl HN In another preferred embodiment, the halopiperidine ring is In another preferred embodiment, the halopiperidinyl is chloropiperidinyl. Cl In another preferred embodiment, the halopiperidinyl is In another preferred embodiment, the azacycloheptane ring is In another preferred embodiment, the azacycloheptane group is . In another preferred embodiment, the (R20R21)N- piperazinyl- is . 10 In another preferred embodiment, the (R20R21) N-piperidine ring is In another preferred embodiment, R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C8 aryl-substituted or unsubstituted C1-C4 alkyl-; or R18 and R19 are connected to form 15 wherein, R42, R43, R44, R45, R46, R47, R48, R49, R50 and R51 are each independently hydrogen, C1-C10 alkyl, C1-C10 haloalkyl, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, halogen; R52, R53, R54, R55, R56, R57, R58, R59 and R60 are each independently hydrogen, C1-C10 alkyl, C1-C10 haloalkyl, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, halogen. 2026242260   02 Oct 2026 In another preferred 10 15 20 25 embodiment, (R20R21)N-   is or R42, R43, R44, R45, R46, R47, R48, R49, R50 and R51 are each independently hydrogen, C1-C10 alkyl, C1-C10 haloalkyl, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, halogen; R52, R53, R54, R55, R56, R57, R58, R59 and R60 are each independently hydrogen, C1-C10 alkyl, C1-C10 haloalkyl, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, halogen. In another preferred embodiment, R20 and R21 are each independently hydrogen, substituted or unsubstituted C1-C10 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C2-C8 ester group; or R20 and R21 are connected to form a substituted or unsubstituted 3-10 membered heterocycloalkyl. In another preferred embodiment, R20 and R21 are each independently hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C8 ester group; or R20 and R21 are connected to form a substituted or unsubstituted 3-8 membered heterocycloalkyl. In another preferred embodiment, R20 and R21 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C3-C7 ester group; or R20 and R21 are connected to form a substituted or unsubstituted 5-8 membered heterocycloalkyl. In another preferred embodiment, R20 and R21 are each independently hydrogen, substituted or unsubstituted amyl ester group; or R20 and R21 are connected to form a substituted or unsubstituted piperidine ring. In another preferred embodiment, R20 and R21 are each independently hydrogen, amyl ester group; or R20 and R21 are connected to form piperidine ring. o I JI In another preferred embodiment, amyl ester group is     O . In another preferred embodiment, (R20R21)N-hexyl- is In another preferred embodiment, (R20R21)N-butyl- is 2026242260   02 Oct 2026 10 15 20 25 30 35 In another preferred embodiment, (R20R21) N-ethyl- is                      . In another preferred embodiment, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C6 ester group, C2-C4 amide group, C1-C6 alkoxyl, C1-C6 alkylthio, C1-C6 haloalkoxyl, C1-C6 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl. In another preferred embodiment, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently hydrogen, C1-C6 alkyl, C1-C6 alkoxyl, C1-C6 alkylthio. In another preferred embodiment, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently hydrogen, C1-C4 alkyl, C1-C4 alkoxyl, C1-C4 alkylthio. In another preferred embodiment, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently hydrogen, C1-C3 alkyl, C1-C2 alkoxyl, C1-C2 alkylthio. In another preferred embodiment, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently hydrogen, trifluoromethoxyl, propyl. In another preferred embodiment, propyl is isopropyl. In another preferred embodiment, Z1 and Z2 are each independently substituted or unsubstituted C1-C6 alkylidene. In another preferred embodiment, Z1 and Z2 are each independently substituted or unsubstituted C1-C4 alkylidene. In another preferred embodiment, Z1 and Z2 are each independently substituted or unsubstituted methylidene, substituted or unsubstituted ethylidene, substituted or unsubstituted propylidene, substituted or unsubstituted butylidene, substituted or unsubstituted pentylidene, substituted or unsubstituted hexylidene. In another preferred embodiment, Z1 and Z2 are each independently methylidene, ethylidene, propylidene, butylidene, pentylidene, hexylidene. In another preferred embodiment, ethylidene is In another preferred embodiment, propyl is In another preferred embodiment, propylidene is n-propylidene. In another preferred embodiment, propylidene is In another preferred embodiment, butylidene is In another preferred embodiment, R31, R32, R33, R34 and R35 are each independently hydrogen, C1-C6 alkyl. In another preferred embodiment, R31, R32, R33, R34 and R35 are each independently hydrogen, C1-C4 alkyl. In another preferred embodiment, R41 is hydrogen, substituted or unsubstituted C1-C6 alkyl. In another preferred embodiment, R41 is hydrogen, substituted or unsubstituted C1-C4 alkyl. In another preferred embodiment, R42, R43, R44, R45, R46, R47, R48, R49, R50 and R51 are each independently hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 haloalkoxyl, C1-C8 haloalkylthio, 2026242260   02 Oct 2026 halogen In another preferred embodiment, R42, R43, R44, R45, R46, R47, R48, R49, R50 and R51 are each independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxyl, C1-C6 haloalkylthio, halogen. 5        In another preferred embodiment, R42, R43, R44, R45, R46, R47, R48, R49, R50 and R51 are each independently hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxyl, C1-C4 haloalkylthio, halogen. In another preferred embodiment, R42, R43, R44, R45, R46, R47, R48, R49, R50 and R51 are each independently hydrogen, methyl, butyl, trifluoromethyl, trifluoromethoxyl, halogen (e.g., chlorine). 10       In another preferred embodiment, R52, R53, R54, R55, R56, R57, R58, R59 and R60 are each independently hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 haloalkoxyl, C1-C8 haloalkylthio, halogen In another preferred embodiment, R52, R53, R54, R55, R56, R57, R58, R59 and R60 are each independently hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 haloalkoxyl, C1-C6 haloalkylthio, 15 halogen. In another preferred embodiment, R52, R53, R54, R55, R56, R57, R58, R59 and R60 are each independently hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxyl, C1-C4 haloalkylthio, halogen. In another preferred embodiment, R52, R53, R54, R55, R56, R57, R58, R59 and R60 are each 20 independently hydrogen, methyl, butyl, trifluoromethyl, trifluoromethoxyl, halogen (e.g., chlorine). In another preferred embodiment, halogen is F. Cl, Br or I. In another preferred embodiment, halo is fluoro, chloro, bromo and / or iodo. In another preferred embodiment, the halon is mono-halo, di-halo or tri-halo. In another preferred embodiment, the aryl is phenyl. 25       In another preferred embodiment, the compound of formula I has no optical activity or has optical activity. In another preferred embodiment, the compound of formula I has no chiral carbon atom or has chiral carbon atom. In another preferred embodiment, the compound of formula I has one chiral carbon atom. 30       In another preferred embodiment, the configuration of the compound of formula I is racemate, R configuration (rectus), or S configuration (sinister). In another preferred embodiment, the compound of formula I has the following structure of formula I-1: 35                                                         I-1 wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 are each independently defined as described above. In another preferred embodiment, "*" represents the configuration of the compound. In another preferred embodiment, "*" means that the configuration of the compound is racemate, R configuration (rectus), or S configuration (sinister). 5       In another preferred embodiment, "*" represents a chiral carbon atom. In another preferred embodiment, the configuration of chiral carbon atom is R configuration (rectus), S configuration (sinister) or racemate. In another preferred embodiment, the configuration of chiral carbon atom is R configuration (rectus) and / or S configuration. 10       In another preferred embodiment, the R configuration (rectus) and S configuration of chiral carbon atom refers to racemate. In another preferred embodiment, the compound of formula I has the following structure of formula I-2: 2026242260   02 Oct 2026 15                                                         I-2 wherein, R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R31, W3 and W4 are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of 20 formula I-3: I-3 wherein, R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R31, W3, W4 and *are each independently 25 defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-4: 2026242260   02 Oct 2026 wherein, R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, W5 and W6 are each 5 independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-5: I-5 10       wherein, R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, W5, W6 and * are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-6: wherein, R1, R2, R5, R6, R7, R8, R11, R12, R13, R14, R15, R31, R41, W1, W2, W3and W4 are each independently 2026242260   02 Oct 2026 defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-7: wherein, R1, R2, R5, R6, R7, R8, R11, R12, R13, R14, R15, R31, R41, W1, W2, W3, W4 and * are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of 10 formula I-8: I-8 wherein, R1, R2, R3, R6, R7, R8, R11, R12, R13, R14, R15, R31, R41, W1, W2, W3 and W4 are each independently 15 defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-9: 2026242260   02 Oct 2026 I-9 wherein, R1, R2, R3, R6, R7, R8, R11, R12, R13, R14, R15, R31, R41, W1, W2, W3, W4 and * are each 5 independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-11: I-11 10       wherein, R1, R2, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R31, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, W3 and W4 are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-12: 2026242260   02 Oct 2026 I-12 wherein, R1, R2, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R31, R42, R43, R44, R45, R46, R47, R48, R49, R50, 5   R51, W3, W4 and * are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-13: I-13 10       wherein, R1, R2, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R31, R52, R53, R54, R55, R56, R57, R58, R59, R60, W3 and W4 are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-14: 2026242260   02 Oct 2026 wherein, R1, R2, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R31, R52, R53, R54, R55, R56, R57, R58, R59, R60, 5   W3, W4 and * are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-15: I-15 10       wherein, R1, R2, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, W5 and W6 are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-16: 2026242260   02 Oct 2026 I-16 wherein, R1, R2, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, R42, R43, R44, R45, R46, R47, R48, R49, R50, R51, W5, W6 and * are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-17: 10       wherein, R1, R2, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, R52, R53, R54, R55, R56, R57, R58, R59, R60, W5 and W6 are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-18: 2026242260   02 Oct 2026 I-18 wherein, R1, R2, R4, R5, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, R52, R53, R54, R55, R56, R57, 5   R58, R59, R60, W5, W6 and * are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-19: 10 wherein, R1, R2, R5, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, R41, W1, W2, W5 ft W6 are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-20: 15 2026242260   02 Oct 2026 wherein, R1, R2, R5, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, R41, W1, W2, W5, W6 and *are each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of 5 formula I-21: I-21 wherein, R1, R2, R3, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, R41, W1, W2, W5 and W6 are 10 each independently defined as described above. In another preferred embodiment, the compound of formula I has the following structure of formula I-22: I-22 15       wherein, R1, R2, R3, R6, R7, R8, R11, R12, R13, R14, R15, R32, R33, R34, R35, R41, W1, W2, W5, W6 and * are each independently defined as described above. In another preferred embodiment, the pharmaceutically acceptable salt of the compound of formula I comprises the salt formed by the compound of formula I and an acid. 20       In another preferred embodiment, the acid comprises one or more of hydrochloric acid, mucic acid, D-glucuronic acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenemethanesulfonic acid, benzenesulfonic acid, aspartic acid 25 and glutamic acid. 2026242260   02 Oct 2026 In another preferred embodiment, the pharmaceutically acceptable salt of the compound of formula I comprises the salt formed by the compound of formula I and one or more of hydrochloric acid, mucic acid, D-glucuronic acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic 5 acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenemethanesulfonic acid, benzenesulfonic acid, aspartic acid and glutamic acid. In another preferred embodiment, the pharmaceutically acceptable salt of the compound of formula I comprises the salt formed by the compound of formula I and hydrochloric acid, mucic 10 acid, D-glucuronic acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenemethanesulfonic acid, benzenesulfonic acid, aspartic acid or glutamic acid. 15       In another preferred embodiment, the salt root of the pharmaceutically acceptable salt of the compound of formula I comprises the salt root formed by the loss of a H+in the acid. In another preferred embodiment, the salt root of the pharmaceutically acceptable salt of the compound of formula I comprises the salt root formed by the loss of a H+in hydrochloric acid, mucic acid, D-glucuronic acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, sulfuric acid, nitric 20 acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenemethanesulfonic acid, benzenesulfonic acid, aspartic acid or glutamic acid. In another preferred embodiment, the salt root of the pharmaceutically acceptable salt of the 25 compound of formula I comprises F-, Cl-, Br-, I-, HCOO-, CH3COO-, SO42-or NO3-. In another preferred embodiment, the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof is selected from the following group: 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 oX^XyyCcyH^o ।  XX^Cn^ XX\--N J    O^X           1  1 11                 r \ < XX1 X> < XX o^X / \ / N V^7    O'^k / Y-- XT      1 XX \<3 O— / < XX'n .       < XX J J    XX    ( X O^Xx / X               O^y^CCC ^(r                           X'X'--^^ XX Cl XX / Il |          | ^oXXXn 'CCI3               'o^\ C o Xj        t t CX 0 -41- CC13           SjC^X^N^.-'CC'j Br           \X\^      Br I /           X1 o                     ;-^k XXX (°cc Xx       ° C  Q^kJ O— / N^.CCI3          ^0 X..C XX^°\    x^k.x\ XX   (J   XX O-^y^Y^X >             'oXx,^^001^ XXXo^ / ^^ XX /                                     -' o'' 1 .cc|3        Xx^cx bCC¥N.7 X X X — 2026242260   02 Oct 2026 2026242260   02 Oct 2026 2026242260   02 Oct 2026 I                                                                                                                                                                                                                                                                                                                                             I 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 27077616—1 (GHMalters) P12M32.MJ.' 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 27077616_1 (GHMatters) P124432.AU.1 2026242260   02 Oct 2026 2026242260   02 Oct 2026 In the second aspect of the present invention, it provides a composition, the composition comprises (a) the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention; and (b) a pharmaceutically acceptable carrier. 5        In another preferred embodiment, the content of the (a) the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is 0.001-99.9 wt%, based on the weight of the composition. In another preferred embodiment, the composition is pharmaceutical composition. 10        In another preferred embodiment, the composition further comprises a pharmaceutically acceptable carrier. In another preferred embodiment, the dosage form of the composition is a solid preparation, liquid preparation or semi-solid preparation. In another preferred embodiment, the dosage form of the composition is oral preparation, 15 external preparation or injection preparation. In another preferred embodiment, the injection preparation is intravenous injection preparation. In another preferred embodiment, the dosage form of the composition is tablet, injection, infusion, paste, gel, solution, microsphere or film. 20       In the third aspect of the present invention, it provides a use of the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention in the preparation of a composition or a preparation for preventing and / or treating tumor. In another preferred embodiment, the tumor is human-derived tumor. 25        In another preferred embodiment, the tumor is human tumor. In another preferred embodiment, the tumor comprises tumor with low or no expression of NNMT gene. In another preferred embodiment, the tumor comprises tumor with high expression of DNA methylase. 30        In another preferred embodiment, the DNA methylase is selected from the group consisting of DNMT1, DNMT3a, DNMT3b, and combinations thereof. In another preferred embodiment, the tumor comprises tumor with high expression of DNMT1. In another preferred embodiment, the tumor comprises tumor with high expression of DNMT3a. In another preferred embodiment, the tumor comprises tumor with high expression of DNMT3b. 35        In another preferred embodiment, the tumor comprises tumor with high expression of UHRFl. In another preferred embodiment, the tumor comprises tumor with high methylation level of nucleotide site of NNMT gene and / or high methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the tumor comprises tumor with high methylation level of nucleotide site of NNMT gene. 40        In another preferred embodiment, the methylation of nucleotide site of NNMT gene comprises the methylation of cytosine nucleotide site of NNMT gene. In another preferred embodiment, the methylation of nucleotide site of NNMT gene comprises the methylation of cytosine of NNMT gene. In another preferred embodiment, the methylation of nucleotide site of NNMT gene comprises 45 the methylation of the 5’carbon atom on the cytosine of the NNMT gene. In another preferred embodiment, the tumor comprises tumor with high methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the methylation of DNA CpG site of NNMT gene comprises the methylation of cytosine nucleotide site of DNA CpG site of NNMT gene. 50       In another preferred embodiment, the methylation of DNA CpG site of NNMT gene comprises the methylation of cytosine of DNA CpG site of NNMT gene. 2026242260   02 Oct 2026 In another preferred embodiment, the methylation of DNA CpG site of NNMT gene comprises the methylation of the 5’carbon atom on the cytosine of DNA CpG site of NNMT gene. In another preferred embodiment, the NNMT gene is human-derived NNMT gene. In another preferred embodiment, the NNMT gene is human NNMT gene. 5       In another preferred embodiment, the tumor with low or no expression of NNMT gene means that no NNMT protein can be detected in 1 pg of protein extracted from tumor using NNMT antibody, preferably in 5 pg of protein extracted from tumor, more preferably in 10 pg of protein extracted from tumor, more preferably in 100 pg of protein extracted from tumor, preferably in 1000 pg of protein extracted from tumor. 10       In another preferred embodiment, the tumor with low or no expression of NNMT gene means the expression level of NNMT gene in tumor cell is lower than that in the same type of cell or a normal cell. In another preferred embodiment, the tumor with low or no expression of NNMT gene means the ratio (E1 / E0) of the expression level E1 of NNMT gene in the tumor cell to the expression level 15 E0 of NNMT gene in the same type of cell or a normal cell is <1.0. In another preferred embodiment, the low or no expression of NNMT gene means the ratio (E1 / E0) of the expression E1 of NNMT gene in a cell ( e.g., tumor cell ) to the expression E0 of NNMT gene in the same type of cell or a normal cell is <1.0, preferably < 0.7, more preferably < 0.6, more preferably < 0.5, more preferably < 0.4, more preferably < 0.3, more preferably < 0.2, 20 more preferably < 0.1, more preferably < 0.05, more preferably < 0.01, more preferably < 0.005, more preferably < 0.001, more preferably < 0.0001, more preferably < 0.00001, more preferably < 0.000001, more preferably < 0.0000001. In another preferred embodiment, the cell comprises tumor cell. In another preferred embodiment, the same type of cell comprises the same type of tumor cell. 25        In another preferred embodiment, the same type of cell comprises the cell (e.g., the same type of tumor cell) with normal or high expression of NNMT gene. In another preferred embodiment, the same type of cell comprises the same type of cell (e.g., the same type of tumor cell) with normal or high expression of NNMT gene. In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor 30 origin cell, tumor-adjacent cell or para-tumor tissue cell). In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell) with normal expression of NNMT gene. In another preferred embodiment, E0 refers to the expression level of NNMT gene in the cell with normal or high expression of NNMT gene. 35        In another preferred embodiment, the cell with normal or high expression of NNMT gene comprises the cell that is not sensitive to the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof In another preferred embodiment, the tumor with high expression of DNA methylase means 40 that DNA methylase can be detected in 20 pg of protein extracted from tumor using DNA methylase antibody, preferably in 5 pg of protein extracted from tumor, more preferably in 1 pg of protein extracted from tumor, more preferably in 0.2 pg of protein extracted from tumor, more preferably in 0.05 pg of protein extracted from tumor, more preferably in 0.01 pg of protein extracted from tumor. In another preferred embodiment, the tumor with high expression of DNA methylase means the 45 expression level of DNA methylase in tumor cell is higher than that in the same type of cell or a normal cell. In another preferred embodiment, the tumor with high expression of DNA methylase means the ratio (A1 / A0) of the expression level A1 of DNA methylase in the tumor cell to the expression level A0 of DNA methylase in the same type of cell or a normal cell is > 1.0, preferably > 1.2, more 50 preferably > 1.5, more preferably > 2, more preferably > 3, more preferably > 5, more preferably > 8, more preferably > 10, more preferably > 15, more preferably > 20, more preferably > 30, more 2026242260   02 Oct 2026 preferably > 50, such as 2-50. In another preferred embodiment, the same type of cell comprises the same type of tumor cell. In another preferred embodiment, the same type of cell comprises the cell (e.g., the same type of tumor cell) with normal or low expression of DNA methylase. 5        In another preferred embodiment, the same type of cell comprises the same type of cell (e.g., the same type of tumor cell) with normal or low expression of DNA methylase. In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell). In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor 10 origin cell, tumor-adjacent cell or para-tumor tissue cell) with normal expression of DNA methylase. In another preferred embodiment, A0 refers to the expression level of DNA methylase in the cell with normal or low expression of DNA methylase. In another preferred embodiment, the cell with normal or low expression of DNA methylase comprises the cell that is not sensitive to the compound of formula I, or an optical isomer thereof, or 15 a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof In another preferred embodiment, the tumor with high expression of DNMT1 means that DNMT1 protein can be detected in 20 pg of protein extracted from tumor using DNMT1 antibody, preferably in 5 pg of protein extracted from tumor, more preferably in 1 pg of protein extracted from 20 tumor, more preferably in 0.2 pg of protein extracted from tumor, more preferably in 0.05 pg of protein extracted from tumor, more preferably in 0.01 pg of protein extracted from tumor. In another preferred embodiment, the tumor with high expression of DNMT1 means the expression level of DNMT1 in tumor type of cell is higher than that in the same type of cell or a normal cell. 25        In another preferred embodiment, the tumor with high expression of DNMT1 means the ratio (B1 / B0) of the expression level B1 of DNMT1 in the tumor cell to the expression level B0 of DNMT1 in the same type of cell or a normal cell is > 1.0, preferably > 1.2, more preferably > 1.5, more preferably > 2, more preferably > 3, more preferably > 5, more preferably > 8, more preferably > 10, more preferably > 15, more preferably > 20, more preferably > 30, more preferably > 50, such 30 as 2-50. In another preferred embodiment, the same type of cell comprises the same type of tumor cell. In another preferred embodiment, the same type of cell comprises the cell (e.g., the same type of tumor cell ) with normal or low expression of DNMT1. In another preferred embodiment, the same type of cell comprises the same type of cell (e.g., 35 the same type of tumor cell ) with normal or low expression of DNMT1. In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell). In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell) with normal expression of DNMT1. 40        In another preferred embodiment, B0 refers to the expression level of DNMT1 in the cell with normal or low expression of DNMT1. In another preferred embodiment, the cell with normal or low expression of DNMT1 comprises the cell that is not sensitive to the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound 45 thereof In another preferred embodiment, the tumor with high expression of DNMT3a means that DNMT3a protein can be detected in 20 pg of protein extracted from tumor using DNMT3a antibody, preferably in 5 pg of protein extracted from tumor, more preferably in 1 pg of protein extracted from tumor, more preferably in 0.2 pg of protein extracted from tumor, more preferably in 0.05 pg of 50 protein extracted from tumor, more preferably in 0.01 pg of protein extracted from tumor. In another preferred embodiment, the tumor with high expression of DNMT3a means the 2026242260   02 Oct 2026 expression level of DNMT3a in tumor cell is higher than that in the same type of cell or a normal cell. In another preferred embodiment, the tumor with high expression of DNMT3a means the ratio (C1 / C0) of the expression level C1 of DNMT3a in the tumor cell to the expression level C0 of 5 DNMT3a in the same type of cell or a normal cell is > 1.0, preferably > 1.2, more preferably > 1.5, more preferably > 2, more preferably > 3, more preferably > 5, more preferably > 8, more preferably > 10, more preferably > 15, more preferably > 20, more preferably > 30, more preferably > 50, such as 2-50. In another preferred embodiment, the same type of cell comprises the same type of tumor cell. 10        In another preferred embodiment, the same type of cell comprises the cell (e.g., the same type of tumor cell ) with normal or low expression of DNMT3a. In another preferred embodiment, the same type of cell comprises the same type of cell (e.g., the same type of tumor cell) with normal or low expression of DNMT3a. In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor 15 origin cell, tumor-adjacent cell or para-tumor tissue cell). In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell) with normal expression of DNMT3a. In another preferred embodiment, C0 refers to the expression level of DNMT3a in the cell with normal or low expression of DNMT3a. 20        In another preferred embodiment, the cell with normal or low expression of DNMT3a comprises the cell that is not sensitive to the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof. In another preferred embodiment, the tumor with high expression of DNMT3b means that 25 DNMT3b protein can be detected in 20 pg of protein extracted from tumor using DNMT3b antibody, preferably in 5 pg of protein extracted from tumor, more preferably in 1 pg of protein extracted from tumor, more preferably in 0.2 pg of protein extracted from tumor, more preferably in 0.05 pg of protein extracted from tumor, more preferably in 0.01 pg of protein extracted from tumor. In another preferred embodiment, the tumor with high expression of DNMT3b means the 30 expression level of DNMT3b in tumor type of cell is higher than that in the same type of cell or a normal cell. In another preferred embodiment, the tumor with high expression of DNMT3b means the ratio (D1 / D0) of the expression level D1 of DNMT3b in the tumor cell to the expression level D0 of DNMT3b in the same type of cell or a normal cell is > 1.0, preferably > 1.2, more preferably > 1.5, 35 more preferably > 2, more preferably > 3, more preferably > 5, more preferably > 8, more preferably > 10, more preferably > 15, more preferably > 20, more preferably > 30, more preferably > 50, such as 2-50. In another preferred embodiment, the same type of cell comprises the same type of tumor cell. In another preferred embodiment, the same type of cell comprises the cell (e.g., the same type 40 of tumor cell) with normal or low expression of DNMT3b. In another preferred embodiment, the same type of cell comprises the same type of cell (e.g., the same type of tumor cell) with normal or low expression of DNMT3b. In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell). 45        In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell) with normal expression of DNMT3b In another preferred embodiment, D0 refers to the expression level of DNMT3b in the cell with normal or low expression of DNMT3b. In another preferred embodiment, the cell with normal or low expression of DNMT3b 50 comprises the cell that is not sensitive to the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated 2026242260   02 Oct 2026 compound. In another preferred embodiment, the tumor with high expression of UHRF1 means that UHRF1 protein can be detected in 20 ug of protein extracted from tumor using UHRF1 antibody, preferably in 5 pg of protein extracted from tumor, more preferably in 1 pg of protein extracted from 5 tumor, more preferably in 0.2 ug of protein extracted from tumor, more preferably in 0.05 ug of protein extracted from tumor, more preferably in 0.01 pg of protein extracted from tumor. In another preferred embodiment, the tumor with high expression of UHRF1 means the expression level of UHRF1 in tumor type of cell is higher than that in the same type of cell or a normal cell. 10        In another preferred embodiment, the tumor with high expression of UHRF1 means the ratio (F1 / F0) of the expression level F1 of UHRF1 in the tumor cell to the expression level F0 of UHRF1 in the same type of cell or a normal cell is > 1.0, preferably > 1.2, more preferably > 1.5, more preferably > 2, more preferably > 3, more preferably > 5, more preferably > 8, more preferably > 10, more preferably > 15, more preferably > 20, more preferably > 30, more preferably > 50, such as 215    50. In another preferred embodiment, the same type of cell comprises the same type of tumor cell. In another preferred embodiment, the same type of cell comprises the cell (e.g., the same type of tumor cell) with normal or low expression of UHRF1. In another preferred embodiment, the same type of cell comprises the same type of cell (e.g., 20 the same type of tumor cell) with normal or low expression of UHRF1. In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell). In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell) with normal expression of UHRF1 25        In another preferred embodiment, F0 refers to the expression level of UHRF1 in the cell with normal or low expression of UHRF1. In another preferred embodiment, the cell with normal or low expression of UHRF1 comprises the cell that is not sensitive to the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound. 30        In another preferred embodiment, the high methylation level of nucleotide site of NNMT gene means the methylation level of nucleotide site of NNMT gene in a cell ( e.g., tumor cell ) is higher than that in the same type of cell or a normal cell. In another preferred embodiment, the high methylation level of nucleotide site of NNMT gene means the ratio (L1 / L0) of the methylation level L1 of nucleotide site of NNMT gene in a cell ( e.g., 35 tumor cell ) to the methylation level L0 of nucleotide site of NNMT gene in the same type of cell or a normal cell (e.g., para-tumor tissue cell) is > 1.0, preferably > 1.2, more preferably > 1.5, more preferably > 2, more preferably > 3, more preferably > 5, more preferably > 8, more preferably > 10, more preferably > 15, more preferably > 20, more preferably > 30, more preferably > 50, such as 250. 40        In another preferred embodiment, the high methylation level of nucleotide site of NNMT gene means the methylation level of nucleotide site of NNMT gene in a cell ( e.g., tumor cell ) is > 1%, more preferably > 3%, more preferably > 5%, more preferably > 10%, more preferably > 15%, more preferably > 20%, more preferably > 25%, more preferably > 30%, more preferably > 40%, more preferably > 50%. 45        In another preferred embodiment, the cell comprises tumor cell. In another preferred embodiment, the same type cell comprises the same type of tumor cell. In another preferred embodiment, the same type of cell comprises the cell (e.g., the same type of tumor cell) with normal or low methylation level of nucleotide site of NNMT gene. In another preferred embodiment, the same type of cell comprises the same type of cell (e.g., 50 the same type of tumor cell) with normal or low methylation level of nucleotide site of NNMT gene. In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor 2026242260   02 Oct 2026 origin cell, tumor-adjacent cell or para-tumor tissue cell). In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell) with normal methylation level of nucleotide site of NNMT gene. 5        In another preferred embodiment, the cell with normal or low methylation level of nucleotide site of NNMT gene comprises the cell that is not sensitive to the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound. In another preferred embodiment, the high methylation level of nucleotide site of NNMT gene 10 means the methylation level (M%) of nucleotide site of NNMT gene in a cell ( e.g., tumor cell ) is > 3% and < M1%, wherein Ml is any positive integer from 3 to 100. In another preferred embodiment, M1 is 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95 or 100. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene refers 15 to the ratio of the number of methylated nucleotides to the number of all nucleotides in the NNMT gene. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide site in promoter region of NNMT gene. In another preferred embodiment, the nucleotide sequence of the promoter region of NNMT 20 gene is as shown in SEQ ID NO: 1. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide sites from 1050 bp before the transcription start site to 499 bp after the transcription start site in NNMT gene. In another preferred embodiment, the sites from 1050 bp before the transcription start site to 25   499 bp after the transcription start site in NNMT gene is sites 951-2500 of nucleotide sequence as shown in SEQ ID NO: 1. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide sites from 1050 bp to 193 bp before the transcription start site in NNMT gene. 30        In another preferred embodiment, the sites from 1050 bp to 193 bp before the transcription start site in NNMT gene is sites 951-1808 of nucleotide sequence as shown in SEQ ID NO: 1. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide sites from 840 bp to 469 bp before the transcription start site in NNMT gene. 35        In another preferred embodiment, the sites from 840 bp to 469 bp before the transcription start site in NNMT gene is sites 1161-1532 of nucleotide sequence as shown in SEQ ID NO: 1. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide site between any two sites (including the two sites itself) selected from group consisting of site 114165695, site 114165730, site 114165769, site 40   114165804, site 114165938, site 114166050 and site 114166066 on human chromosome 11. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide site of one or more (e.g., 2, 3, 4, 5, 6, or 7 ) of site 114165695, site 114165730, site 114165769, site 114165804, site 114165938, site 114166050 and site 114166066 on human chromosome 11. 45        In another preferred embodiment, the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide sites selected from group consisting of site 114165695 on human chromosome 11, site 114165730 on human chromosome 11, site 114165769 on human chromosome 11, site 114165804 on human chromosome 11, site 114165938 on human chromosome 11, site 114166050 on human chromosome 11, site 114166066 on human chromosome 11, and 50 combinations thereof. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene 2026242260   02 Oct 2026 comprises the methylation level of nucleotide site between any two sites (including the two sites itself) selected from group consisting of site 1161, site 1196, site 1235, site 1270, site 1404, site 1516 and site 1532 in nucleotide sequence of SEQ ID NO: 1. In another preferred embodiment, the methylation level of nucleotide site of NNMT gene 5 comprises the methylation level of nucleotide site of one or more (e.g., 2, 3, 4, 5, 6, or 7 ) of site 1161, site 1196, site 1235, site 1270, site 1404, site 1516 and site 1532 in nucleotide sequence of SEQ ID NO: 1. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene comprises the methylation level of nucleotide sites selected from group consisting of site 1161 in 10 SEQ ID NO: 1, site 1196 in SEQ ID NO: 1, site 1235 in SEQ ID NO: 1, site 1270 in SEQ ID NO: 1, site 1404 in SEQ ID NO: 1, site 1516 in SEQ ID NO: 1, site 1532 in SEQ ID NO: 1, and combinations thereof. In another preferred embodiment, the high methylation level of DNA CpG site of NNMT gene means the methylation level of DNA CpG site of NNMT gene in a cell ( e.g., tumor cell ) is higher 15 than that in the same type of cell or a normal cell. In another preferred embodiment, the high methylation level of DNA CpG site of NNMT gene means the ratio (W1 / W0) of the methylation level W1 of DNA CpG site of NNMT gene in a cell ( e.g., tumor cell ) to the methylation level W0 of DNA CpG site of NNMT gene in the same type of cell or a normal cell (e.g., para-tumor tissue cell) is > 1.0, preferably > 1.2, more preferably > 1.5, 20 more preferably > 2, more preferably > 3, more preferably > 5, more preferably > 8, more preferably > 10, more preferably > 15, more preferably > 20, more preferably > 30, more preferably > 50, such as 2-50. In another preferred embodiment, the high methylation level of DNA CpG site of NNMT gene means the methylation level of DNA CpG site of NNMT gene in a cell ( e.g., tumor cell ) is > 1%, 25 more preferably > 3%, more preferably > 5%, more preferably > 10%, more preferably > 15%, more preferably > 20%, more preferably > 25%, more preferably > 30%, more preferably > 40%, more preferably > 50%. In another preferred embodiment, the cell comprises tumor cell. In another preferred embodiment, the same type of cell comprises the same type of tumor cell. 30        In another preferred embodiment, the same type of cell comprises the cell (e.g., the same type of tumor cell) with normal or low methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the same type of cell comprises the same type of cell (e.g., the same type of tumor cell) with normal or low methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor 35 origin cell, tumor-adjacent cell or para-tumor tissue cell). In another preferred embodiment, the normal cell comprises normal tissue cell (e.g., tumor origin cell, tumor-adjacent cell or para-tumor tissue cell) with normal methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the cell with normal or low methylation level of DNA CpG 40   site of NNMT gene comprises the cell that is not sensitive to the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof In another preferred embodiment, the high methylation level of DNA CpG site of NNMT gene means the methylation level (M%) of DNA CpG site of NNMT gene in a cell ( e.g., tumor cell ) is 45   > 3% and < M2%, wherein M2 is any positive integer from 3 to 100. In another preferred embodiment, M2 is 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95 or 100. In another preferred embodiment, the methylation level of CpG site refers to the ratio of the number of methylated CpG nucleotides to the number of all nucleotides in a gene. 50       In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene refers to the ratio of the number of methylated CpG nucleotides to the number of all nucleotides in the 2026242260   02 Oct 2026 NNMT gene. In another preferred embodiment, the methylation level of CpG site refers to the ratio of the number of methylated CpG nucleotides to the number of all CpG nucleotides in a gene. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene refers 5 to the ratio of the number of methylated DNA CpG nucleotides to the number of all CpG nucleotides in the NNMT gene. In another preferred embodiment, the methylation level of DNA CpG site refers to the ratio of the number of methylated CpG sites to the number of all CpG sites in a DNA. In another preferred embodiment, the methylation level of DNA CpG site refers to the ratio of 10 the number of methylated CpG nucleotides to the number of all nucleotides in a DNA. In another preferred embodiment, the methylation level of DNA CpG site refers to the ratio of the number of methylated CpG nucleotides to the number of all CpG nucleotides in a DNA. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene refers to the ratio of the number of methylated DNA CpG sites to the number of all DNA CpG sites in the 15 NNMT gene. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene refers to the ratio of the number of methylated DNA CpG nucleotides to the number of all DNA CpG nucleotides in the NNMT gene. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene 20 comprises the methylation level of DNA CpG site in promoter region of NNMT gene. In another preferred embodiment, the nucleotide sequence of the promoter region of NNMT gene is as shown in SEQ ID NO: 1. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene comprises the methylation level of DNA CpG sites from 1050 bp before the transcription start site 25 to 499 bp after the transcription start site in NNMT gene. In another preferred embodiment, the sites from 1050 bp before the transcription start site to 499 bp after the transcription start site in NNMT gene is sites 951-2500 of nucleotide sequence as shown in SEQ ID NO: 1. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene 30 comprises the methylation level of the DNA CpG sites from 1050 bp to 193 bp before the transcription start site in NNMT gene. In another preferred embodiment, the sites from 1050 bp to 193 bp before the transcription start site in NNMT gene is sites 951-1808 of nucleotide sequence as shown in SEQ ID NO: 1. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene 35 comprises the methylation level of DNA CpG sites from 840 bp to 469 bp before the transcription start site in NNMT gene. In another preferred embodiment, the sites from 840 bp to 469 bp before the transcription start site in NNMT gene is sites 1161-1532 of nucleotide sequence as shown in SEQ ID NO: 1. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene 40 comprises the methylation level of DNA CpG site between any two sites (including the two sites itself) selected from group consisting of site 114165695, site 114165730, site 114165769, site 114165804, site 114165938, site 114166050 and site 114166066 on human chromosome 11. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene comprises the methylation level of site of one or more (e.g., 2, 3, 4, 5, 6, or 7) of site 114165695, 45 site 114165730, site 114165769, site 114165804, site 114165938, site 114166050 and site 114166066 on human chromosome 11. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene comprises the methylation level of sites selected from group consisting of site 114165695 on human chromosome 11, site 114165730 on human chromosome 11, site 114165769 on human chromosome 50   11, site 114165804 on human chromosome 11, site 114165938 on human chromosome 11, site 114166050 on human chromosome 11, site 114166066 on human chromosome 11, and combinations 2026242260   02 Oct 2026 thereof. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene comprises the methylation level of DNA CpG site between any two sites (including the two sites itself) selected from group consisting of site 1161, site 1196, site 1235, site 1270, site 1404, site 1516 5 and site 1532 in nucleotide sequence of SEQ ID NO: 1. In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene comprises the methylation level of the site of one or more (e.g., 2, 3, 4, 5, 6, or 7) of site 1161, site 1196, site 1235, site 1270, site 1404, site 1516 and site 1532 in nucleotide sequence of SEQ ID NO: 1. 10       In another preferred embodiment, the methylation level of DNA CpG site of NNMT gene comprises the methylation level of sites selected from group consisting of site 1161 in SEQ ID NO: 1, site 1196 in SEQ ID NO: 1, site 1235 in SEQ ID NO: 1, site 1270 in SEQ ID NO: 1, site 1404 in SEQ ID NO: 1, site 1516 in SEQ ID NO: 1, site 1532 in SEQ ID NO: 1, and combinations thereof. In another preferred embodiment, the NNMT gene inhibitor is administered to achieve low or 15 no expression of the NNMT gene in tumor. In another preferred embodiment, the DNA methylase promoter is administered to achieve high expression of DNA methylase in tumor. In another preferred embodiment, the DNMT1 promoter is administered to achieve high expression of DNMT1 in tumor. 20        In another preferred embodiment, the DNMT3a promoter is administered to achieve high expression of DNMT3a in tumor. In another preferred embodiment, the DNMT3b promoter is administered to achieve high expression of DNMT3b in tumor. In another preferred embodiment, the UHRFl promoter is administered to achieve high 25 expression of UHRFl in tumor. In another preferred embodiment, the methylation promoter of nucleotide site of NNMT gene is administered to achieve high methylation level of nucleotide site of NNMT gene in tumor. In another preferred embodiment, the methylation promoter of DNA CpG site of NNMT gene is administered to achieve high methylation level of DNA CpG site of NNMT gene in tumor. 30        In another preferred embodiment, the inhibitor comprises specific inhibitor. In another preferred embodiment, the promoter comprises specific promoter. In another preferred embodiment, the NNMT gene inhibitor comprises inhibitor that can achieve low or no expression of the NNMT gene in tumor. In another preferred embodiment, the DNA methylase promoter comprises promoter that can 35 achieve high expression of DNA methylase in tumor. In another preferred embodiment, the DNMT1 promoter comprises promoter that can achieve high expression of DNMT1 in tumor. In another preferred embodiment, the DNMT3a promoter comprises promoter that can achieve high expression of DNMT3a in tumor. 40       In another preferred embodiment, the DNMT3b promoter comprises promoter that can achieve high expression of DNMT3b in tumor. In another preferred embodiment, the UHRFl promoter comprises promoter that can achieve high expression of UHRFl in tumor. In another preferred embodiment, the methylation promoter of nucleotide site of NNMT gene 45 comprises promoter that can achieve high methylation level of nucleotide site of NNMT gene in tumor. In another preferred embodiment, the methylation promoter of DNA CpG site of NNMT gene comprises promoter that can achieve high methylation promoter of DNA CpG site of NNMT gene in tumor. 50        In another preferred embodiment, the tumor is selected from the group consisting of lung cancer, renal carcinoma, breast cancer, colon cancer, lymphoma, leukemia, pancreatic cancer, brain tumor, 2026242260   02 Oct 2026 liver cancer, prostate cancer, and combinations thereof. In another preferred embodiment, the lung cancer is selected from the group consisting of nonsmall cell lung cancer, small cell lung cancer, and combinations thereof. In another preferred embodiment, the lung cancer cell comprises NCI-H82 cell. 5        In another preferred embodiment, the colon cancer comprises colon adenocarcinoma. In another preferred embodiment, the colon cancer cell comprises SW48 cell. In another preferred embodiment, the breast cancer cell comprises MDA-MB-453 cell. In another preferred embodiment, the breast cancer comprises triple negative breast cancer. In another preferred embodiment, the lymphoma is selected from the group consisting of B-cell 10 lymphoma, skin T-cell lymphoma, and combinations thereof. In another preferred embodiment, the lymphoma comprises diffuse large B-cell lymphoma. In another preferred embodiment, the brain tumor is selected from the group consisting of brain glioblastoma, neuroglioma, brain medulloblastoma, brain neuroblastoma, and combination thereof. In another preferred embodiment, the brain medulloblastoma comprises cerebellar 15 medulloblastoma. In another preferred embodiment, the brain glioblastoma comprises glioblastoma multiforme. In another preferred embodiment, the brain tumor comprises glioblastoma. In another preferred embodiment, the brain tumor cell comprises one or more of GB-1 cell, SF126 cell, D341 Med cell, Kelly cell and NB-1 cell. 20        In another preferred embodiment, the renal carcinoma is selected from the group consisting of clear cell renal cell adenocarcinoma, renal carcinoma Wilms, and combination thereof. In another preferred embodiment, the renal carcinoma comprises clear cell renal cell adenocarcinoma. In another preferred embodiment, the renal carcinoma comprises renal carcinoma Wilms. 25        In another preferred embodiment, the renal carcinoma cell comprises renal carcinoma Wilms cell. In another preferred embodiment, the renal carcinoma cell comprises one or more of G-401 cell and 786-O cell. In another preferred embodiment, the pancreatic cancer comprises pancreatic ductal carcinoma. 30        In another preferred embodiment, the pancreatic cancer cell comprises CFPAC-1 cell. In another preferred embodiment, the leukemia is selected from the group consisting of T-lymphocyte leukemia, myeloid leukemia, and combinations thereof. In another preferred embodiment, the T-lymphocytic leukemia comprises acute T-lymphocytic leukemia. 35        In another preferred embodiment, the myeloid leukemia comprises type M4 of acute myeloid leukemia. In another preferred embodiment, the myeloid leukemia comprises FAB type M4 of acute myeloid leukemia. In another preferred embodiment, the expression comprises protein expression and / or mRNA 40 expression. In another preferred embodiment, the composition or preparation is a pharmaceutical composition or pharmaceutical preparation. In another preferred embodiment, the composition or preparation further comprises a pharmaceutically acceptable carrier. 45        In another preferred embodiment, the expression is mRNA expression or protein expression. In another preferred embodiment, the dosage form of the composition or preparation is a solid preparation, liquid preparation or semi-solid preparation. In another preferred embodiment, the dosage form of the composition or preparation is oral preparation, external preparation or injection preparation. 50        In another preferred embodiment, the dosage form of the composition or preparation is tablet, injection, infusion, paste, gel, solution, microsphere or film. 2026242260   02 Oct 2026 In the fourth aspect of the present invention, it provides a marker for determining whether the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first 5 aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor, the marker comprises the expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the compound of formula I, or an optical isomer thereof, or 10 a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene. 15        In another preferred embodiment, the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is not suitable for use in the prevention and / or treatment of patient tumor with high expression of NNMT gene, low expression of DNA methylase, low expression of UHRFl, low methylation level of nucleotide site of NNMT 20 gene, and / or low methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, “the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor” comprises “the patient tumor is sensitive to the 25 compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention”. In another preferred embodiment, “the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated 30 compound thereof according to the first aspect of the present invention is not suitable for use in the prevention and / or treatment of patient tumor” comprises “the patient tumor is not sensitive to the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention”. 35        In another preferred embodiment, the tumor with low or no expression of NNMT gene is as described in the third aspect of the invention. In another preferred embodiment, the DNA methylase is selected from the group consisting of DNMT1, DNMT3a, DNMT3b, and combinations thereof. In another preferred embodiment, the tumor with high expression of DNA methylase (e.g., 40 DNMT1) is as described in the third aspect of the invention. In another preferred embodiment, the tumor with high expression of UHRFl is as described in the third aspect of the invention. In another preferred embodiment, the tumor with high methylation level of nucleotide site of NNMT gene is as described in the third aspect of the invention. 45        In another preferred embodiment, the tumor with high methylation level of DNA CpG site of NNMT gene is as described in the third aspect of the invention. In another preferred embodiment, the high expression of NNMT gene means the ratio (E1 / E0) of the expression E1 of NNMT gene in a cell ( e.g., tumor cell ) to the expression E0 of NNMT gene in the same type of cell or a normal cell is >1.0, preferably >1.2, more preferably >1.5, more 50 preferably >2, more preferably >3, more preferably >5, more preferably >8, more preferably >10, more preferably >15, more preferably >20, more preferably >30, more preferably >50, such as 2-50. 2026242260   02 Oct 2026 In another preferred embodiment, the tumor with low expression of DNA methylase means the ratio (A1 / A0) of the expression level A1 of DNA methylase in the tumor cell to the expression level A0 of DNA methylase in the same type of cell or a normal cell is <1.0, preferably < 0.7, more preferably < 0.6, more preferably < 0.5, more preferably < 0.4, more preferably < 0.3, more 5 preferably < 0.2, more preferably < 0.1, more preferably < 0.05, more preferably < 0.01, more preferably < 0.005, more preferably < 0.001, more preferably < 0.0001, more preferably < 0.00001, more preferably < 0.000001, more preferably < 0.0000001. In another preferred embodiment, the tumor with low expression of DNMT1 means the ratio (B1 / B0) of the expression level B1 of DNMT1 in the tumor cell to the expression level B0 of 10 DNMT1 in the same type of cell or a normal cell is <1.0, preferably < 0.7, more preferably < 0.6, more preferably < 0.5, more preferably < 0.4, more preferably < 0.3, more preferably < 0.2, more preferably < 0.1, more preferably < 0.05, more preferably < 0.01, more preferably < 0.005, more preferably < 0.001, more preferably < 0.0001, more preferably < 0.00001, more preferably < 0.000001, more preferably < 0.0000001. 15        In another preferred embodiment, the tumor with low expression of DNMT3a means the ratio (C1 / C0) of the expression level C1 of DNMT3a in the tumor cell to the expression level C0 of DNA methylase in the same type of cell or a normal cell is <1.0, preferably < 0.7, more preferably < 0.6, more preferably < 0.5, more preferably < 0.4, more preferably < 0.3, more preferably < 0.2, more preferably < 0.1, more preferably < 0.05, more preferably < 0.01, more preferably < 0.005, more 20 preferably < 0.001, more preferably < 0.0001, more preferably < 0.00001, more preferably < 0.000001, more preferably < 0.0000001. In another preferred embodiment, the tumor with low expression of DNMT3b means the ratio (D1 / D0) of the expression level D1 of DNMT3b in the tumor cell to the expression level D0 of DNA methylase in the same type of cell or a normal cell is <1.0, preferably < 0.7, more preferably < 0.6, 25 more preferably < 0.5, more preferably < 0.4, more preferably < 0.3, more preferably < 0.2, more preferably < 0.1, more preferably < 0.05, more preferably < 0.01, more preferably < 0.005, more preferably < 0.001, more preferably < 0.0001, more preferably < 0.00001, more preferably < 0.000001, more preferably < 0.0000001. In another preferred embodiment, the tumor with low expression of UHRF1 means the ratio 30   (F1 / F0) of the expression level F1 of UHRF1 in the tumor cell to the expression level F0 of UHRF1 in the same type of cell or a normal cell is <1.0, preferably < 0.7, more preferably < 0.6, more preferably < 0.5, more preferably < 0.4, more preferably < 0.3, more preferably < 0.2, more preferably < 0.1, more preferably < 0.05, more preferably < 0.01, more preferably < 0.005, more preferably < 0.001, more preferably < 0.0001, more preferably < 0.00001, more preferably < 35   0.000001, more preferably < 0.0000001. In another preferred embodiment, the low methylation level of nucleotide site of NNMT gene means the ratio (L1 / L0) of the methylation level L1 of nucleotide site of NNMT gene in a cell ( e.g., tumor cell ) to the methylation level L0 of nucleotide site of NNMT gene in the same type of cell or a normal cell (e.g., para-tumor tissue cell) is <1.0, preferably < 0.7, more preferably < 0.6, more 40 preferably < 0.5, more preferably < 0.4, more preferably < 0.3, more preferably < 0.2, more preferably < 0.1, more preferably < 0.05, more preferably < 0.01, more preferably < 0.005, more preferably < 0.001, more preferably < 0.0001, more preferably < 0.00001, more preferably < 0.000001, more preferably < 0.0000001. In another preferred embodiment, the low methylation level of DNA CpG site of NNMT gene 45 means the ratio (W1 / W0) of the methylation level W1 of DNA CpG site of NNMT gene in a cell ( e.g., tumor cell ) to the methylation level W0 of DNA CpG site of NNMT gene in the same type of cell or a normal cell (e.g., para-tumor tissue cell) is <1.0, preferably < 0.7, more preferably < 0.6, more preferably < 0.5, more preferably < 0.4, more preferably < 0.3, more preferably < 0.2, more preferably < 0.1, more preferably < 0.05, more preferably < 0.01, more preferably < 0.005, more 50 preferably < 0.001, more preferably < 0.0001, more preferably < 0.00001, more preferably < 0.000001, more preferably < 0.0000001. 2026242260   02 Oct 2026 In the fifth aspect of the present invention, it provides a detection kit, which comprises: (i) a detection reagent for detecting the expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of 5 NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the test sample of the detection kit comprises tumor cell. In another preferred embodiment, the level comprises protein level and / or mRNA level. In another preferred embodiment, the expression comprises mRNA expression and / or protein expression. 10 In the sixth aspect of the present invention, it provides a use of the detection kit according to the fifth aspect of the present invention in the preparation of concomitant diagnose kit for determining whether the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof 15 according to the first aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor. In another preferred embodiment, the concomitant diagnose kit further comprises instruction or label. In another preferred embodiment, the instruction or label records that the compound of formula 20 I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site 25 of NNMT gene. In another preferred embodiment, the instruction or label records that the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is not suitable for use in the prevention and / or treatment of patient tumor with high 30 expression of NNMT gene, low expression of DNA methylase, low expression of UHRFl, low methylation level of nucleotide site of NNMT gene, and / or low methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, “the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated 35 compound thereof according to the first aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor” is as described in the fourth aspect of the invention. In another preferred embodiment, “the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is not suitable for use in the 40 prevention and / or treatment of patient tumor” is as described in the fourth aspect of the invention. In the seventh aspect of the present invention, it provides a medicine kit, which comprises: (i) a detection reagent for detecting the expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of 45 NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene; and (ii) the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention. In another preferred embodiment, the expression level of NNMT gene, the expression level of 50 DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene comprises the expression level 2026242260   02 Oct 2026 of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene in the tumor. In another preferred embodiment, the detection sample comprises tumor. 5        In another preferred embodiment, the medicine kit further comprises instruction or label. In another preferred embodiment, the instruction or label records that the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor with low or no 10 expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the instruction or label records that the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically 15 acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is not suitable for use in the prevention and / or treatment of patient tumor with high expression of NNMT gene, low expression of DNA methylase, low expression of UHRFl, low methylation level of nucleotide site of NNMT gene, and / or low methylation level of DNA CpG site of NNMT gene. 20 In the eighth aspect of the present invention, it provides a method for preventing and / or treating tumor, which comprises administering the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention to a subject in need, thereby 25 preventing and / or treating tumor. In another preferred embodiment, the tumor is as described in the third aspect of the invention. In another preferred embodiment, the subject is human and non-human mammals (rodent, rabbit, monkey, livestock, dog, cat, etc.). In another preferred embodiment, the method comprises: 30        firstly achieving low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene in the subject tumor, then administering the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof to prevent and / or treat 35 tumor. In another preferred embodiment, the method comprises: firstly administering NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene to achieve low or no expression of NNMT gene, high expression of DNA 40 methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene in the subject tumor, then administering the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof to prevent and / or treat tumor. 45       In another preferred embodiment, the NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene is as described in the third aspect of the invention. In the ninth aspect of the present invention, it provides a device or system, the device or system 50 comprises: (i) a detection module, the detection module is used to detect the expression level of NNMT 2026242260   02 Oct 2026 gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene; (ii) an output module, the output module comprises the information as follows: the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate 5 thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene; and / or 10        the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is not suitable for use in the prevention and / or treatment of patient tumor with high expression of NNMT gene, low expression of DNA methylase, low expression of UHRFl, low methylation level of nucleotide site of NNMT gene, and / or low 15 methylation level of DNA CpG site of NNMT gene. In another preferred embodiment, the detection sample comprises tumor. In another preferred embodiment, the device comprises a gene detector or protein detector. In another preferred embodiment, the device or system further comprises sample injection module. 20        In another preferred embodiment, the injection module is used to inject tumor cell extract. In another preferred embodiment, the device or system further comprises data processing module. In another preferred embodiment, the expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT 25 gene, and / or the methylation level of DNA CpG site of NNMT gene can be obtained by the procession of the data processing module. In another preferred embodiment, the expression level of NNMT gene and the methylation level of DNA CpG site in promoter region of NNMT gene can be obtained by the procession of the data processing module. 30 In the tenth aspect of the present invention, it provides a use of NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene in the preparation of a composition or a preparation for enhancing the anti-tumor effect of anti-tumor drug. 35        In another preferred embodiment, the NNMT gene inhibitor comprises inhibitor that can achieve low or no expression of the NNMT gene in tumor. In another preferred embodiment, the DNA methylase promoter comprises promoter that can achieve high expression of DNA methylase in tumor. In another preferred embodiment, the DNA methylase is selected from the group consisting of 40 DNMT1, DNMT3a, DNMT3b, and combinations thereof. In another preferred embodiment, the DNA methylase promoter comprises DNMT1 promoter. In another preferred embodiment, the DNMT1 promoter comprises promoter that can achieve high expression of DNMT1 in tumor. In another preferred embodiment, the DNA methylase promoter comprises DNMT3a promoter. 45       In another preferred embodiment, the DNMT3a promoter comprises promoter that can achieve high expression of DNMT3a in tumor. In another preferred embodiment, the DNA methylase promoter comprises DNMT3b promoter. In another preferred embodiment, the DNMT3b promoter comprises promoter that can achieve high expression of DNMT3b in tumor. 50        In another preferred embodiment, the UHRFl promoter comprises promoter that can achieve high expression of UHRFl in tumor. 2026242260   02 Oct 2026 In another preferred embodiment, the methylation promoter of nucleotide site of NNMT gene comprises promoter that can achieve high methylation level of nucleotide site of NNMT gene in tumor. In another preferred embodiment, the methylation promoter of DNA CpG site of NNMT gene 5 comprises promoter that can achieve high methylation level of nucleotide site of NNMT gene in tumor. In another preferred embodiment, the inhibitor comprises specific inhibitor. In another preferred embodiment, the promoter comprises specific promoter. In another preferred embodiment, the anti-tumor drug comprises the compound of formula I, 10 or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention. In another preferred embodiment, the tumor is as described in the third aspect of the invention. In another preferred embodiment, the composition or preparation is a pharmaceutical 15 composition or pharmaceutical preparation. In another preferred embodiment, the composition or preparation further comprises a pharmaceutically acceptable carrier. In another preferred embodiment, the dosage form of the composition or preparation is a solid preparation, liquid preparation or semi-solid preparation. 20        In another preferred embodiment, the dosage form of the composition or preparation is oral preparation, external preparation or injection preparation. In another preferred embodiment, the injection preparation is intravenous injection preparation. In another preferred embodiment, the dosage form of the composition or preparation is tablet, injection, infusion, paste, gel, solution, microsphere or film. 25 In the eleventh aspect of the present invention, it provides an active ingredient combination, the active ingredient combination comprises: (1) a first active ingredient, the first active ingredient comprises anti-tumor drug; and (2) a second active ingredient, the second active ingredient comprises NNMT gene inhibitor, 30 DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene. In another preferred embodiment, the anti-tumor drug comprises the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present 35 invention. In another preferred embodiment, the NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene is as described in the tenth aspect of the invention. In another preferred embodiment, the molar ratio of the first active ingredient to the second 40 active ingredient is 0.01-600:1, preferably 0.05-500:1, more preferably 0.1-400:1, more preferably 0.2-200:1, more preferably 0.5-100:1, more preferably 0.5-80:1, most preferably 1-50:1. In another preferred embodiment, at least one active ingredient is independent in the active ingredient combination. In another preferred embodiment, the first active ingredient and the second active ingredient 45 are independent of each other in the active ingredient combination. In the twelfth aspect of the present invention, it provides a composition, the composition comprises: (1) a first active ingredient, the first active ingredient comprises anti-tumor drug; and (2) a second active ingredient, the second active ingredient comprises NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene. In another preferred embodiment, the anti-tumor drug comprises the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present 5 invention. In another preferred embodiment, the NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene is as described in the tenth aspect of the invention. In another preferred embodiment, the composition is a pharmaceutical composition. 10        In another preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In another preferred embodiment, the content of the first active ingredient is 0.01-99.99 wt%, preferably 0.1-99.9 wt%, more preferably 1-99 wt%, more preferably 10-99 wt%, most preferably 20-99 wt%, based on the total weight of the active ingredient in the composition. 15        In another preferred embodiment, the content of the second active ingredient is 0.01-99.99 wt%, preferably 0.1-99.9 wt%, more preferably 1-99 wt%, more preferably 10-99 wt%, most preferably 20-99 wt%, based on the total weight of the active ingredient in the composition. 2026242260   02 Oct 2026 In the thirteenth aspect of the present invention, it provides a medicine kit, the medicine kit 20 comprises: (A) a first preparation comprising a first active ingredient, the first active ingredient comprises anti-tumor drug; and (B) a second preparation comprising a second active ingredient, the second active ingredient comprises NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation 25 promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene. In another preferred embodiment, the anti-tumor drug comprises the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present 30 invention. In another preferred embodiment, the NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene is as described in the tenth aspect of the invention. In another preferred embodiment, the medicine kit further comprises a user manual. 35        In another preferred embodiment, the first preparation and the second preparation are independent preparation of each other. In another preferred embodiment, the first preparation and the second preparation are combined preparation. In another preferred embodiment, the user manual records that the first preparation and the 40 second preparation are used together to enhance anti-tumor activity of anti-tumor drug. In another preferred embodiment, the method for using together means the second preparation comprising NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene is administered firstly, then the anti-tumor drug is administered. 45 In the fourteenth aspect of the present invention, it provides a method for inhibiting tumor cell, which comprises contacting the tumor cell with the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention, thereby 50 inhibiting tumor cell. In another preferred embodiment, the method is vitro method. 2026242260   02 Oct 2026 In another preferred embodiment, the method is non-therapeutic and non-diagnostic method. In another preferred embodiment, the contact is performed in vitro culture. In another preferred embodiment, the tumor is as described in the third aspect of the invention. In another preferred embodiment, the method comprises: 5        firstly achieving low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene in the tumor cell, then contacting the tumor cell with the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according 10 to the first aspect of the present invention, thereby inhibiting tumor cell. In another preferred embodiment, the method comprises: firstly administering NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene to achieve low or no expression of NNMT gene, high expression of DNA 15 methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene in the tumor cell, then contacting the tumor cell with the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention, thereby inhibiting tumor cell. 20       In another preferred embodiment, the NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene is as described in the tenth aspect of the invention. In the fifteenth aspect of the present invention, it provides a use of medicine kit according to 25 the seventh aspect of the present invention in the preparation of medicine box for preventing and / or treating tumor. In another preferred embodiment, the medicine box further comprises instruction or label. In another preferred embodiment, the instruction or label records that the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically 30 acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is suitable for use in the prevention and / or treatment of patient tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene. 35        In another preferred embodiment, the instruction or label records that the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof according to the first aspect of the present invention is not suitable for use in the prevention and / or treatment of patient tumor with high expression of NNMT gene, low expression of DNA methylase, low expression of UHRFl, low 40 methylation level of nucleotide site of NNMT gene, and / or low methylation level of DNA CpG site of NNMT gene. It should be understood that, in the present invention, each of the technical features specifically described above and below can be combined with each other, thereby constituting new or preferred 45 technical solutions which need not be redundantly described one-by-one. DESCRIPTION OF THE DRAWINGS Fig.1 shows the expression content of NNMT protein in Con-NCI-H82 cell and ov-NNMT NCI-H82 cell using Western Blot test, wherein, Con-NCI-H82 refers to the expression content of NNMT protein in NCI-H82 cell transfected with empty virus vector without carrying NNMT gene and shRNA, which is used as control; ov-NNMT NCI-H82 refers to the expression content of NNMT 2026242260   02 Oct 2026 protein in NCI-H82 cell transfected with virus vector carrying NNMT gene. Fig.2 shows the expression content of DNMT1 protein in Con-NCI-H82 cell and sh-DNMT1 NCI-H82 cell using Western Blot test, wherein, Con-NCI-H82 refers to the expression content of DNMT1 protein in NCI-H82 cell transfected with empty virus vector without carrying NNMT gene 5 and shRNA, which is used as control; sh-DNMT1 NCI-H82 refers to the expression content of DNMT1 protein in NCI-H82 cell transfected with virus vector carrying shRNA. Fig.3 shows the relative cell viability of Con-NCI-H82 cell and ov-NNMT NCI-H82 cell, wherein, Con-NCI-H82 refers to the cell viability of NCI-H82 cell transfected with empty virus vector without carrying NNMT gene and shRNA, which is used as control; ov-NNMT NCI-H82 10 refers to the cell viability of NCI-H82 cell transfected with virus vector carrying NNMT gene. Fig.4 shows the relative cell viability of Con-NCI-H82 cell and sh-DNMT1 NCI-H82 cell, wherein, Con-NCI-H82 refers to the cell viability of NCI-H82 cell transfected with empty virus vector without carrying NNMT gene and shRNA, which is used as control; sh-DNMT1 NCI-H82 refers to the cell viability of NCI-H82 cell transfected with virus vector carrying shRNA. 15        Fig.5 shows the expression of NNMT gene in tumor cells sensitive and insensitive to the compounds prepared in the example. Fig.6 shows the methylation level of DNA CpG site of promoter region of NNMT gene in tumor cells sensitive and insensitive to the compounds prepared in the example. Fig.7 shows the methylation level of DNA CpG sites from 1050 bp before the transcription start 20 site to 499 bp after the transcription start site in NNMT gene in tumor cells sensitive and insensitive to the compounds prepared in the example. Fig.8 shows the methylation level of DNA CpG sites from 1050 bp to 193 bp before the transcription start site in NNMT gene in tumor cells sensitive and insensitive to the compounds prepared in the example. 25        Fig.9 shows the methylation level of DNA CpG sites of specific NNMT gene (ie, site 114165695, site 114165730, site 114165769, site 114165804, site 114165938, site 114166050, site 114166066 on human chromosome 11) in tumor cells sensitive and insensitive to the compounds prepared in the example, black dot indicates that the relevant site is methylated, white dot indicates that the relevant site is not methylated, SST refers to the transcription starting site, and Chr11 refers 30 to human chromosome 11 according to human genome version GCF_ 00000 1405.25 (GRCh37. p13). Fig.10 shows the expression of NNMT gene in brain tumor cells sensitive and insensitive to the compounds prepared in the example. Fig.11 shows the methylation level of DNA CpG site of promoter region of NNMT gene in 35 brain tumor cells sensitive and insensitive to the compounds prepared in the example. Fig.12 shows the methylation level of DNA CpG sites from 1050 bp before the transcription start site to 499 bp after the transcription start site in NNMT gene in brain tumor cells sensitive and insensitive to the compounds prepared in the example. Fig.13 shows the methylation level of DNA CpG sites from 1050 bp to 193 bp before the 40 transcription start site in NNMT gene in brain tumor cells sensitive and insensitive to the compounds prepared in the example. Fig.14 shows the correlation between the expression of NNMT and the expression of DNMT1, UHRF1, DNMT3a and DNMT3b in tumor cells. 45     EMBODIMENTS FOR CARRYING OUT THE INVENTION Based on an extensive and intensive research, the inventors have unexpectedly developed a compound, the compound has excellent precision treatment effect on tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site 50 of NNMT gene. The expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene can be used as a marker for determining whether the compound of present invention is suitable for use in the prevention and / or treatment of patient tumor. On this basis, the inventors has completed the present invention. Terms Unless otherwise defined, the meanings of all technical and scientific terms used in the invention are the same as those generally understood by the skilled in the art. As used herein, the term "comprise", " comprising", and "containing" are used interchangeably, which not only comprise open definitions, but also semi-closed and closed definitions. In other words, the term comprises "consisting of" and "essentially consisting of". As used herein, the term “anti-tumor cancer” and “anti-tumor drug” are used interchangeably. As used herein, the term “cancer” and “tumor” are used interchangeably. As used herein, the term “high methylation level of DNA CpG site”, “high level of DNA CpG site methylation” and “high methylation of DNA CpG site” are used interchangeably. As used herein, the term “low methylation level of DNA CpG site”, “low level of DNA CpG site methylation” and “low methylation of DNA CpG site” are used interchangeably. As used herein, the term “high methylation level of nucleotide site”, “high level of nucleotide site methylation” and “high methylation of nucleotide site” are used interchangeably. As used herein, the term “low methylation level of nucleotide site”, “low level of nucleotide site methylation” and “low methylation of nucleotide site” are used interchangeably. As used herein, the term "IC50" and "IC50" are used interchangeably, which refers to 50% inhibiting concentration, ie, the concentration of the inhibitor when 50% inhibitory effect is achieved. As used herein, the term “methylation of CpG site", "methylation of CpG nucleotide" and "CpG methylation" are used interchangeably. As used herein, the term "P / S" refers to adding penicillin and streptomycin into the culture medium. As used herein, the term "a cell" refers to a cell (e.g., single tumor cell) or a group of cells containing multiple similar cells ((e.g., a tumor tissue). As used herein, “the compound of present invention is suitable for use in the prevention and / or treatment of patient tumor” comprises “patient tumor is sensitive to compound of present invention”. As used herein, “the compound of present invention is not suitable for use in the prevention and / or treatment of patient tumor” comprises “patient tumor is not sensitive to compound of present invention”. As used herein, “the expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene” refers to one or more of the expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene and the methylation level of DNA CpG site of NNMT gene. As used herein, “the low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene” refers to one or more of the low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene and high methylation level of DNA CpG site of NNMT gene. As used herein, “the high expression of NNMT gene, low expression of DNA methylase, low expression of UHRFl, low methylation level of nucleotide site of NNMT gene, and / or low methylation level of DNA CpG site of NNMT gene” refers to one or more of the high expression of NNMT gene, low expression of DNA methylase, low expression of UHRFl, low methylation level of nucleotide site of NNMT gene and low methylation level of DNA CpG site of NNMT gene. As used herein, the term "NNMT" refers to Nicotinamide N-Methyltransferase. As used herein, the term "bp" refers to base pair. 2026242260   02 Oct 2026 As used herein, the term "SST" refers to the transcription start site. As used herein, the term "Chr11" refers to human chromosome 11 according to human genome version GCF_ 000001405.25 (GRCh37. p13). As used herein, the term “human chromosome 11” refers to human chromosome 11 according 5 to human genome version GCF_ 000001405.25 (GRCh37. p13). As used herein, the terms "before the transcription start site" and "after the transcription start site" do not comprise the transcription start site itself. As used herein, the terms “site 114165695 on human chromosome 11” refers to nucleotide of site 114165695 on human chromosome 11; “site 114165730 on human chromosome 11” refers to 10 nucleotide of site 114165730 on human chromosome 11; “site 114165769 on human chromosome 11” refers to nucleotide of site 114165769 on human chromosome 11; “site 114165804 on human chromosome 11” refers to nucleotide of site 114165804 on human chromosome 11; “site 114165938 on human chromosome 11” refers to nucleotide of site 114165938 on human chromosome 11; “site 114166050 on human chromosome 11” refers to nucleotide of site 114166050 on human 15 chromosome 11; “site 114166066 on human chromosome 11” refers to nucleotide of site 114166066 on human chromosome 11. As used herein, the gene expression comprises the protein expression of the gene and / or the mRNA expression of the gene. As used herein, the term "DNMT3a" and "DNMT3A" are used interchangeably, which refers to 20 DNA methyltransferase 3a. As used herein, the term "DNMT3b" and "DNMT3B" are used interchangeably, which refers to DNA methyltransferase 3b. As used herein, the term "DNMT1" refers to DNA methyltransferase 1. As used herein, the term "UHRF1" refers to ubiquitin-like with PHD and ring finger domain 1. 25       As used herein, the term "MS-ESI" refers to Electro Spray Ionization-Mass Spectroscopy. As used herein, the term "1H NMR" and "1H NMR" are used interchangeably, which refers to H Nuclear Magnetic Resonance Spectra. It should be understood that the skilled in the art can choose the substituents and substituted forms on the compound of the present invention to obtain chemically stable compounds, the 30 compound can be synthesized by the techniques known in the art and the methods described below. If the compound is substituted by more than one substituents, it should be understood that the substituents can be on the same carbon or different carbons, as long as a stable structure is obtained. As used herein, the term "substitute" or "substituted" means the hydrogen atom on the group is substituted by non-hydrogen atom group, but it needs to meet its valence requirements and the 35 substituted compound is chemically stable, that is, the substituted compound does not spontaneously undergo transformations such as cyclization and elimination, etc. As used herein, the term "deuterated" refers to one or more hydrogen atoms in a compound or group are substituted by deuterium. The deuterated can be mono-substituted, di-substituted, multisubstituted or fully-substituted. 40       As used herein, the term "solvate" refers to a complex formed by the coordination of a compound with a solvent molecule in a specific ratio. As used herein, "R1", "R1" and "R1" have the same meaning and can be used interchangeably, the other similar definitions have the same meaning. As used herein, "jwv" denotes the linking site of the group. 45       As used herein, the term "alkyl" refers to a saturated hydrocarbon group with linear chain (ie, unbranched chain) or branched chain, or a combination of linear and branched chains, the alkyl only have carbon and hydrogen atoms. When the number of carbon atoms is limited in front of the alkyl (e.g., C1-C6 alkyl), it refers to the number of carbon atoms (e.g., 1-6) in the alkyl, for example, C1-C4 alkyl refers to an alkyl having 1-4 carbon atoms. Representative examples comprise but are not 50 limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, or the like. As used herein, the term "alkylidene" refers to a group formed by removing one hydrogen on 2026242260   02 Oct 2026 the alkyl, the alkyl is as defined above. When the number of carbon atoms is limited in front of the alkylidene (e.g., C1-C6 alkylidene), it refers to the number of carbon atoms (e.g., 1-6) in the alkylidene, for example, C1-C4 alkylidene refers to an alkylidene having 1-4 carbon atoms. Representative examples comprise but are not limited to methylidene, ethylidene, propylidene, 5 isopropylidene, butylidene, isobutylidene, sec-butylidene, tert-butylidene, or the like. As used herein, the term "alkenyl" refers to a hydrocarbon group formed by the loss of one hydrogen atom connected to the double bond in linear or branched alkene with one or more double bonds. When the number of carbon atoms is limited in front of the alkenyl (e.g., C2-C6 alkenyl), it refers to the number of carbon atoms (e.g., 1-6) in the alkenyl, for example, C2-C4 alkenyl refers to 10 an alkenyl having 2-4 carbon atoms in the alkenyl. Representative examples comprise but are not limited to ethylenyl (e.g.,CH2=CH-), butenyl (e.g.,C (CH3) 2=CH-), or the like. As used herein, the term "halogen" refers to F, Cl, Br or I. As used herein, the term "halo" means the group is substituted by halogen. As used herein, the term "haloalkyl" means that one or more (preferably 1, 2, 3 or 4) hydrogens 15 on the alkyl are substituted by halogen, the alkyl and halogen are as defined above. When the number of carbon atoms is limited in front of the haloalkyl (e.g., C1-C8 haloalkyl), it refers to the number of carbon atoms (e.g., 1-8) in the haloalkyl, for example, C1-C6 haloalkyl refers to an haloalkyl having 1-6 carbon atoms. Representative examples comprise but are not limited to -CF3, -CHF2, monofluoroisopropyl, difluorobutyl, or the like. 20       As used herein, the term "cycloalkyl" refers to a cyclic group having a saturated or partially saturated monocyclic ring, bicyclic ring or polycyclic ring (fused ring, bridged ring or spiro ring). When the number of carbon atoms is limited in front of the cycloalkyl (e.g., C3-C12 cycloalkyl), it refers to the number of ring carbon atoms (e.g., 3-12) in the cycloalkyl. For example, C3-C8 cycloalkyl refers to a saturated or partially saturated monocycloalkyl or dicycloalkyl having 3-8 ring 25 carbon atoms, comprising cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, or the like. The term "spirocycloalkyl" refers to a bicyclic or polycyclic group that shares a carbon atom (referred to spiroatom) between single rings, the spirocycloalkyl can contain one or more double bonds, but no ring has a fully conjugated n electron system. Fused cycloalkyl refers to all carbon bicyclic or polycyclic group in which each rings in the system shares an adjacent pair of carbon atoms with other rings, 30 one or more rings can have one or more double bonds, but no ring has a fully conjugated n electron system. Bridged cycloalkyl refers to all carbon polycyclic group in which any two rings share two non-directly connected carbon atoms, the bridged cycloalkyl can have one or more double bonds, but no ring has a fully conjugated n electron system. The representative examples of cycloalkyl comprise but are not limited to ? P P P KO W w A 35                                                                                                 . As used herein, the term "halocycloalkyl" means that one or more (preferably 1, 2, 3 or 4) hydrogens on cycloalkyl are substituted by halogen, the cycloalkyl and halogen are as defined above, When the number of carbon atoms is limited in front of the halocycloalkyl (e.g, C3-C8 halocycloalkyl), it refers to the number of ring carbon atoms (e.g., 3-8) in the halocycloalkyl, for 40 example, C3-C8 halocycloalkyl refers to an halocycloalkyl having 3-8 ring carbon atoms. Representative examples comprises but are not limited to monofluorocyclopropyl, monochlorocyclobutyl, monofluorocyclopentyl, difluorocycloheptyl, or the like. As used herein, the term "alkoxyl" refers to R-O- group, wherein R is alkyl, the alkyl is as defined above. When the number of carbon atoms is limited in front of the alkoxyl, for example, C1-45 C8 alkoxyl means that the alkyl in the alkoxyl has 1-8 carbon atoms. Representative examples of -79- 2026242260   02 Oct 2026 alkoxyl comprise but are not limited to methoxyl, ethoxyl, n-propoxyl, isopropoxyl, tert-butoxyl, or the like. As used herein, the term "alkylthio" refers to R-S- group, wherein R is alkyl, the alkyl is as defined above. When the number of carbon atoms is limited in front of the alkylthio, for example, 5 C1-C8 alkylthio means that the alkyl in the alkylthio has 1-8 carbon atoms. Representative examples of alkylthio comprise but are not limited to methylthio, ethylthio, n-propylthio, isopropylthio, tertbutylthio, or the like. As used herein, the term "haloalkoxyl" refers to haloalkyl-O-, wherein the haloalkyl is as defined above, for example, C1-C6 haloalkoxyl refers to a haloalkoxyl having 1-6 carbon atoms. 10 Representative examples comprise but are not limited to monofluoromethoxyl, monofluoroethoxyl, bisfluorobutoxyl, or the like. As used herein, the term "haloalkylthio" refers to haloalkyl-S-, wherein the haloalkyl is as defined above, for example, C1-C6 haloalkylthio refers to a haloalkylthio having 1-6 carbon atoms. Representative examples of haloalkylthio comprise but are not limited to monofluoromethylthio, 15 monofluoroethylthio, difluorobutylthio, or the like. As used herein, the term "cycloalkoxyl" refers to R-O-, wherein R is cycloalkyl, the cycloalkyl is as defined above. When the number of carbon atoms is limited in front of the cycloalkoxyl, for example, C3-C8 cycloalkoxyl means that the cycloalkyl in the cycloalkoxyl has 3-8 ring carbon atoms. Representative examples of cycloalkoxyl comprise but are not limited to cyclopropyloxyl, 20 cyclobutoxyl, or the like. As used herein, the term "cycloalkylthio" refers to R-S- group, wherein R is cycloalkyl, the cycloalkyl is as defined above. When the number of carbon atoms is limited in front of the cycloalkylthio, for example, C3-C8 cycloalkylthio means that the cycloalkyl in the cycloalkylthio has 3-8 ring carbon atoms. Representative examples of cycloalkylthio comprise but are not limited 25 to cyclopropylthio, cyclobutythio, or the like. As used herein, the term "halocycloalkoxyl" means that one or more (preferably 1, 2, 3 or 4) hydrogens on the cycloalkoxyll are substituted by halogen, the cycloalkoxyl and halogen are as defined above. When the number of carbon atoms is limited in front of the halocycloalkoxyl (e.g., C3-C8 halocycloalkoxyl), it refers to the number of ring carbon atoms (e.g., 3-8) in the 30 halocycloalkoxyl, for example, C3-C8 halocycloalkoxyl refers to an halocycloalkoxyl having 3-8 ring carbon atoms. Representative examples comprises but are not limited to monofluorocyclopropyl-O-,       monochlorocyclobutyl-O-,       monofluorocyclopentyl-O-, difluorocycloheptyl-O -, or similar functional groups, or the like. As used herein, the term "halocycloalkylthio" means that one or more (preferably 1, 2, 3 or 4) 35 hydrogens on the cycloalkoxyll are substituted by halogen, the cycloalkoxyl and halogen are as defined above. When the number of carbon atoms is limited in front of the halocycloalkylthio (e.g., C3-C8 halocycloalkylthio), it refers to the number of ring carbon atoms (e.g., 3-8) in the halocycloalkylthio, for example, C3-C8 halocycloalkylthio refers to an halocycloalkylthio having 3-8 ring carbon atoms. Representative  examples comprises but are not limited to 40 monofluorocyclopropyl-S-,        monochlorocyclobutyl-S-,        monofluorocyclopentyl-S-, difluorocycloheptyl-S-, or similar functional groups, or the like. As used herein, the term "heterocycloalkane ring" refers to fully saturated or partially unsaturated ring (comprising but not limited to such as 3-7 membered monocyclic ring, 7-11 membered bicyclic ring, or 8-16 membered tricyclic ring), at least one heteroatom is present in a 45 ring with at least one carbon atom. When the number of members is limited in front of the heterocycloalkane ring, it refers to the number of ring atoms in the heterocycloalkane ring, for example, 3-16 membered heterocycloalkane ring refers to a heterocycloalkane ring having 3-16 ring atoms. Each heterocyclic ring having heteroatoms can have one or more (e.g., 1, 2, 3 or 4) heteroatoms, each of heteroatoms is independently selected from the group consisting of nitrogen 50 atom, oxygen atom or sulfur atom, wherein the nitrogen atom or sulfur atom can be oxidized, and the nitrogen atom can also be quaternized. Representative examples of monocyclic 2026242260   02 Oct 2026 heterocycloalkane ring comprise but are not limited to azetidine ring, oxetane ring, tetrahydrofuran ring, piperidine ring, piperazine ring. Polycyclic heterocycloalkane ring comprises spiro, fused and bridged ring, the spiro, fused and bridged heterocycloalkane ring is optionally linked with other rings by single bond, or further linked with other cycloalkane ring and heterocycloalkane ring by any two 5 or more atoms on the ring. As used herein, the term "heterocycloalkyl" refers to fully saturated or partially unsaturated cyclic (comprising but not limited to such as 3-7 membered monocyclic ring, 7-11 membered bicyclic ring, or 8-16 membered tricyclic ring) group, at least one heteroatom is present in a ring with at least one carbon atom. When the number of members is limited in front of the 10 heterocycloalkyl, it refers to the number of ring atoms in the heterocycloalkyl, for example, 3-16 membered heterocycloalkyl refers to a heterocycloalkyl having 3-16 ring atoms. Each heterocyclic ring having heteroatoms can have one or more (e.g., 1, 2, 3 or 4) heteroatoms, each of heteroatoms is independently selected from the group consisting of nitrogen atom, oxygen atom or sulfur atom, wherein the nitrogen atom or sulfur atom can be oxidized, and the nitrogen atom can also be 15 quaternized. Representative examples of monocyclic heterocycloalkyl comprise but are not limited to azetidinyl, oxetanyl, tetrahydrofuranyl, piperidinyl, piperazinyl. Polycyclic heterocycloalkyl comprises spiro, fused and bridged heterocyclyl, the spiro, fused and bridged heterocycloalkyl is optionally linked with other groups by single bond, or further linked with other cycloalkane rings and heterocycloalkane ring by any two or more atoms on the ring. 20        As used herein, the term "aryl" refers to an full carbon monocyclic ring or fused polycyclic ring (i.e., a ring that shares adjacent carbon atom pairs) group with a conjugated n electron system, which is aromatic cyclic hydrocarbon compound group. When the number of carbon atoms is limited in front of the aryl, for example, C6-C12 aryl means that the aryl has 6-12 ring carbon atoms, such as phenyl and naphthyl. 25        As used herein, the term "heteroaryl" refers to aromatic heterocyclic ring group having one to more (preferably 1, 2, 3 or 4) heteroatoms, the heteroaryl can be monocyclic ring, or polycyclic ring (bicyclic, tricyclic or polycyclic ring) fused together or covalently connected. Each of heterocyclic ring having heteroatom can have one or more (e.g., 1, 2, 3, 4) heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen. When the number of members is limited 30 in front of the heteroaryl, it refers to the number of ring atoms of the heteroaryl, for example, 5-12 membered heteroaryl refers to a heteroaryl having 5-12 ring atoms. Representative examples comprise but are not limited to pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, furanyl, pyridyl, pyrimidinyl, etc. As used herein, the term "carboxyl" refers to -COOH or -alkyl-COOH, the alkyl is as defined 35 above. For example, "C2-C4 carboxyl" refers to -C1-C3 alkyl-COOH. Representative examples of carboxyl comprise but are not limited to -COOH, -CH2COOH, or the like. As used herein, the term "ester group" refers to R-C(O)-O- or -C(O)-O-R, wherein, R is alkyl, the alkyl is defined as above. For example, "C2-C4 ester group" refers to C1-C3 alkyl-C(O)-O- or -C(O)-O-C1-C3 alkyl. Representative examples of ester group comprise but are not limited to 40   CH3C(O)O-, C2H5C(O)O-, (CH3)2CHC(O)O-, -C(O)OCH3, -C(O)OC2H5, or the like. As used herein, the term "amide group" refers to R-C(O)-N- or -C(O)-N-R , wherein, R is alkyl, the alkyl is defined as above. For example, "C2-C4 amide group" refers to C1-C3 alkyl-C(O)-N- or -C(O)-N-C1-C3 alkyl. Representative examples of amide group comprise but are not limited to CH3C(O)-N-, C2H5C(O)-N-, (CH3)2CHC(O)-N-, -C(O)-N-CH3, -C(O)-N-C2H5, or the like. o Ai 45       As used herein, the term "acyl" refers to R ^, wherein R is alkyl, the alkyl is as defined above. When the number of carbon atoms is limited in front of the acyl (e.g, C2-C6 acyl), it refers to the number of carbon atoms (e.g., 2-6) in the acyl, for example, C2-C6 acyl refers to acyl having 2-6 carbon atoms. For example, the C2-C4 acyl refers to C1-C3 alkyl -C(O)-, representative examples comprises but are not limited to CH3C(O)-, C2H5C (O)- , or the like. 2026242260   02 Oct 2026 0 Ai As used herein, the term "-C(O)-" and “     ~ ” are used interchangeably. As used alone or as part of other substituent, the term "amino" refers to -NH2. As used alone or as part of other substituent, the term 'nitro' refers to -NO2. As used alone or as part of other substituent, the term "cyano" refers to -CN. 5       As used alone or as part of other substituent, the term "hydroxyl" refers to -OH. As used alone or as part of other substituent, the term "sulfhydryl" refers to -SH. / R21 As used herein, the term "(R2oR2i)N-" and “       20 ” are used interchangeably. As used herein, “R3 and R4, or R4 and R5 are connected to form a substituted or unsubstituted 312 membered heterocycloalkane ring" means that R3 and R4 are connected to form a substituted or 10 unsubstituted 3-12 membered heterocycloalkane ring, or R4 and R5 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkane ring, and the like. In present invention, it should be understood that all substituents are unsubstituted, unless explicitly described herein as "substituted". The "substituted" means that one or more hydrogen atoms on group are substituted by a substituent. The substituent is the substituent as described above 15 or the substituent in each Example. Preferably, each "substituted" means that one or more (preferably 1, 2, 3, 4, 5, 6, 7, or 8) hydrogen atoms on the ring or group are independently substituted by substituent selected from the group consisting of C1-C10 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, carbonyl (=O), hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C8 ester group, C2-C4 20 amide group, C2-C6 acyl, C1-C10 alkoxyl, C1-C10 alkylthio, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl, (R20R21) N-. In the present invention, the term "prevention" refers to a method of preventing the occurrence of disease and / or its accompanying symptoms, or protecting a subject from getting disease. The term 25 'prevention' also comprises delaying the occurrence of disease and / or its accompanying symptoms and reducing the risk of getting disease for subject. In the present invention, the term "treatment" comprises delaying and terminating the progression of the disease, or eliminating the disease, and it does not require 100% inhibition, elimination and reversal. In some embodiments, compared to the level observed in the absence of 30 the compound of present invention, the compound of present invention alleviates, inhibits and / or reverses related disease (e.g., tumor) and its accompanying symptoms, for example, by at least about 10%, at least about 30%, at least about 50%, at least about 80%, at least about 90%, or 100%. Compound 35       As used herein, the terms "compound of the present invention", "compound of formula I of the present invention" and "compound of formula I" are used interchangeably, and refer to a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof. It should be understood that the term also comprises a mixture of the above components. 2026242260   02 Oct 2026 I Specifically, the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof is 5 as described above in the first aspect of the present invention. In the present invention, the configuration of the compound of formula I can be racemate, R configuration (rectus) or S configuration (sinister). The structure and determination method of the racemate, R configuration (rectus) or S configuration (sinister) of the compound of the present invention are well known to the skilled in the art. For example, the structure of the racemate, R 10 configuration (rectus) or S configuration (sinister) of a compound is as follows: racemate R configuration (rectus) or S configuration (sinister) J Li <    '^''O 1 0 vUvN >-'Cci3 o^\                          ii JL o d / tr 1     । A 1 0    O \ 2026242260   02 Oct 2026 amino acid such as aspartic acid and glutamic acid. A preferred type of salt is a metal salt formed by the compound of the present invention and a base. Bases suitable for salt formation comprise but are not limited to inorganic base such as sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, sodium phosphate and the like; and organic base such as ammonia, 5 triethylamine, diethylamine and the like. The compound of formula I in present invention can be converted into its pharmaceutically acceptable salt using conventional methods. For example, a solution of corresponding acid can be added into the solution of above compounds, and the solvent is removed after the salt is formed, thereby forming the corresponding salt of the compound of the present invention. 10        The compounds of the present invention is preferably prepared as described in the Examples of the present invention. NNMT gene In the present invention, the English name of NNMT is Nicotinamide N-Methyltransferase. 15 Different databases have different identification numbers for NNMT gene as follows: HGNC: 7861; Entrez Gene: 4837; Ensembl: ENSG00000166741; OMIM: 600008; UniProtKB: P40261 According to version GCF_000001405.25 (GRCh37.p13) of human genome, the NNMT gene is located at 114,128,528 bp to 114,184,258 bp on human chromosome 11, the total length of DNA sequence of NNMT gene is 55,731 bp, the NNMT gene comprises promoter region, exon region and 20 intron region, the transcription start site of NNMT gene is at site 114,166,535 bp. The promoter region of NNMT gene is the nucleotide sequence from the 114164535 bp to 114167034 bp on human chromosome 11, i.e. the sequence from 2000 bp before the transcription start site (bold section) and 499 bp after the transcription start site (non-bold section) in NNMT gene, the total length of promoter region of NNMT gene is 2500 bp, The nucleotide sequence of the 25 promoter region of NNMT gene is as shown in SEQ ID NO: 1 as follows: SEQ ID NO: 1: TATCCAAGAGCTATCAGCACTCCCATGTTTATTGTAGCACTGTTCACAATAGC CAAGATTTGGAAGTACTCTAAGTGTCCATTAGCAGATGAATGGATAAAGACAATG TGGTAATACACATAATGGAGTACTATTCAGTCATAAAGAAGAATTAGATCCTGTC 30 ATTTGCAATAACATGGATGGAACTGGAGGTCATAATGTTGAGTGAAATAAACCAG GCACAGAAAGACAAACTTTGCATGTTCTCACTTATTTATGGGAGCTAAAAACTAA AATAACTGAACTCACAGAGATAGAGAGTAGAAGGATGGTTACGAGAGGATGGGA AGGGTAGCGAGGTGGGTAGGGGGGATGTGGGGATCATTAATGGGTATAAAAAAT AGTTAGAGGCCAGGCGCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGC 35 CGAGGTAGGCGGAACACCTGAGGAGTTCAAGACCAGCCTGGCCAATATGATGAA ACCCCGTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGATGGTGTGCACCTGT AGTCCCAGCTGCTTGGGAGGCTGAGGCAGGAGAATCGCTGGAACCCAAGAGGTG AAGGTTGCAGTGAGCTGAGATCGCGTCACTGCACTCCAGCCTGGGTGACAGAGT GAGACTCCACATCAAAAAAAAAAAAAAAAAGTTAGAAAGATTGAATAAGACCTAA 40 TATTTGCTAGCACAACAGGGTGAATATAGTAAAAAATAATTTATTTGTACCTTCA AAAATAACTAGACAAGTATAATTGGGTTGTTTGTAACACACAAAAAATAAGTACT TGAAGTGGTGGATACCCCATTTACCCTGATGTGATTATTTTGTATTGCAGGCCTC TATCAGAATATCTCATGTAACCCATAAATATATACACCTACTCTGTACCCACAAAA AGTTTTTAAAAAGAAAAATAAATAGCAACCGAAAAAAAAAGAGAGGGAGAAAAG 45 AAAAAAGAAAAAAAAATCAAGTGCCTGGCTGGGTAGAATAAATTCTAAGGCCAC AATGTTACTGACCATGGGTTTTTTGGCTCTCAGTGTATAGAAATTGACACAAGGC CAATAGTCTTCCCAAACATGCTTTACTGGAACTTACGCCCTGGCATAAGGGCCAC AACAAAAGAGAGAGCGAATTCTCTGGCTTGCTGACTCCTTGGAAAAAACCGGTA GGGATTTTTTTATTAGGCAAAGCACAGGAATTGACGTCAGAGGCAGGATGTGCT 50 GCTGGGCAAAGCATACGAGAAGTGGGGTATGCAGGTCAGCATTACTTGGTTGCA ATGGTTATCTTGAGGAATGGGCCAACTGGTGGTCTGGCCAGTGGCAACAAGGCT 2026242260   02 Oct 2026 GTAAATCAATTATTCAGCATTCCTTCCCAAGGTGGGACACCCGGCAACATTGTTT ATCTCCTAAGGCCAGTTCCTGGAATTAAGTGAAAGGATGACTAATGGACATGTTG TCAGTGAGGTAGTGGTGTGGGTTTTGTGACCAGTGGGAATGCACGAAAGAATGC TTTAGCGGGGAGTGAGCTGAAGCCAAGCCCCATCCCTACTCTGTCTCAAAGTGA 5 GTTCAGAAAAGGGGATTTAAAGAATTCTTTTTTTTTTTTTTTTTTTTTTTGAGACA GAGTCTTGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCGCCATCTTGGCTCACTG CAAGCTCCGCCCCCCGGGTTCATGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCT GGGACTGCAGGTGCCTACCACCAAGCCCAGCTAATTTTTTGTATTTTTTTTTTAG TAGAGACGGGGTTTCACCATGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTG 10 ATCTGCCCGCCTTAGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCTCCGCC CCCGGCCTTAAATAATTCTTAAAGGAAGTAAAGTTAACTTTGAAAGAACTATCAG GATTTGGATTGACTGAAAGGAGTGGGGAAGCTTAGGGAGGAGGTGCTTGCCAGAC ACTGGGTCATGGCAGTGGTCGGTGAAGCTGCAGTTGCCTAGGGCAGGGATGGAGAGA GAGTCTGGGCATGAGGAGAGGGTCTCGGGATGTTTGGCTGGACTAGATTTTACAGAA 15 AGCCTTATCCAGGCTTTTAAAATTACTCTTTCCAGACTTCATCTGAGACTCCTTCTTCA GCCAACATTCCTTAGCCCTGAATACATTTCCTATCCTCATCTTTCCCTTCTTTTTTTTCC TTTCTTTTACATGTTTAAATTTAAACCATTCTTCGTGACCCCTTTTCTTGGGAGATTCAT GGCAAGAACGAGAAGAATGATGGTGCTTGTTAGGGGATGTCCTGTCTCTCTGAACTTT GGGGTCCTATGCATTAAATAATTTTCCTGACGAGCTCAAGTGCTCCCTCTGGTCTACAA 20 TCCCTGGCGGCTGGCCTTCATCCCTTGGGCAAGCATTGCATACAGCTCATGGCCCTCCC TCTACCATACCC. In the present invention, the nucleotide sites from 1050 bp before the transcription start site to 499 bp after the transcription start site in NNMT gene is sites 951-2500 of nucleotide sequence as shown in SEQ ID NO: 1. 25        In the present invention, the nucleotide sites from 1050 bp to 193 bp before the transcription start site in NNMT gene is sites 951-1808 of nucleotide sequence as shown in SEQ ID NO: 1. In the present invention, the nucleotide sites from 840 bp to 469 bp before the transcription start site in NNMT gene is sites 1161-1532 of nucleotide sequence as shown in SEQ ID NO: 1. In present invention, the site 114165695, site 114165730, site 114165769, site 114165804, 30 site 114165938, site 114166050 and site 114166066 on the human chromosome 11 correspond to the nucleotide site in SEQ ID NO: 1 as shown in Table 1: Table 1 Site on the human chromosome 11 Corresponding to the nucleotide site in SEQ ID NO: 1 site 114165695 site 1161 site 114165730 site 1196 site 114165769 site 1235 site 114165804 site 1270 site 114165938 site 1404 site 114166050 site 1516 site 114166066 site 1532 DNA methylation 35       DNA methylation is a form of chemical modification of DNA, which can change genetic performance under no change of DNA sequence. Many studies have shown that DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability and the way DNA interacts with protein, thereby regulating gene expression. DNA methylation is one of the earliest discovered and most deeply studied epigenetic 40 regulatory mechanisms. Broadly speaking, DNA methylation refers to the chemical modification process in which a specific base in the DNA sequence is modified with a methyl by covalent bonding 2026242260   02 Oct 2026 with S-adenosyl methionine (SAM) as methyl donor under the catalysis of DNA methyltransferase (DNMT). This DNA methylation can occur at position C-5 of cytosine, position N-6 of adenine and position N-7 of guanine. DNA methylation in general studies mainly refers to the methylation process that occurs at the carbon atom of position C-5 on cytosine in CpG dinucleotides, the product 5 is called 5-methylcytosine (5-mC). The 5-methylcytosine (5-mC) is the main form of DNA methylation in eukaryotic organisms such as plants and animals. DNA methylation, as a relatively stable modification state, can be passed on to new generations of DNA during DNA replication process under the action of DNA methyltransferase, which is an important epigenetic mechanism. There are two types of DNA methylation reactions. One type is that the two unmethylated 10 strands in the DNA are methylated, which is called denovo methylation; the other type is that the unmethylated strand of double-stranded DNA with one methylated strand and one unmethylated strand is methylated, which is called maintenance methylation. Typically, DNA methylation is the methylation of DNA CpG site. The distribution of CpG binucleotide is very uneven in the human genome, while CpG remains or is higher than normal level 15 in some regions of the genome. The CpG site rich region (also known as CpG island) is mainly located in the promoter region and exon regions of the gene, which is a region rich in CpG dinucleotide. About 60% of the promoters of the gene contains CpG island. The CpG is the abbreviation of cytosine (C)-phosphate (p)-guanine (G). Gene expression is regulated by various signaling pathways, transcription factors and 20 epigenetic modifications in the cell. DNA methylation modification is an important way in which epigenetic modifications regulate gene expression. The level of DNA methylation in a specific gene region often affects the expression level of the gene. Compared to the regulation of gene expression by signal transduction pathways and transcription factors, the effect of DNA methylation modification on gene expression is more stable in epigenetic modification, which is not easily 25 affected by the extracellular environment. DNA methylation modification can be easily and accurately detected using existing technologies, so the DNA methylation is an ideal biomarker. Tumor The studies of the present invention shows the compound of present invention can be used for 30 preventing and / or treating tumor. As used herein, the term "tumor" and "cancer" are used interchangeably. In a preferred embodiment of the present invention, the tumor comprises tumor with low or no expression of NNMT gene. Typically, the tumor with low or no expression of NNMT gene is as described above in the third aspect of the present invention. 35        In a preferred embodiment of the present invention, the tumor comprises tumor with high expression of DNA methylase. Typically, the tumor with high expression of DNA methylase is as described above in the third aspect of the present invention. The DNA methylase of present invention comprises but is not limited to DNMT1, DNMT3a, DNMT3b, and combinations thereof. Preferably, the DNA methylase comprises DNMT1. 40        In a preferred embodiment of the present invention, the tumor comprises tumor with high expression of DNMT1. Typically, the tumor with high expression of DNMT1 is as described above in the third aspect of the present invention. In a preferred embodiment of the present invention, the tumor comprises tumor with high expression of DNMT3a. Typically, the tumor with high expression of DNMT3a is as described 45 above in the third aspect of the present invention. In a preferred embodiment of the present invention, the tumor comprises tumor with high expression of DNMT3b. Typically, the tumor with high expression of DNMT3b is as described above in the third aspect of the present invention. In a preferred embodiment of the present invention, the tumor comprises tumor with high 50 expression of UHRF1(ubiquitin-like with PHD and ring finger domain 1). Typically, the tumor with high expression of UHRF1 is as described above in the third aspect of the present invention. In a preferred embodiment of the present invention, the tumor comprises tumor with high methylation level of nucleotide site of NNMT gene. Typically, the tumor with high methylation level of nucleotide site of NNMT gene is as described above in the third aspect of the present invention. In a preferred embodiment of the present invention, the tumor comprises tumor with high 5 methylation level of DNA CpG site of NNMT gene. Typically, the tumor with high methylation level of DNA CpG site of NNMT gene is as described above in the third aspect of the present invention. Typically, the tumor of present invention is as described above in the third aspect of the present invention. 10       In present invention, the type of tumors corresponding to tumor cell lines are shown in Table 2 2026242260   02 Oct 2026 Table 2 Tumor cell line The corresponding type of tumor NCI-H82 Human small cell lung cancer cell G-401 Human renal carcinoma Wilms cell MDA-MB-453 Breast cancer cell SW48 Human colon adenocarcinoma cell GB-1 Human brain glioblastoma cell CFPAC-1 Human pancreatic cancer cell SF126 Human glioblastoma multiforme cell 786-O Clear cell renal cell adenocarcinoma cell D341 Med Cerebellar medulloblastoma cell Kelly Brain neuroblastoma cell NB-1 Brain neuroblastoma cell Anti-tumor drug The anti-tumor drug can be the compound of formula I, or an optical isomer thereof, or a 15 racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of the present invention. Use A use of the compound of formula I of the present invention for preventing and / or treating 20 tumor is provided. Specifically, the compound of present invention has remarkable and excellent prevention and treatment effect on tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene. That is, the tumor with low or no 25 expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene is sensitive to the compound of the present invention. The expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene 30 can be used as a marker for determining whether the compound of the present invention is suitable for use in the precision treatment on tumor, the biomarker can be used to effectively identify patient tumor sensitive to the compound of the present invention, improve treatment effects and avoid administrating the compound of the present invention to patient tumor insensitive to the compound of the present invention, thereby achieving precision treatment on tumor. 35        The present invention further provides a method for preventing and / or treating tumor, which comprises administering the compound of the present invention to a subject in need. 2026242260   02 Oct 2026 The compound of present invention has more remarkable and excellent prevention and treatment effect on tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene, therefore, during the prevention 5 and / or treatment of tumor, firstly administering NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene to achieve low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene in the subject tumor, 10 then administering the compound of the present invention to prevent and / or treat tumor. Therefore, the present invention develops a compound that can significantly enhance anti-tumor effects when combined with NNMT gene inhibitor, DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene. The compound of the present invention can be combined with NNMT gene inhibitor, 15 DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene to significantly enhance the treatment effect of the compound on tumor. In another preferred embodiment, the subject is human and non-human mammals (rodent, rabbit, monkey, livestock, dog, cat, etc.). 20        In the present invention, there are no special limitations to the method for achieving low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene in the tumor. For example, the low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT 25 gene, and / or high methylation level of DNA CpG site of NNMT gene in the tumor can be specifically achieved using methods such as gene insertion, gene knockout, or gene silencing (e.g, shRNA transfection), etc. Marker 30        The present invention provides a marker for determining whether the compound of present invention is suitable for use in the prevention and / or treatment of patient tumor, the marker comprises the expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene. 35        In a preferred embodiment, the expression level of NNMT gene, the expression level of DNA methylase, the expression level of UHRF1, the methylation level of nucleotide site of NNMT gene, and / or the methylation level of DNA CpG site of NNMT gene are used as a marker for determining whether the compound of present invention is suitable for use in the prevention and / or treatment of patient tumor, the method comprises as follows: 40        the compound of present invention is suitable for use in the prevention and / or treatment of patient tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene; and / or the compound of present invention is not suitable for use in the prevention and / or treatment of 45 patient tumor with high expression of NNMT gene, low expression of DNA methylase, low expression of UHRFl, low methylation level of nucleotide site of NNMT gene, and / or low methylation level of DNA CpG site of NNMT gene. Specifically, the tumor with low or no expression of NNMT gene, high expression of DNA methylase (e.g, NNMT1), high expression of UHRFl, high methylation level of nucleotide site of 50 NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene is as described above in the third aspect of the present invention. 2026242260   02 Oct 2026 In a preferred embodiment, the tumor with high expression of NNMT gene, low expression of DNA methylase (e.g, NNMT1), low expression of UHRFl, low methylation level of nucleotide site of NNMT gene, and / or low methylation level of DNA CpG site of NNMT gene is as described above in the fourth aspect of the present invention. 5        The present invention further provides a use of the marker (or the expression level of marker) or its detection reagent in the preparation of reagent kit for determining whether the compound of the present invention is suitable for use in the prevention and / or treatment of patient tumor. Composition or preparation, active ingredient combination, medical kit and 10 administration method Preferably, the composition of the present invention is pharmaceutical composition. The compositions of the present invention can comprise a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" refers to one or more compatible solid, semisolid, liquid or gel fillers, which are suitable for use in human or animal and must have sufficient 15 purity and sufficiently low toxicity. The "compatible" means each component and drug active ingredient in the pharmaceutical composition can be blended with each other without significantly reducing the efficacy. It should be understood that the pharmaceutically acceptable carrier is not particularly limited in the present invention, the carrier can be selected from materials commonly used in the art, or can 20 be obtained by a conventional method, or is commercially available. Some examples of pharmaceutically acceptable carriers are cellulose and its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, plant oil (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, 25 etc.), emulsifier (e.g., Tween), wetting agent (e.g., sodium lauryl sulfate), buffer agent, chelating agent, thickener, pH regulator, transdermal enhancer, colorant, flavoring agent, stabilizer, antioxidant, preservative, bacteriostatic agent, pyrogen-free water, etc. In a preferred embodiment of the present invention, the dosage form of the composition or preparation is a solid preparation, liquid preparation or semi-solid preparation. 30        In a preferred embodiment of the present invention, the dosage form of the composition or preparation is oral preparation, external preparation or injection preparation Typically, the dosage form of the composition or preparation is tablet, injection, infusion, paste, gel, solution, microsphere or film. The pharmaceutical preparation should be matched with the mode of administration. The 35 pharmaceutical preparation of the present invention can also be given together with other synergistic therapeutic drugs before, during or after the administration. When the pharmaceutical composition or preparation is administrated, a safe and effective amount of the drug is administered to a subject in need (e.g. human or non-human mammal). The safe and effective amount is usually at least about 10 Ligkg.bw, and does not exceed about 8 Ligkg.bw in most case, preferably, the dose is about 10 40 gg / kg.bw to 1 mg / kg.bw. Of course, the specific dose should also take into account the route of administration, the patient's health and other factors, which are within the skill range of skilled doctors. The main advantages of the present invention comprise: 45        1. The present has developed a compound, the compound has excellent precision treatment effect on tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene. The tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of 50 nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene is highly sensitive to the compound of present invention, ie, the compound of present invention has 2026242260   02 Oct 2026 more remarkable and excellent treatment effect on tumor with low or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene. Therefore, the compound of present invention can realize precise treatment on tumor with low or no expression of 5 NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene, thus improving the treatment effect of the compound of present invention on tumor and avoiding administrating the compound of present invention to patient tumor insensitive to such anti-tumor drug. Therefore, the precision treatment of the compound of the present invention on tumor with low 10 or no expression of NNMT gene, high expression of DNA methylase, high expression of UHRFl, high methylation level of nucleotide site of NNMT gene, and / or high methylation level of DNA CpG site of NNMT gene has advantages such a more excellent prevention and treatment effect on tumors, low drug dose, and minimal side effects, which improve the precision prevention and treatment effect on tumor, reduce the side effects and improve patient compliance. 15 The present invention will be further illustrated below with reference to the specific examples. It should be understood that the following specific Examples are based on the technical solution and provide detailed implementation methods and specific operation processes, but the scope of protection of the present invention is not limited to the Example. 20 Example DNMT3a refers to DNA methyltransferase 3a, NCBI entrez gene: 1788; Uniprotkb / Swiss-port: Q9Y6K1. DNMT3b refers to DNA methyltransferase 3b, NCBI entrez gene: 1789; Uniprotkb / Swiss-port: 25 Q9UBC3. DNMT1 refers to DNA methyltransferase 1, NCBI entrez gene: 1786; Uniprotkb / Swiss-port: P26358. UHRF1 refers to ubiquitin-like with PHD and ring finger domain 1. NNMT refers to Nicotinamide N-Methyltransferase. 30       The nucleotide sequence of the promoter region of NNMT gene was as shown in SEQ ID NO: 1. The nucleotide sites from 1050 bp before the transcription start site to 499 bp after the transcription start site in NNMT gene was sites 951-2500 of nucleotide sequence as shown in SEQ ID NO: 1. 35        The nucleotide sites from 1050 bp to 193 bp before the transcription start site in NNMT gene was sites 951-1808 of nucleotide sequence as shown in SEQ ID NO: 1. The nucleotide sites from 840 bp to 469 bp before the transcription start site in NNMT gene was sites 1161-1532 of nucleotide sequence as shown in SEQ ID NO: 1. 40       Example 1 Synthesis of compound AB31866 The structure of compound AB31866 was as follows: compound AB31866 2026242260   02 Oct 2026 The synthesis method of compound AB31866 was as follows: 1 AB31866 Compound 1 (100 mg, 0.29 mmol, 1 eq) and compound 2 (122 mg, 0.58 mmol, 2.0 eq) were dissolved in acetonitrile (4 mL), and sodium iodide (87 mg, 0.58 mmol, 2.0 eq) was added. The 5 mixture was reacted at 80 °C for 30 min under microwave condition, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB31866. 10      Compound AB31866: MS-ESI: calculated [M+H]+:512.16, Found: 512.10. 1H NMR (400 MHz, CDC13) 8 7.24 (s, 1H), 7.09 (d, J = 8.0 Hz, 2H), 7.01-6.93 (m, 4H), 6.77 (s, 1H), 6.08 (d, J = 12.0 Hz, 2H), 5.66 (d, J = 20.0 Hz, 1H), 5.06 (d, J = 20.0 Hz, 1H), 4.90-4.86 (m, 1H), 4.48-4.44 (m, 1H), 4.07-3.98 (m, 1H), 3.94 (s, 3H), 3.89 (m, 3H), 3.49-3.43 (m, 1H), 3.28-3.23 15   (m, 1H), 309-3.02 (m, 1H). Example 2 Synthesis of compound AB31870 The structure of compound AB31870 was as follows: 20                                   compound AB31870 The synthesis method of compound AB31870 was as follows: Compound 1 (100 mg, 0.29 mmol, 1 eq) and compound 2 (97 mg, 0.58 mmol, 2.0 eq) were dissolved in acetonitrile (4 mL), and sodium iodide (87 mg, 0.58 mmol, 2.0 eq) was added. The 25 mixture was reacted at 80 °C for 30 min under microwave condition, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by reversed phase preparation 2026242260   02 Oct 2026 chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB31870. Compound AB31870: MS-ESI: Calculated [M+H]+: 470.23, Found: 470.20. 1H NMR (400 MHz, CDC13) 8 7.52 (s, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.98 (d, J = 8.0 Hz, 3H), 5   6.86 (s, 1H), 6.55 (d, J = 8.0 Hz, 2H), 6.13 (s, 2H), 5.04-4.92 (m, 2H), 4.17-4.13 (m, 2H), 3.89 (s, 3H), 3.85 (m, 3H), 3.36-3.17 (m, 4H), 2.86-2.79 (m, 1H), 1.17 (d, J = 8.0 Hz, 6H). Example 3 Synthesis of compound AB31873 The structure of compound AB31873 was as follows: compound AB31873 The synthesis method of compound AB31873 was as follows: Step (1): Br2 (5 eq), HOAc 120 °C, 4 h 15                                 1                                                    2 Compound 1 (1.0 g, 2.69 mmol, 1 eq) was dissolved in acetic acid (10 mL), and bromine (2.1 g, 13.45 mmol, 5 eq) was added slowly. The mixture was reacted at 120 °C for 4 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was washed with brine once, dried 20 over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by fast chromatography (100-200 mesh silica gel, DCM / MeOH=30 / 1) to afford compound 2. MS-ESI: Calculated [M]+ 415.04, Found: 413.95. Step (2): 2 AB31873 25        Compound 2 (200 mg, 0.40 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and butylmagnesium bromide (0.4 mL, 1.2 mmol, 5 eq, 3M) was added slowly at 0 °C under N2. The mixture was reacted for 0.5 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and 30 rotary dried. The crude product was purified by thin layer chromatography (DCM:MeOH=30:1) to afford compound AB31873. Compound AB31873: 2026242260   02 Oct 2026 MS-ESI: Calculated [M+H]+: 472.11, Found: 472.10. 1H NMR (400 MHz, CDC13) 5 7.23 (s, 1H), 6.97 (s, 1H), 6.60 (s, 1H), 6.02 (s, 1H), 5.95 (d, J= 4.0 Hz, 2H), 4.70-4.67 (m, 1H), 3.86(s, 3H), 3.83 (s, 3H), 3.48-3.45 (m, 1H), 3.33-3.30 (m, 1H), 2.88-2.80 (m, 2H), 1.71-1.64 (m, 2H),1.25-1.17 (m, 4H), 0.82-078 (m, 3H). 5 Example 4 Synthesis of compound AB31880 The structure of compound AB31880 was as follows: compound AB31880 10       The synthesis method of compound AB31880 was as follows: Step (1): Compound 2 (300 mg, 0.70 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), 15 and hexylmagnesium bromide (3.5 mL, 3.50 mmol, 5 eq, 1M / L) was added slowly at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by thin 20 layer chromatography (dichloromethane: methanol=50:1) to afford compound AB31880. Compound AB31880: MS-ESI: Calculated [M+H]+: 436.24, Found: 436.20. 1H NMR (400 MHz, CDCl3) 5 7.19 (s, 1H), 6.75-6.68 (m, 2H), 6.62 (s, 1H), 5.81 (s, 1H), 4.704.67 (m, 1H), 4.26 (s, 4H), 3.87 (s, 3H), 3.84 (s, 3H), 3.46-3.45 (m, 1H), 3.31-3.29 (m, 1H), 2.8725   2.78 (m, 2H), 1.75-1.50 (m, 4H), 1.38-1.26 (m, 6H), 0.82-0.79 (m, 3H). Example 5 Synthesis of compound AB31881 The structure of compound AB31881 was as follows: 30                                   compound AB31881 The synthesis method of compound AB31881 was as follows: Step (1): 2026242260   02 Oct 2026 The compound 0 (10.0 g, 26.89 mmol, 1 eq) was added in a 500 mL eggplant-shaped flask, and heated at 190 C for 8 h under vacuum, the reaction was detected to be performed completely using LCMS to afford compound 1. 5        MS-ESI: Calculated [M]+: 322.11, Found: 322.30. Step (2): Compound 1 (500 mg, 1.40 mmol, 1 eq) and compound 1 (642 mg, 2.80 mmol, 2.0 eq) were dissolved in acetonitrile (10 mL). The mixture was reacted at 80 C for overnight under N2, and the 10 reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by fast chromatography (100-200 mesh silica gel, DCM / MeOH=50 / 1) to afford compound 3. MS-ESI: Calculated [M]+: 470.20, Found: 470.10. 15         Step (3): Compound 3 (200 mg, 0.36 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.6 mL, 1.8 mmol, 5 eq, 3M) was added slowly at 0 C under N2. The mixture was reacted for 0.5 h, and the reaction was detected to be performed completely using 20 LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by thin layer chromatography (DCM:MeOH=30:1) to afford compound AB31881. Compound AB31881: 25        MS-ESI: Calculated [M+H]+: 486.22, Found: 486.20. 1H NMR (400 MHz, CDC13) 5 7.31-7.27 (m, 2H), 7.16 (s, 1H), 6.96-6.92 (m, 3H), 6.73 (s, 2H), 6.59 (s, 1H), 5.94 (s, 2H), 5.86 (s, 1H), 4.87-4.82 (m, 1H), 4.20-4.14 (m, 1H), 4.10-4.07 (m, 3H), 3.82 (s, 3H), 3.42-3.36 (m, 1H), 3.21-3.18 (m, 1H), 2.95-2.88 (m, 1H), 2.78-2.74 (m, 1H), 2.06-1.98 (m, 4H), 1.18 (d, J= 8.0 Hz, 3H). 30 Example 6 Synthesis of compound AB31887 The structure of compound AB31887 was as follows: 2026242260   02 Oct 2026 compound AB31887 The synthesis method of compound AB31887 was as follows: Step (1): 10 The compound 0 (10.0 g, 26.89 mmol, 1 eq) was added in a 500 mL eggplant-shaped flask, and heated at 190 C for 8 h under vacuum, the reaction was detected to be performed completely using LCMS to afford compound 1. MS-ESI: Calculated [M]+: 322.11, Found: 322.30. Step (2): Compound 1 (500 mg, 1.40 mmol, 1 eq) and compound 2 (565 mg, 2.80 mmol, 2.0 eq) were dissolved in acetonitrile (10 mL). The mixture was reacted at 80 C for overnight under N2, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted 15 with water and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by fast chromatography (100-200 mesh silica gel, DCM / MeOH=50 / 1) to afford compound 3. MS-ESI: Calculated [M]+: 444.06, Found: 444.00. Step (3): 25 Compound 3 (160 mg, 0.30 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.5 mL, 1.5 mmol, 5 eq, 3M) was added slowly at 0 C under N2. The mixture was reacted for 0.5 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by thin layer chromatography (DCM:MeOH=30:1) to afford compound AB31887. Compound AB31887: MS-ESI: Calculated [M+H]+: 458.09, Found: 458.05. -95- 2026242260   02 Oct 2026 1H NMR (400 MHz, CDCl3) 5 7.15 (s, 1H), 6.74 (s, 2H), 6.59 (s, 1H), 5.94 (s, 2H), 5.85 (s, 1H), 4.90-4.85 (m, 1H), 4.20-4.11 (m, 2H), 3.83 (s, 3H), 3.71-3.69 (m, 2H), 3.42-3.25 (m, 2H), 2.982.77 (m, 2H), 2.43-2.23 (m, 2H), 1.18 (d, J= 4.0 Hz, 3H). Example 7 Synthesis of compound AB31888 The structure of compound AB31888 was as follows: compound AB31888 10 The synthesis method of compound AB31888 was as follows: Step (1): Compound 1 (300 mg, 0.84 mmol, 1 eq) and compound 2 (592 mg, 4.20 mmol, 5.0 eq) were dissolved in N, N-dimethylformamide (10 mL). The mixture was reacted at 80 °C for overnight 15 under N2, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by fast chromatography (100-200 mesh silica gel, DCM:MeOH=50:1) to afford compound 3. MS-ESI: Calculated [M]+: 443.18, Found: 443.05. 20         Step (2): Compound 3 (100 mg, 0.21 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.4 mL, 1.5 mmol, 5 eq, 3M) was added slowly at 0 °C under N2. The mixture was reacted for 0.5 h, and the reaction was detected to be performed completely using 25 LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by thin layer chromatography (DCM:MeOH=30:1) to afford compound AB31888. Compound AB31888: 30        MS-ESI: Calculated [M+H]+: 456.19, Found: 456.15. 1H NMR (400 MHz, DMSO-d6) 5 7.25 (s, 1H), 6.81(d, J= 4.0 Hz, 2H), 6.77 (s, 1H), 6.66 (d, J= 4.0 Hz, 1H), 6.00 (d, J= 4.0 Hz, 2H), 5.93 (s, 1H), 4.77-4.73 (m, 1H), 3.97-3.94 (m, 2H), 3.75 (s, 3H), 3.68-3.64 (m, 2H), 3.27-3.21 (m, 2H), 2.84-2.74 (m, 2H), 1.78-1.70 (m, 4H), 1.49-1.45 (m, 4H), 1.05 (d, J= 8.0 Hz, 3H). Example 8 Synthesis of compound AB31895 2026242260   02 Oct 2026 The structure of compound AB31895 was as follows: compound AB31895 The synthesis method of compound AB31895 was as follows: Step (1): Compound 1 (1.0 g, 2.69 mmol, 1 eq) was dissolved in ethanol (20 mL) in a 50 mL sealed tube, and phenylethylamine (326 mg, 26.9 mmol, 10 eq) was added. The mixture was reacted at 100 C for 48 h, and the reaction was detected to be performed completely using LCMS. The reaction 10 mixture was diluted with water and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by fast chromatography (dichloromethane: methanol=30:1) to afford compound 3. MS-ESI: Calculated [M]+: 425.19, Found: 425.15. Step (2): o.xxX _            °ZXX lXYx\ YY u j " l ¥ Y j XX 0 °C 15                                      3                                       AB31895 Compound 3 (190 mg, 0.41 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.7 mL, 2.05 mmol, 5 eq, 3M) was added slowly at 0 C under N2. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium 20 chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by thin layer chromatography (dichloromethane: methanol=50:1) to afford compound AB31895. Compound AB31895: MS-ESI: Calculated [M+H]+: 441.21, Found: 441.20. 25        1H NMR (400 MHz, DMSO-d6) 5 7.28-7.18 (m, 6H), 6.72 (s, 1H), 6.68 (d, J= 8.0 Hz, 1H), 6.48 (d, J= 8.0 Hz, 1H), 5.96 (d, J= 4.0 Hz, 2H), 5.87 (s, 1H), 4.54-4.50 (m, 1H), 3.68 (s, 3H), 3.183.04 (m, 5H), 2.76-2.73 (m, 4H), 0.91 (d, J= 4.0 Hz, 3H). Example 9 Synthesis of compound AB31896 30       The structure of compound AB31896 was as follows: compound AB31896 2026242260   02 Oct 2026 The synthesis method of compound AB31896 was as follows: Step (1): (COCI)2, DMF DCM, 0 °C-RT 2 Compound 1 (500 mg, 2.57 mmol, 1 eq) was dissolved in dichloromethane (10 mL) and cooled to 0 C, oxalyl chloride (1.6 g, 12.85 mmol, 5 eq) and two drops of N, N-dimethylformamide were added. The mixture was reacted at room temperature for 2 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was distilled under reduced pressure to 10 afford compound 2. MS-ESI: Calculated [M+H]+: 213.10, Found: not measured. Step (2): Compound 3 (100 mg, 0.29 mmol, 1 eq) was dissolved in dichloromethane (10 mL), 15 triethylamine (88 mg, 0.87 mmol, 3 eq) was added, the mixture was cooled to 0 C, and compound 2 (420 mg, 1.97 mmol, 6.8 eq) was added. The mixture was reacted at 0 C for 0.5 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted with ethyl acetate, the organic phase was dried over sodium sulfate, filtered and spin dried. The crude product was purified by reversed phase preparation chromatography 20 (acetonitrile / water+0.01% formic acid) to afford compound AB 31896. MS-ESI: Calculated [M+H]+: 514.25, Found: 514.25. 1H NMR (400 MHz, DMSO-d6) 5 7.27 (s, 1H), 6.91-6.83 (m, 2H), 6.77 (s, 1H), 6.01 (s, 1H), 5.99 (s, 2H), 4.61-4.55 (m, 1H), 3.71 (s, 3H), 3.28-3.14 (m, 2H), 2.79-2.74 (m, 2H), 2.34 (s, 2H), 1.72-1.63 (m, 15H), 1.02 (d, J= 8.0 Hz, 3H). 25 Example 10 Synthesis of compound AB31897 The structure of compound AB31897 was as follows: 2026242260   02 Oct 2026 compound AB31897 The synthesis method of compound AB31897 was as follows: Step (1): The compound 0 (10.0 g, 26.89 mmol, 1 eq) was added in a 500 mL eggplant-shaped flask, and heated at 190 C for 8 h under vacuum, and the reaction was detected to be performed completely using LCMS to afford compound 1. Step (2): 10        Compound 1 (2 g, 5.59 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (11.2 mL, 33.54 mmol, 6 eq, 3M) was added slowly at 0 C under N2. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over 15 anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by thin layer chromatography (dichloromethane: methanol=100:1 to 50:1) to afford compound 2. Step (3): Compound 2 (300 mg, 0.89 mmol, 1 eq) was dissolved in acetonitrile (10 mL), and potassium 20 carbonate (491 mg, 3.56 mmol, 4 eq) and compound 3 (868 mg, 3.56 mmol, 4 eq) were added. The mixture was reacted at 80 C for overnight, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by fast chromatography (dichloromethane: methanol=50:1) to afford 25 compound AB31897. Compound AB31897: MS-ESI: Calculated [M+H]+: 501.13, Found: 501.10. 1H NMR (400 MHz, DMSO-d6) 8 7.22 (s, 1H), 6.79-6.74 (m, 2H), 6.64 (d, J= 12.0 Hz, 1H), 5.97 (d, J= 4.0 Hz, 2H), 5.89 (s, 1H), 4.74-4.69 (m, 1H), 3.94-3.91 (m, 2H), 3.72 (s, 3H), 3.55-3.51 30   (m, 2H), 3.25-3.15 (m, 2H), 2.79-2.68 (m, 2H), 1.85-1.79 (m, 2H), 1.72-1.65 (m, 2H), 1.44 (s, 4H), 1.03 (d, J= 4.0 Hz, 3H). 2026242260   02 Oct 2026 Example 11 Synthesis of compound AB31898 The structure of compound AB31898 was as follows: compound AB31898 5       The synthesis method of compound AB31898 was as follows: BrMg— THF,0°C,0.5h AB31898 Compound 1 (200 mg, 0.52 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (2.7 mL, 2.7 mmol, 5 eq, 3M) was added slowly at 0 °C under N2. 10 The mixture was reacted for 0.5 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and rotary dried. The crude product was purified by thin layer chromatography (DCM:MeOH=30:1) to afford compound AB31898. 15       Compound AB31898: MS-ESI: Calculated [M+H]+: 366.17, Found: 366.10. 1H NMR (400 MHz, DMSO-d6) 8 7.11 (s, 1H), 6.81 (d, J= 8.0 Hz, 1H), 6.68 (s, 1H), 6.67 (s, 1H), 5.87(s, 1H), 4.77-4.73 (m, 1H), 4.23 (s, 4H), 3.77 (d, J= 8.0 Hz, 6H), 3.28-3.20 (m, 2H), 2.792.66 (m, 2H), 1.05 (d, J= 8.0 Hz, 3H). 20 Example 12 Synthesis of compound AB35402 The structure of compound AB35402 was as follows: compound AB35402 25 The synthesis method of compound AB35402 was as follows: Step (1): The compound 0 (10.0 g, 26.89 mmol, 1 eq) was added in a 500 mL eggplant-shaped flask, and 2026242260   02 Oct 2026 heated at 190 °C for 8 h under vacuum, and the reaction was detected to be performed completely using LCMS to afford compound 1. MS-ESI: Calculated [M+H]+: 322.11, Found: 322.30. Step (2): 10 Compound 1 (500 mg, 1.40 mmol, 1 eq) was dissolved in acetonitrile (10 mL), and potassium carbonate (773 mg, 5.6 mmol, 4 eq) and compound 2 (912 mg, 4.20 mmol, 3 eq) were added. The mixture was reacted at room temperature for overnight, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by fast chromatography (dichloromethane: methanol=30:1) to afford compound 3. MS-ESI: Calculated [M]+: 458.23, Found: 458.30. 15 Compound 3 (200 mg, 0.37 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.6 mL, 1.85 mmol, 5 eq, 3M) was added slowly at 0 C under N2. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium 20 chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by thin layer chromatography (dichloromethane: methanol=50:1) to afford compound AB35402. Compound AB35402: MS-ESI: Calculated [M+H]+: 474.26, Found: 474.35. 25        1H NMR (400 MHz, DMSO-d6) 8 7.24 (s, 1H), 6.821 (d, J= 8.0 Hz, 1H), 6. 77 (s, 1H), 6.67 (d, J= 12.0 Hz, 1H), 6.03 (s, 2H), 5.92 (s, 1H), 5.51-5.48 (m, 1H), 5.10-5.05 (m, 1H), 4.76-4.73 (m, 1H), 4.54-4.46 (m, 2H), 3.76 (s, 3H), 3.29-3.15 (m, 2H), 2.78-2.66 (m, 2H), 2.09-1.99 (m, 4H), 1.63 (s, 6H), 1.55 (s, 3H), 1.03 (d, J= 4.0 Hz, 3H). 30 Example 13 Synthesis of compound AB35405 The structure of compound AB35405 was as follows: compound AB35405 The synthesis method of compound AB35405 was as follows: 35         Step (1): 2026242260   02 Oct 2026 Compound 1 (200 mg, 0.37 mmol, 1 eq) was dissolved in chloroform (5 mL), and aqueous ammonia (2 mL) was added. The mixture was reacted at room temperature for overnight, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted 5 and extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by fast chromatography (PE:EA= 200:1) to afford compound AB35405. Compound AB35405: MS-ESI: Calculated [M+H]+: 576.14, Found: 576.15. 10        1H NMR (400 MHz, CDC13) 8 7.17 (s, 1H), 6.98-6.86 (m, 2H), 6.62 (s, 1H), 6.10 (s, 1H), 5.95 (d, J= 4.0 Hz, 2H), 5.67 (s, 1H), 5.57-5.53 (m, 1H), 5.10-5.06 (m, 1H), 4.72-4.56 (m, 2H), 3.89-3.83 (m, 4H), 3.69-3.64 (m, 1H), 3.37-3.32 (m, 1H), 2.74-2.70 (m, 1H), 2.11-2.03 (m, 4H), 1.66 (d, J= 8.0 Hz, 6H), 1.58 (s, 3H). 15 Example 14 Synthesis of compound AB35407 The structure of compound AB35407 was as follows: compound AB35407 20 25 The synthesis method of compound AB35407 was as follows: Step (1): The compound 0 (10.0 g, 26.89 mmol, 1 eq) was added in a 500 mL eggplant-shaped flask, and heated at 190 °C for 8 h under vacuum, and the reaction was detected to be performed completely using LCMS to afford compound 1. MS-ESI: Calculated [M]+: 322.11, Found: 322.30. Compound 1 (600 mg, 1.67 mmol, 1 eq) was dissolved in N, N-dimethylformamide (10 mL), and potassium carbonate (926 mg, 6.71 mmol, 4 eq) and compound 2 (1.9 g, 6.71 mmol, 4 eq) were added. The mixture was reacted at 60C for overnight under N2, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then extracted 2026242260   02 Oct 2026 with ethyl acetate twice, the phase was dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by fast chromatography (dichloromethane: methanol=50:1) to afford compound 3. MS-ESI: Calculated [M]+: 521.26, Found: 521.30. 5         Step (3): Compound 3 (200 mg, 0.33 mmol, 1 eq) was dissolved in a mixture of chloroform (5 mL) and aqueous ammonia (2 mL). The mixture was reacted at 40C for 48 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted with water and then 10 extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by fast chromatography (PE:EA= 200:1) to afford compound AB35407. MS-ESI: Calculated [M+H]+: 639.18, Found: 639.15. 1H NMR (400 MHz, CDC13) 6 7.16 (s, 1H), 6.97-6.85 (m, 2H), 6.62 (s, 1H), 6.08 (s, 1H), 5.95 15   (d, J= 4.0 Hz, 2H), 5.62 (s, 1H), 4.52 (s, 1H), 4.28-4.23 (m, 1H), 3.89-3.82 (m, 5H), 3.69-3.67 (m, 1H), 3.36-3.31 (m, 1H), 3.16-3.09 (m, 2H), 2.76-2.72 (m, 1H), 1.83-1.69 (m, 4H), 1.58-1.51 (m, 4H), 1.44 (s, 9H). 20 Example 15 Synthesis of compound AB35411 The structure of compound AB35411 was as follows: The synthesis method of compound AB35411 was as follows: Step (1): 25        Compound 1 (2.0 g, 5.93 mmol, 1 eq) was dissolved in ethanol / acetic acid (10 mL / 8 mL), and benzaldehyde (7.9 g, 59.3 mmol, 10 eq) was added. The mixture was reacted at 80C for 4 h, an appropriate amount of hydrochloric acid was added, and the mixture was concentrated. To crude product was added a small amount of dichloromethane and an appropriate amount of ethyl acetate, the mixture was stewed for 0.5 h and then filtered to remove solid. The filtrate was stewed for 30 overnight to precipitate a solid, the solid was filtered and collected to afford compound 3 (1.4 g). Step (2): 2026242260   02 Oct 2026 Compound 3 (200 mg, 0.41 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.7 mL, 2.05 mmol, 5 eq, 3M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with 5 saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by thin layer chromatography (DCM / MeOH=20 / 1) to afford compound AB35411. Compound AB35411: 10        MS-ESI: Calculated [M+H]+: 470.23; Found [M+H]+: 470.30. 1H NMR (400 MHz, CDCh) 8 7.34-7.28 (m, 2H), 7.24-7.16 (m, 3H), 6.97 (s, 1H), 6.90-6.76 (m, 2H), 6.65 (s, 1H), 5.97-5.96 (m, 2H), 4.77-4.73 (m, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.24-3.22 (m, 2H), 2.84-2.65 (m, 6H), 2.14-2.08 (m, 1H), 1.90-1.81 (m, 1H), 1.07 (d, J= 4.0 Hz, 3H). 15       Example 16 Synthesis of compound AB35413 The structure of compound AB35413 was as follows: The synthesis method of compound AB35413 was as follows: 20        Compound 1 (100 mg, 0.28 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.5 mL, 1.4 mmol, 5 eq, 3M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and spin dried. 25 The crude product was purified by thin layer chromatography (DCM / MeOH=30 / 1) to afford compound AB35413. Compound AB35413: MS-ESI: Calculated [M+H]+: 336.12; Found[M+H]+: 336.10. 1H NMR (400 MHz, DMSO-d6) 8 7.25 (s, 1H), 6.78 (s, 1H), 6.79 (d, J= 8.0 Hz, 1H), 6.46 (d, 30   J= 8.0 Hz, 1H), 6.04 (s, 1H), 6.00 (d, J= 4.0 Hz, 2H), 5.94 (s, 1H), 5.89 (s, 1H), 4.71-4.66 (m, 1H), 3.28-3.20 (m, 2H), 2.83-2.70 (m, 2H), 1.11 (d, J= 8.0 Hz, 3H). Example 17 Synthesis of compound AB35415 — 104 — 2026242260   02 Oct 2026 The structure of compound AB35415 was as follows: The synthesis method of compound AB35415 was as follows: 5       Compound 1 (200 mg, 0.59 mmol, 1 eq) was dissolved in N, N-dimethylformamide (10 mL), and potassium carbonate (326 mg, 2.36 mmol, 4 eq) and compound 2 (661 mg, 2.36 mmol, 4 eq) were added. The mixture was reacted at 60 °C for overnight, the reaction mixture was diluted with water and then extracted with ethyl acetate twice, the organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by reversed 10 phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB35415. Compound AB35415: MS-ESI: Calculated [M+H]+: 537.29; Found [M+H]+: 537.35. 1H NMR (400 MHz, CDCh) 8 7.15 (s, 1H), 6.72 (s, 2H), 6.59 (s, 1H), 5.94 (s, 2H), 5.85 (s, 15    1H), 4.85-4.80 (m, 1H), 4.53 (s, 1H), 4.05-4.09 (m, 2H), 3.82 (s, 3H), 3.44-3.39 (m, 1H), 3.24-3.14 (m, 3H), 2.98-2.77 (m, 2H), 1.82-1.79 (m, 2H), 1.55-1.50 (m, 4H), 1.44 (s, 11H), 1.17 (d, J= 8.0 Hz, 3H). 20 Example 18 Synthesis of compound AB35416 The structure of compound AB35416 was as follows: The synthesis method of compound AB35416 was as follows: Compound 1 (200 mg, 0.33 mmol, 1 eq) was dissolved in chloroform (5 mL), and aqueous 25 ammonia (2 mL) was added. The mixture was reacted at 40C for 48 h. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by thin layer chromatography (PE / EA=10 / 1) to afford compound AB35416. Compound AB35416 2026242260   02 Oct 2026 10 15 20 25 MS-ESI: Calculated [M+H]+: 583.11; Found [M+H]+: 583.10. 1H NMR (400 MHz, CDCI3) 6 7.16 (s, 1H), 6.97-6.89 (m, 2H), 6.62 (s, 1H), 6.09 (s, 1H), 5.96 (s, 2H), 5.64 (s, 1H), 4.34 (s, 1H), 4.24 (s, 1H), 3.96-3.87 (m, 5H), 3.71 (s, 1H), 3.56-3.49 (m, 2H), 3.35-3.30 (m, 1H), 2.76-2.73 (m, 1H), 1.47 (s, 9H) Example 19 Synthesis of compound AB35417 The structure of compound AB35417 was as follows: The synthesis method of compound AB35417 was as follows: Compound 1 (200 mg, 0.41 mmol, 1 eq) was dissolved in chloroform (5 mL), and aqueous ammonia (2 mL) was added. The mixture was reacted at room temperature for 24 h. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by thin layer chromatography (PE / EA=10 / 1) to afford compound AB35417. Compound AB35417 MS-ESI: Calculated [M+H]+: 572.11; Found [M+H]+: 572.1. 1H NMR (400 MHz, CDCl3) 6 7.32-7.30 (m, 2H), 7.24-7.20 (m, 3H), 6.99-6.90 (m, 2H), 6.85 (s, 1H), 6.68 (s, 1H), 5.99 (s, 2H), 5.58 (s, 1H), 4.09-4.03 (m, 1H), 3.93 (s, 3H), 3.90 (s, 3H), 3.463.44 (m, 1H), 2.75-2.56 (m, 6H), 2.12-2.04 (m, 1H), 1.88-1.77 (m, 1H). Example 20 Synthesis of compound AB35418 The structure of compound AB35418 was as follows: The synthesis method of compound AB35418 was as follows: 2026242260   02 Oct 2026 Compound 1 (200 mg, 0.45 mmol, 1 eq) was dissolved in chloroform (5 mL), and aqueous ammonia (2 mL) was added. The mixture was reacted at room temperature for overnight. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase 5 was washed with brine, dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by thin layer chromatography (PE / EA=10 / 1) to afford compound AB35418. Compound AB35418 MS-ESI: Calculated [M+H]+: 524.11; Found [M+H]+: 524.15. 1H NMR (400 MHz, DMSO-d6) 5 7.13-7.04 (m, 2H), 6.91 (s, 1H), 6.68 (s, 1H), 5.99 (s, 2H), 10   5.60 (s, 1H), 4.11-4.05 (m, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.47-3.45 (m, 1H), 2.73-2.53 (m, 4H), 1.82-1.74 (m, 1H), 1.46-1.38 (m, 5H), 0.95-0.92 (m, 3H). Example 21 Synthesis of compound AB35420 The structure of compound AB35420 was as follows: 15 The synthesis method of compound AB35420 was as follows: Step (1): Compound 1 (5.0 g, 13.97 mmol, 1 eq) and compound 2 (21.0 g, 111.76 mmol, 8 eq) were 20 dissolved in N, N-dimethylformamide (50 mL). The mixture was reacted at 60 °C for overnight. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH=50 / 1 to 20 / 1) to afford compound 3. 25          Step (2): 2026242260   02 Oct 2026 Compound 3 (250 mg, 0.49 mmol, 1 eq) and compound 4 (167 mg, 1.96 mmol, 4 eq) were dissolved in N, N-dimethylformamide (10 mL), and potassium carbonate (270 mg, 1.96 mmol, 4 eq) was added. The mixture was reacted at 60 °C for overnight, the reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was washed with brine, dried over 5 anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH= 10 / 1) to afford compound 5. Step (3): Compound 5 (100 mg, 0.19 mmol, 1 eq) was dissolved in chloroform (5 mL), and aqueous 10 ammonia (2 mL) was added. The mixture was reacted at room temperature for 48 h. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by thin layer chromatography (PE / EA=10 / 1) to afford compound AB35420. 15      Compound AB35420 MS-ESI: Calculated [M+H]+: 551.12; Found [M+H]+: 551.10. 1H NMR (400 MHz, CDCI3) 5 7.14 (s, 1H), 6.95-6.84 (m, 2H), 6.60 (s, 1H), 6.06 (s, 1H), 5.93 (s, 2H), 5.84 (s, 1H), 4.41-4.36 (m, 1H), 3.93-3.88 (m, 1H), 3.84 (s, 3H), 3.75-3.27 (m, 1H), 3.333.27 (m, 1H), 2.86-2.56 (m, 6H), 1.66-1.47 (m, 10). 20 Example 22 Synthesis of compound AB35421 The structure of compound AB35421 was as follows: The synthesis method of compound AB35421 was as follows: ( I I \ ci            / tYi b-A^Y^-N_,CCI3 [I I            chci3, nh4oh UQ        XX > ~ 0                     YY-o _                                1                                    AB35421 25 Compound 1 (100 mg, 0.28 mmol, 1 eq) was dissolved in chloroform (5 mL), and aqueous ammonia (2 mL) was added. The mixture was reacted at room temperature for 48 h. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The 30 crude product was purified by thin layer chromatography (PE / EA=10 / 1) to afford compound AB35421. Compound AB35421: MS-ESI: Calculated [M+H]+: 438.00; Found[M+H]+: 437.95. 1H NMR (400 MHz, CDCl3) 5 7.16 (s, 1H), 6.86 (d, J= 8.0 Hz, 1H), 6.87 (d, J= 8.0 Hz, 1H), — 108 — 2026242260   02 Oct 2026 6.61 (s, 1H), 6.14 (s, 1H), 6.03 (s, 1H), 5.96-5.94 (m, 2H), 5.91 (s, 1H), 5.41 (s, 1H), 3.86-3.80 (m, 1H), 3.72-3.68 (m, 1H), 3.39-3.32 (m, 1H), 2.75-2.68 (m, 1H). Example 23 Synthesis of compound AB35422 5       The structure of compound AB35422 was as follows: The synthesis method of compound AB35422 was as follows: Compound 1 (110 mg, 0.25 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), 10 and methylmagnesium bromide (0.4 mL, 1.25 mmol, 5 eq, 3M) was added slowly at 0 °C under N2. The mixture was reacted for 0.5 h, and the reaction was detected to be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by thin layer chromatography 15   (DCM:MeOH=20:1) to afford compound AB35422. Compound AB35422: MS-ESI: Calculated [M+H]+: 422.23, Found[M+H]+: 422.20. 1H NMR (400 MHz, DMSO-d6) 8 6.88-6.83 (m, 4H), 6.00 (d, J= 8.0 Hz, 2H), 4.65-4.61 (m, 1H), 3.76 (d, J= 8.0 Hz, 6H), 3.16-3.08 (m, 3H), 2.74-2.70 (m, 3H), 1.71-1.63 (m, 1H), 1.42-1.32 20   (m, 5H), 0.94 (d, J= 4.0 Hz, 3H), 0.89-0.86 (m, 3H). Example 24 Synthesis of compound AB35423 The structure of compound AB35423 was as follows: 25 The synthesis method of compound AB35423 was as follows: Step (1): Compound 1 (300 mg, 0.84 mmol, 1 eq) was dissolved in N, N-dimethylformamide (10 mL), and potassium carbonate (464 mg, 3.36 mmol, 4 eq) and compound 2 (847 mg, 3.36 mmol, 4 eq) 30 were added. The mixture was reacted at 60C for overnight. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the phase was dried over anhydrous sodium 2026242260   02 Oct 2026 sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH=50 / 1 to 20 / 1) to afford compound 3. Step (2): 5       Compound 3 (200 mg, 0.35 mmol, 1 eq) was dissolved in chloroform (5 mL), and aqueous ammonia (2 mL) was added. The mixture was reacted at 40C for 48 h. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by thin layer chromatography (PE:EA= 200:1) to afford compound AB35423. 10       Compound AB35423: MS-ESI: Calculated [M+H]+: 611.14; Found [M+H]+: 611.05. 1H NMR (400 MHz, CDCI3) 5 7.16 (s, 1H), 6.97-6.86 (m, 2H), 6.62 (s, 1H), 6.09 (s, 1H), 5.955.94 (m, 2H), 5.60 (s, 1H), 4.64 (s, 1H), 4.27-4.23 (m, 1H), 3.90-3.86 (m, 5H), 3.73-3.67 (m, 1H), 3.35-3.22 (m, 3H), 2.77-2.71 (m, 1H), 1.84-1.72 (m, 4H), 1.44 (s, 9H). 15 Example 25 Synthesis of compound AB35424 The structure of compound AB35424 was as follows: o AB35424   | The synthesis method of compound AB35424 was as follows: 20         Step (1): Compound 1 (300 mg, 0.84 mmol, 1 eq) was dissolved in N, N-dimethylformamide (10 mL), and potassium carbonate (464 mg, 3.36 mmol, 4 eq) and compound 2 (753 mg, 3.36 mmol, 4 eq) were added. The mixture was reacted at 60C for overnight. The reaction mixture was diluted with 25 water and then extracted with dichloromethane twice, the phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH=50 / 1 to 20 / 1) to afford compound 3. Step (2): 2026242260   02 Oct 2026 Compound 3 (50 mg, 0.09 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.15 mL, 0.45 mmol, 5 eq, 3M) was added slowly at 0 °C under N2. The mixture was reacted for 0.5 h. The reaction mixture was quenched with saturated aqueous 5 ammonium chloride solution and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB35424. Compound AB35424: 10        MS-ESI: Calculated [M+H]+: 481.23; Found [M+H]+: 481.20. 1H NMR (400 MHz, DMSO-d6) 8 7.25 (s, 1H), 7.04-7.02 (m, 1H), 6.82-6.66 (m, 3H), 6.00 (d, J= 4.0 Hz, 2H), 5.92 (s, 1H), 4.86-4.81 (m, 1H), 3.96-3.91 (m, 2H), 3.75 (s, 3H), 3.28-3.26 (m, 4H), 2.84-2.74 (m, 2H), 1.39 (s, 9H), 1.03 (d, J= 8.0 Hz, 3H). 15       Example 26 Synthesis of compound AB35426 The structure of compound AB35426 was as follows: ''<--' 0 compound AB35426 The synthesis method of compound AB35426 was as follows: 20         Step (1): AB35426 Compound 3 (200 mg, 0.56 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and hexylmagnesium bromide (3.4 mL, 3.36 mmol, 6 eq, 1 M) was added slowly at 0 C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with 25 saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by thin layer chromatography (dichloromethane: methanol=30:1) to afford compound AB35426. Compound AB35426: 30        MS-ESI: Calculated [M+H]+: 405.19; Found: 406.25. 1H NMR (400 MHz, CDCl3) 8 7.13 (s, 1H), 6.66 (d, J= 4.0 Hz, 1H), 6.59 (s, 1H), 6.51 (d, J= 8.0 Hz, 1H), 5.95-5.94 (m, 3H), 5.83 (d, J= 8.0 Hz, 2H), 4.58-4.56 (m, 1H), 3.46-3.41 (m, 1H), 3.263.23 (m, 1H), 2.89-2.77 (m, 2H), 1.85-1.76 (m, 1H), 1.64-1.57 (m, 1H), 1.28-1.19 (m, 8H), 0.840.81 (m, 3H). 2026242260   02 Oct 2026 10 Example 27 Synthesis of compound AB35427 The structure of compound AB35427 was as follows: The synthesis method of compound AB35427 was as follows: Step (1): Compound 1 (500 mg, 1.41 mmol, 1 eq) was dissolved in methanol (10 mL), and potassium carbonate (583 mg, 4.22 mmol, 3.0 eq) was added, then a mixture of sodium borohydride (53 mg, 1.41 mmol, 1.0 eq) in 5% sodium hydroxide solution was slowly added dropwise at 0 °C. The mixture was reacted for 2 h. The reaction mixture was filtered, the solid was washed with ethanol 23 times and collected to afford compound 2 (800 mg, yield: 99.9%) as a yellow solid. Step (2): 15 20 Compound 2 (400 mg, 1.26 mmol, 1 eq) was dissolved in ethanol / acetic acid (12 mL / 2 mL), and phenylpropionaldehyde (1.69 g, 12.58 mmol, 10 eq) was added. The mixture was reacted at 90°C for 4 h, an appropriate amount of hydrochloric acid was added, and the mixture was concentrated. To crude product was added a small amount of dichloromethane and an appropriate amount of ethyl acetate, the mixture was stewed for 0.5 h and then filtered to remove solid. The filtrate was stewed for overnight to precipitate a solid, the solid was filtered and collected to afford compound 4 (160 mg, yield: 29.0%) as a yellow solid. Step (3): Compound 4 (90 mg, 0.21 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), -112- and methylmagnesium bromide (1 mL, 1.03 mmol, 5 eq, 3M) was added slowly at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate 5 was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford solid compound AB35427. Compound AB35427: MS-ESI: Calculated [M+H]+: 453.20; Found: 454.20. 1H NMR (400 MHz, DMSO-d6) 5 7.23-7.21 (m, 2H), 7.17-7.15 (m, 3H), 6.81 (s, 2H), 6.69 (d, 10   J= 8.0 Hz, 1H), 6.53 (d, J= 8.0 Hz, 1H), 6.00-5.99 (m, 3H), 5.90 (s, 1H), 4.55-4.51 (m, 1H), 3.16 3.04 (m, 2H), 2.73-2.46 (m, 6H), 1.95-1.69 (m, 2H), 20.99 (d, J= 4.0 Hz, 3H). 2026242260   02 Oct 2026 Example 28 Synthesis of compound AB35428 The structure of compound AB35428 was as follows: 0 .. ,CCI3 xxx° X XX > o AB 3 5428 The synthesis method of compound AB35428 was as follows: Compound 1 (100 mg, 0.21 mmol, 1 eq) was dissolved in chloroform (4 mL), and aqueous ammonia (2 mL) was added. The mixture was reacted at room temperature for 48 h. The reaction 20 mixture was washed with water and then extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by thin layer chromatography (dichloromethane: methanol=30:1) to afford compound AB35428. Compound AB35428: 25        MS-ESI: Calculated [M+H]+: 556.08; Found[M+H]+: 556.00. 1H NMR (400 MHz, DMSO-d6) 5 7.28-7.24 (m, 2H), 7.21-7.14 (m, 3H), 6.96 (d, J= 12.0 Hz, 1H), 6.85 (s, 1H), 6.73-6.71 (m, 2H), 6.07 (s, 1H), 6.02 (d, J= 4.0 Hz, 2H), 5.97 (s, 1H), 5.44 (s, 1H), 3.80-3.75 (m, 1H), 3.63-3.61 (m, 1H), 2.70-2.53 (m, 6H), 1.88-1.74 (m, 2H). 30       Example 29 Synthesis of compound AB35429 The structure of compound AB35429 was as follows: The synthesis method of compound AB35429 was as follows: Step (1): 2026242260   02 Oct 2026 Compound 1 (400 mg, 0.81 mmol, 1.0 eq) was dissolved in methanol (30 mL), and aqueous ammonia (7 mL) and ammonium chloride (44 mg, 0.81 mmol, 1.0 eq) were added in sequence. The mixture was stirred at 70 °C for 16 h, and the reaction was detected to be performed completely 5 using TLC and LCMS. The reaction mixture was diluted with water and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried, the crude product was purified by fast chromatography (DCM / MeOH=100 / 1 to 50 / 1) to afford compound 2 (190 mg, yield: 42.2%) as a yellow solid. Step (2): Compound 2 (80 mg, 0.19 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (5 mL), and methylmagnesium bromide (0.4 mL, 1.14 mmol, 6.0 eq, 3M) was added slowly at 0 C under N2. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was quenched with saturated 15 aqueous ammonium chloride solution and then extracted with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford solid compound AB35429 (10 mg, yield: 12.5%) as a yellow solid Compound AB35429: 20       MS-ESI: Calculated [M+H]+: 409.21, Found[M+H+H2O]+: 428.10. 1H NMR (400 MHz, DMSO-d6) 5 7.23 (s, 1H), 6.80-6.64 (m, 3H), 5.98 (d, J= 4.0 Hz, 2H), 5.90 (s, 1H), 4.75-4.70 (m, 1H), 3.96-3.87 (m, 2H), 3.74-3.71 (m, 5H), 3.26-3.20 (m, 2H), 2.81-2.72 (m, 2H), 1.95-1.79 (m, 4H), 1.03 (d, J= 8.0 Hz, 3H). 25 Example 30 Synthesis of compound AB35430 The structure of compound AB35430 was as follows: The synthesis method of compound AB35430 was as follows: 2026242260   02 Oct 2026 Compound 1 (150 mg, 0.28 mmol, 1.0 eq) was dissolved in tetrahydrofuran (10 mL), and cyclopentylmagnesium bromide (1.4 mL, 1.4 mmol, 5 eq, 1M) was added at 0 °C. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely 5 using TLC and LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by thin layer chromatography (dichloromethane / methanol=30 / 1) to afford compound AB35430. Compound AB35430: 10        MS-ESI: Calculated [M+H]+: 512.14, Found: 512.10. 1H NMR (400 MHz, CDC13) 5 7.13 (s, 1H), 6.74 (s, 2H), 6.58 (s, 1H), 5.93 (s, 2H), 5.83 (s, 1H), 4.65 (d, J= 4.0 Hz, 1H), 4.26-4.21 (m, 1H), 4.03-3.97 (m, 1H), 3.82 (s, 3H), 3.80-3.67 (m, 2H), 3.60-3.44 (m, 2H), 2.89-2.76 (m, 2H), 2.46-2.16 (m, 3H), 1.76-1.70 (m, 1H), 1.48-1.30 (m, 7H). 15 Example 31 Synthesis of compound AB35434 The structure of compound AB35434 was as follows: The synthesis method of compound AB35434 was as follows: Step (1): 20 Compound 1 (500 mg, 1.4 mmol, 1.0 eq) was dissolved in DMF (10 mL), and compound 2 (949 mg, 8.4 mmol, 6 eq) was added. The mixture was reacted at 75C for 16 h, and the reaction was detected to be performed completely using TLC and LCMS. The organic phase was spin dried, the crude product was purified by fast chromatography (100-200 mesh silica gel, DCM / MeOH=20 / 1) to 25 afford compound 3 (300 mg, yield: 49.3 %) as a yellow solid. Step (2): 2026242260   02 Oct 2026 Compound 3 (200 mg, 0.46 mmol, 1.0 eq) was dissolved in tetrahydrofuran (10 mL), and cyclopentylmagnesium bromide (2.8 mL, 2.76 mmol, 6.0 eq, 1M) was added at 0 °C under N2. The mixture was reacted at 0C for 0.5 h, and the reaction was detected to be performed completely using 5 TLC and LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB35434. 10      Compound AB35434: MS-ESI: Calculated [M+H]+: 468.19, Found: 468.45. 1H NMR (400 MHz, CDCI3) 6 7.13 (s, 1H), 6.74 (s, 2H), 6.57 (s, 1H), 5.92 (s, 2H), 5.82 (s, 1H), 4.61 (d, J= 8.0 Hz, 1H), 4.23-4.21 (m, 1H), 4.00-3.84 (m, 2H), 3.79 (s, 4H), 3.58-3.43 (m, 2H), 2.88-2.81 (m, 2H), 2.36-2.28 (m, 2H), 2.16-2.06 (m, 1H), 1.74-1.37 (m, 8H). 15 Example 32 Synthesis of compound AB35436 The structure of compound AB35436 was as follows: The synthesis method of compound AB35436 was as follows: 20         Step (1): Compound 1 (2.0 g, 5.93 mmol, 1 eq) was dissolved in ethanol / acetic acid (10 mL / 8 mL), and phenylpropionaldehyde (7.9 g, 59.3 mmol, 10 eq) was added. The mixtur e was reacted at 80C for 4 h, an appropriate amount of hydrochloric acid was added, and the mixture was concentrated. To 25 crude product was added a small amount of dichloromethane and an appropriate amount of ethyl acetate, the mixture was stewed for 0.5 h and then filtered to remove solid. The filtrate was stewed for overnight to precipitate a solid, the solid was filtered and collected to afford compound 3 (1.4 g, yield: 48.2%) as a yellow solid. Step (2): 2026242260   02 Oct 2026 Compound 3 (200 mg, 0.41 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and cyclopentylmagnesium bromide (0.7 mL, 2.05 mmol, 5 eq, 3M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with 5 saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB35436. Compound AB35436: 10        MS-ESI: Calculated [M+H]+:524.28; Found: 524.30. 1H NMR (400 MHz, CDCh) 8 7.26-7.16 (m, 5H), 6.83-6.74 (m, 4H), 6.01 (d, J= 4.0 Hz, 2H), 4.40 (d, J= 8.0 Hz, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 2.69-2.65 (m, 2H), 2.12-2.05 (m, 1H), 1.98-1.85 (m, 2H), 1.76-1.68 (m, 1H), 1.47-1.43 (m, 4H), 1.34-1.16 (m, 9H). 15 Example 33 Synthesis of compound AB35438 The structure of compound AB35438 was as follows: The synthesis method of compound AB35438 was as follows: Step (1): 20 Compound 1 (2 g, 5.59 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (20 mL), and cyclopentylmagnesium bromide (28 mL, 27.95 mmol, 5 eq, 1M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the 25 organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH=100 / 1 to 50 / 1) to afford compound 3 (1.2 g, yield: 54.5%) as a yellow solid. Step (2): 2026242260   02 Oct 2026 Compound 3 (200 mg, 0.51 mmol, 1 eq) was dissolved in dimethylformamide (10 mL), and compound 4 (222 mg, 1.02 mmol, 2 eq) and potassium carbonate (211 mg, 1.53 mmol, 3 eq) were added. The mixture was reacted at room temperature for 12 h. The reaction mixture was diluted with 5 water and then extracted with ethyl acetate twice, the organic phase was washed with brine, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB35438. Compound AB35438: 10        MS-ESI: Calculated [M+H]+: 528.31; Found: 528.45. 1H NMR (400 MHz, DMSO-d6) 5 6.81 (s, 2H), 6.77 (d, J= 8.0 Hz, 1H), 6.55 (d, J= 8.0 Hz, 1H), 5.98 (d, J= 12.0 Hz, 2H), 5.09-5.00 (m, 2H), 4.58 (d, J= 8.0 Hz, 1H), 3.75 (s, 3H), 3.30-3.10 (s, 5H), 2.70-2.51 (m, 2H), 2.10-1.98 (m, 5H), 1.66 (s, 3H), 1.53 (s, 3H), 1.50 (s, 3H), 1.41-1.37 (m, 4H), 1.30-1.21 (m, 4H). 15 Example 34 Synthesis of compound AB35440 The structure of compound AB35440 was as follows: The synthesis method of compound AB35440 was as follows: 20         Step (1): Compound 1 (500 mg, 1.40 mmol, 1 eq) was dissolved in N, N-dimethylformamide (5 mL), and compound 2 (862 mg, 5.6 mmol, 4 eq) was added. The mixture was reacted at 60 °C for 16h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction 25 mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH=50 / 1 to 20 / 1) to afford compound 3 (100 mg, yield: 15%) as a yellow solid. Step (2): 2026242260   02 Oct 2026 Compound 3 (100g mg, 0.21 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (5 mL), and cyclopentylmagnesium bromide (0.4 mL, 1.05 mmol, 5 eq, 3M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with 5 saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB35440. Compound AB35440: 10        MS-ESI: Calculated [M+H]+510.24; Found: 510.25. 1H NMR (400 MHz, DMSO-d6) 5 7.21 (s, 1H), 6.79 (d, J= 8.0 Hz, 1H), 6.74 (s, 1H), 6.64 (d, J= 8.0 Hz, 1H), 5.97 (s, 2H), 5.89 (s, 1H), 4.50 (d, J= 8.0 Hz, 1H), 4.03-4.00 (m, 1H), 3.77-3.72 (m, 4H), 3.65-3.61 (m, 2H), 3.42-3.36 (m, 2H), 2.90-2.84 (m, 1H), 2.66-2.64 (m, 1H), 2.20-2.13 (m, 1H), 1.73-1.57 (m, 6H), 1.47-1.41 (m, 6H), 1.28-1.15 (m, 4H). 15 Example 35 Synthesis of compound AB35441 The structure of compound AB35441 was as follows: Compound 1 (100 mg, 0.23 mmol, 1 eq) was dissolved in a mixture of aqueous ammonia (3 ml) and chloroform (6 ml). The mixture was reacted at room temperature for 48 h. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by 25 thin layer chromatography (dichloromethane / methanol=50 / 1) to afford compound AB35441. Compound AB35441: MS-ESI: Calculated [M+H]+: 516.02; Found: 516.25. 1H NMR (400 MHz, DMSO-d6) 5 7.31 (s, 1H), 7.09 (d, J= 12.0 Hz, 1H), 6.89 (d, J= 4.0 Hz, 1H), 6.77 (s, 1H), 6.32 (s, 1H), 5.99 (d, J= 4.0 Hz, 2H), 5.63 (s, 1H), 4.23-4.19 (m, 1H), 3.90-3.88 30   (m, 3H), 3.79-3.74 (m, 4H), 3.65-3.60 (m, 1H), 3.27-3.21 (m, 1H), 2.73-2.67 (m, 1H), 2.21-2.20 (m, 1H), 2.09-2.02 (m, 1H). Example 36 Synthesis of compound AB35444 The structure of compound AB35444 was as follows: AB35444 2026242260   02 Oct 2026 The synthesis method of compound AB35444 was as follows: Step (1): 5        Compound 1 (3.0 g, 8.89 mmol, 1 eq) was dissolved in ethanol / acetic acid (30 mL / 5 mL), and phenylacetaldehyde (10.7 g, 88.9 mmol, 10 eq) was added. The mixture was reacted at 90oC for 4 h, an appropriate amount of hydrochloric acid was added, and the mixture was concentrated. To crude product was added a small amount of dichloromethane and an appropriate amount of ethyl acetate, the mixture was stewed for 0.5 h and then filtered to remove solid. The filtrate was stewed for 10 overnight to precipitate a solid, the solid was filtered and collected to afford compound 3 (1.8 g, yield: 42.8%) as a yellow solid. Step (2): Compound 1 (300 mg, 0.63 mmol, 1 eq) was dissolved in aqueous ammonia (4 ml), and 15 chloroform (8 ml) was added. The mixture was reacted at room temperature for 48 h under N2. The reaction mixture was diluted with water and then extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH=100 / 1 to 50 / 1) to afford compound AB 35444. Compound AB35444: 20        MS-ESI: Calculated [M+H]+: 558.10; Found: 558.05. 1H NMR (400 MHz, DMSO-d6) 8 7.30 (d, J= 4.0 Hz, 4H), 7.21-7.18 (m, 3H), 6.97 (s, 1H), 6.87 (s, 1H), 6.03 (s, 1H), 6.00 (s, 1H), 5.58 (s, 1H), 3.85-3.79 (m, 7H), 3.62-3.59 (m, 1H), 2.902.70 (m, 5H), 2.58-2.51 (m, 1H). 25       Example 37 Synthesis of compound AB35445 The structure of compound AB35445 was as follows: 2026242260   02 Oct 2026 AB35445 The synthesis method of compound AB35445 was as follows: Step (1): 5        Compound 1 (5.0 g, 13.97 mmol, 1.0 eq) was dissolved in dichloromethane (300 mL), and trifluoromethanesulfonic anhydride (4.3 g, 15.37 mmol, 1.1 eq) was slowly added dropwise at 0 °C. The mixture was reacted at room temperature for 1 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was quenched with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, 10 the filtrate was spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol=100 / 1 to 50 / 1) to afford compound 2 (3.4 g, yield: 40.5 %) as a yellow solid. Step (2): 15       Compound 2 (300 mg, 0.49 mmol, 1.0 eq) was dissolved in dioxane (10 mL), and compound 3 (330 mg, 2.32 mmol, 4.6 eq), triethylamine (201 mg, 1.99 mmol, 4.0 eq), palladium acetate (22 mg, 0.099 mmol, 0.2 eq), and 1,1 '- binaphthalene-2,2' - biphenylphosphine (62 mg, 0.099 mmol, 0.2 eq) were added. The mixture was reacted at 100C for 16 h under N2, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and 20 then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol= 50 / 1) to afford compound 4 (150 mg, yield: 51.4 %) as a yellow solid. Step (3): 25        Compound 4 (150 mg, 0.25 mmol, 1 eq) was dissolved in a mixture of chloroform (8 ml) and aqueous ammonia (4 ml). The mixture was reacted at 40C for overnight, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol=100 / 1 to 50 / 1) to afford compound AB35445. 5      Compound AB35445: MS-ESI: Calculated [M+H]+: 564.15, Found: 564.40. 1H NMR (400 MHz, DMSO-d6) 5 7.27 (s, 1H), 7.03-6.98 (m, 2H), 6.77 (s, 1H), 6.25 (s, 1H), 5.98 (d, J= 8.0 Hz, 2H), 5.93 (s, 1H), 3.76 (s, 3H), 3.72-3.59 (m, 3H), 3.17-3.03 (m, 2H), 2.81-2.68 (m, 4H), 2.59-2.48 (m, 1H), 2.29-2.25 (m, 2H), 2.18-2.03 (m, 2H), 1.42-1.39 (m, 2H), 1.29-1.26 (m, 10   2H), 0.89-0.85 (m, 3H). 2026242260   02 Oct 2026 Example 38 Synthesis of compound AB35448 The structure of compound AB35448 was as follows: 15       The synthesis method of compound AB35448 was as follows: Compound 1 (300 mg, 0.63 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and cyclopentylmagnesium bromide (3.2 mL, 3.15 mmol, 5.0 eq, 1M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5. The reaction mixture was quenched with 20 saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB35448. MS-ESI: Calculated [M+H]+: 510.26; Found: 510.20. 25       1H NMR (400 MHz, DMSO-d6) 5 7.30-7.25 (m, 4H), 7.20-7.16 (m, 1H), 7.05-6.93 (m, 2H), 6.81 (d, J= 4.0 Hz, 2H), 6.00 (s, 2H), 4.43 (d, J= 8.0 Hz, 1H), 3.79 (s, 3H), 3.75 (s, 3H), 3.35-3.32 (m, 2H), 2.91-2.65 (m, 5H), 2.51-2.48 (m, 1H), 2.21-2.13 (m, 1H), 1.50-1.24 (m, 9H). 30 Example 39 Synthesis of compound AB35453 The structure of compound AB35453 was as follows: The synthesis method of compound AB35453 was as follows: 2026242260   02 Oct 2026 Compound 1 (700 mg, 1.16 mmol, 1.0 eq) was dissolved in dioxane (20 mL), and compound 2 (460 mg, 4.64 mmol, 4.0 eq), triethylamine (469 mg, 4.64 mmol, 4.0 eq), palladium acetate (52 mg, 0.232 mmol, 0.2 eq) and 1,1 '- binaphthalene-2,2' - biphenylphosphine (144 mg, 0.232 mmol, 0.2 5 eq) were added. The mixture was reacted at 100C for 16 h under N2, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol= 50 / 1) to afford compound 3 (280 mg). 10         Step (2): Compound 3 (150 mg, 0.27 mmol, 1 eq) was dissolved in a mixture of chloroform (8 ml) and aqueous ammonia (4 ml). The mixture was reacted at 40C for overnight, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with 15 water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol= 100 / 1 to 50 / 1) to afford compound AB35453. Compound AB35453: MS-ESI: Calculated [M+H]+: 521.11, Found: 521.15. 20        1H NMR (400 MHz, CDCh) 8 7.15 (s, 1H), 6.98-6.90 (m, 2H), 6.61 (s, 1H), 6.07 (s, 1H), 6.03 (s, 1H), 5.95 (d, J= 4.0 Hz, 2H), 3.91-3.86 (m, 1H), 3.81 (s, 3H), 3.68-3.64 (m, 1H), 3.55-3.49 (m, 1H), 3.31-3.26 (m, 1H), 3.06-2.99 (m, 2H), 2.78-2.72 (m, 2H), 1.68-1.61 (m, 1H), 1.49-1.45 (m, 1H), 1.36-1.26 (m, 3H), 0.99 (d, J= 4.0 Hz, 3H). 25 Example 40 Synthesis of compound AB35454 The structure of compound AB35454 was as follows: AB35454 The synthesis method of compound AB35454 was as follows: 2026242260   02 Oct 2026 Compound 1 (200 mg, 0.36 mmol, 1 eq) was dissolved in tetrahydrofuran (10 mL), and cyclopentylmagnesium bromide (2.2 mL, 2.16 mmol, 6.0 eq, 1M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed 5 completely using TLC and LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford compound AB35454. 10        MS-ESI: Calculated [M+H]+: 540.27, Found: 540.40. 1H NMR (400 MHz, DMSO-d6): 8 7.27-7.23 (m, 2H), 7.20 (s, 1H), 6.92-6.89 (m, 3H), 6.79 (d, J= 8.0 Hz, 1H), 6.72 (s, 1H), 6.65 (d, J= 8.0 Hz, 1H), 5.96 (s, 2H), 5.88 (s, 1H), 4.51 (d, J= 8.0 Hz, 1H), 4.11-4.02 (m, 3H), 3.81-3.79 (m, 1H), 3.71 (s, 3H), 3.35-3.28 (m, 2H), 2.89-2.79 (m, 1H), 2.612.56 (m, 1H), 2.18-2.12 (m, 1H), 1.91-1.82 (m, 4H), 1.54-1.15 (m, 8H). 15 Example 41 Synthesis of compound AB35455 The structure of compound AB35455 was as follows: 20 The synthesis method of compound AB35455 was as follows: Step (1): Compound 1 (500 mg, 1.40 mmol, 1.0 eq) was dissolved in DMF (30 mL), and compound 2 25   (784 mg, 2.8 mmol, 2 eq) and potassium carbonate (386 mg, 2.8 mmol, 2 eq) were added. The mixture was reacted at 60C for 16h under N2, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with ethyl acetate twice, the phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography 30 (dichloromethane / methanol=50 / 1) to afford compound 3 (580 mg, yield: 68.9%) as a yellow solid. Step (2): 2026242260   02 Oct 2026 Compound 3 (580 mg, 0.96 mmol, 1 eq) was dissolved in tetrahydrofuran (20 mL), and cyclopentylmagnesium bromide (6 mL, 5.8 mmol, 6.0 eq, 1M) was slowly added dropwise at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to 5 be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.1% formic acid) to afford compound AB35455. 10      Compound AB35455: MS-ESI: Calculated [M+H]+: 591.34, Found: 591.45. 1H NMR (400 MHz, DMSO-d6) 5 7.20(s, 1H), 6.79-6.63 (m, 4H), 5.97 (s, 2H), 5.88 (s, 1H), 4.50 (d, J= 8.0 Hz, 1H), 4.04-4.00 (m, 1H), 3.71 (s, 4H), 3.35-3.33 (m, 2H), 2.90-2.85 (m, 3H), 2.662.61 (m, 1H), 2.19-2.12 (m, 1H), 1.65-1.57 (m, 3H), 1.38-1.15 (m, 22H). 15 Example 42 Synthesis of compound AB35456 The structure of compound AB35456 was as follows: Compound 1 (100 mg, 0.23 mmol, 1 eq) was dissolved in tetrahydrofuran (10 mL), and methylmagnesium bromide (0.4 mL, 1.15 mmol, 5.0 eq, 3M) was added at 0 C. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was quenched with saturated aqueous ammonium 25 chloride solution and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.1% formic acid) to afford compound AB35456. MS-ESI: Calculated [M+H]+: 413.14, Found: 413.90. 30        1H NMR (400 MHz, DMSO-d6) 5 7.23 (s, 1H), 6.80 (d, J= 8.0 Hz, 1H), 6.75 (s, 1H), 6.65 (d, J= 8.0 Hz, 1H), 5.98 (d, J= 4.0 Hz, 2H), 5.91 (s, 1H), 4.78-4.73 (m, 1H), 4.06-4.03 (m, 2H), 3.863.83 (m, 2H), 3.73 (s, 3H), 3.32-3.18 (m, 2H), 2.81-2.72 (m, 2H), 2.17-2.11 (m, 2H), 1.04 (d, J= 4.0 Hz, 3H). 35       Example 43 Synthesis of compound AB35457 2026242260   02 Oct 2026 The structure of compound AB35457 was as follows: The synthesis method of compound AB35457 was as follows: 5        Compound 1 (500 mg, 1.34 mmol, 1.0 eq) was dissolved in ethanol (5 mL) in a sealed tube, and compound 2 (815 mg, 6.72 mmol, 5 eq) was added. The mixture was reacted at 110 °C for 16 h under N2, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was spin dried. The crude product was purified by fast chromatography (dichloromethane: methanol=20:1) to afford compound 3 (150 mg, yield: 24.3 %). 10         Step (2): Compound 3 (150 mg, 0.32 mmol, 1.0 eq) was dissolved in tetrahydrofuran (10 mL), and cyclopentylmagnesium bromide (3 mL) was added at 0 °C. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using TLC and 15 LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.1% formic acid) to afford compound AB35457. Compound AB35457: 20       MS-ESI: Calculated [M+H]+: 495.26, Found: 495.40. 1H NMR (400 MHz, DMSO-d6) 5 7.29-7.19 (m, 6H), 6.72-6.67 (m, 2H), 6.49 (d, J= 8.0 Hz, 1H), 5.96 (s, 2H), 5.84 (s, 1H), 4.23 (d, J= 8.0 Hz, 1H), 3.71-3.68 (m, 4H), 3.34-3.24 (m, 4H), 2.872.77 (m, 3H), 2.62-2.59 (m, 1H), 2.12-2.06 (m, 1H), 1.44-1.33 (m, 4H), 1.15-0.96 (m, 4H). 25       Example 44 Synthesis of compound AB35458 The structure of compound AB35458 was as follows: The synthesis method of compound AB35458 was as follows: Step (1): 2026242260   02 Oct 2026 Compound 1 (500 mg, 1.4 mmol, 1.0 eq) was dissolved in DMF (10 mL), and compound 2 (1.7 g, 7 mmol, 5 eq) was added. The mixture was reacted at 75 °C for 16 h under N2, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was spin 5 dried. The crude product was purified by fast chromatography (dichloromethane / methanol=30 / 1) to afford compound 3 (500 mg, yield: 63.2 %). Step (2): Compound 3 (150 mg, 0.26 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), 10 and cyclopentylmagnesium bromide (1.3 mL, 1.3 mmol, 5.0 eq, 1M) was added at 0 C. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by 15 reversed phase preparation chromatography (acetonitrile / water+0.1% formic acid) to afford compound AB35458. Compound AB35458: MS-ESI: Calculated [M+H]+: 554.19, Found: 554.15. 1H NMR (400 MHz, DMSO-d6) 5 7.23 (s, 1H), 6.81 (d, J= 8.0 Hz, 1H), 6.76 (s, 1H), 6.66 (d, 20   J= 8.0 Hz, 1H), 5.99 (s, 2H), 5.91 (s, 1H), 4.52 (d, J= 8.0 Hz, 1H), 4.08-4.02 (m, 1H), 3.78-3.74 (m, 4H), 23.55-3.53 (m, 2H), 3.42-3.35 (m, 2H), 2.92-2.86 (m, 1H), 2.69-2.63 (m, 1H), 2.22-2.15 (m, 1H), 1.85-1.82 (m, 2H), 1.70-1.66 (m, 2H), 1.60-1.48 (m, 8H), 1.31-1.17 (m, 4H). Example 45 Synthesis of compound AB35459 25       The structure of compound AB35459 was as follows: The synthesis method of compound AB35459 was as follows: Step (1): 2026242260   02 Oct 2026 Compound 1 (1 g, 5.15 mmol, 1 eq) was dissolved in dichloromethane (10 mL), and compound 2 (2.0 g, 15.45 mmol, 3 eq) and a small amount of dimethylformamide (2 drops) were added at 0 °C. The mixture was reacted at room tempearture for 2 h, and the reaction was detected to be performed completely using TLC and LCMS. The organic phase was spin dried to afford compound 3 (1.0 g, yield: 90.9 %). Step (2): Compound 4 (434 mg, 1.11 mmol, 1 eq) was dissolved in dichloromethane, trimethylamine (560 mg, 5.55 mmol, 5 eq) was added, then compound 3 (708 mg, 3.33 mmol, 3 eq) was added at 10   0 ° C. The mixture was reacted at room temperature for 16 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.1% formic acid) to afford compound AB35459. 15       Compound AB35459: MS-ESI: Calculated [M+H]+: 568.30, Found: 568.30. 1H NMR (400 MHz, DMSO-d6) 5 7.22 (s, 1H), 6.89-6.80 (m, 2H), 6.74 (s, 1H),5.97 (s, 2H), 5.94 (s, 1H), 4.33 (d, J= 4.0 Hz, 1H), 3.68 (s, 3H), 3.30-3.26 (m, 2H), 2.88-2.80 (m, 1H), 2.68-2.60 (m, 1H), 2.30 (s, 2H), 2.19-2.11 (m, 1H), 1.70-1.60 (m, 16H), 1.45-1.35 (m, 3H), 1.27-1.20 (m, 4H). 20 Example 46 Synthesis of compound AB35465 The structure of compound AB35465 was as follows: AB35465 The synthesis method of compound AB35465 was as follows: 25         Step (1): Compound 1 (1.0 g, 1.66 mmol, 1.0 eq) was dissolved in dioxane (30 mL), and compound 2 (1.3 g, 6.64 mmol, 4.0 eq), triethylamine (671 mg, 6.64 mmol, 4.0 eq), palladium acetate (74 mg, 0.332 mmol, 0.2 eq), and 1,1 '- binaphthalene-2,2' - biphenylphosphine (207 mg, 0.332 mmol, 0.2 30 eq) were added. The mixture was reacted at 100^ for 16 h under N2, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and 2026242260   02 Oct 2026 then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol= 50 / 1) to afford compound 3 (1.0 g, yield: 92.6 %) as a yellow solid. Step (2): Compound 3 (300 mg, 0.46 mmol, 1 eq) was dissolved in a mixture of chloroform (8 ml) and aqueous ammonia(4 ml). The mixture was reacted at 30°C for overnight, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous 10 sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol= 100 / 1 to 50 / 1) to afford compound AB35465. Compound AB35465: MS-ESI: Calculated [M+H]+: 622.16, Found: 622.30. 1H NMR (400 MHz, CDCh) 5 7.12 (s, 1H), 6.97-6.87 (m, 2H), 6.60 (s, 1H), 6.04 (s, 1H), 5.9615   5.93 (m, 3H), 4.48 (s, 1H), 3.88-3.84 (s, 1H), 3.79 (s, 3H), 3.62-3.53 (m, 3H), 3.24-3.20 (m, 1H), 3.14-3.02 (m, 2H), 2.76-2.71 (m, 2H), 2.02-1.82 (m, 2H), 1.52-1.44 (m, 11H). Example 47 Synthesis of compound AB35466 The structure of compound AB35466 was as follows: 20 The synthesis method of compound AB35466 was as follows: Step (1): Compound 1 (500 mg, 1.40 mmol, 1 eq) was dissolved in N, N-dimethylformamide (10 mL), 25 and compound 2 (1.1 g, 5.6 mmol, 4 eq) was added. The mixture was reacted at 60C for 16 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography ( DCM / MeOH=50 / 1 to 20 / 1) to afford compound 3 (420 mg, yield: 30   57.4%) as a yellow solid. Step (2): 2026242260   02 Oct 2026 Compound 3 (200 mg, 0.38 mmol, 1.0 eq) was dissolved in a mixture of chloroform (8 ml) and aqueous ammonia (4 ml). The mixture was reacted at 30oC for overnight, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with 5 water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol= 100 / 1 to 50 / 1) to afford compound AB35466. Compound AB35466: MS-ESI: Calculated [M+H]+: 559.95, Found: 559.95. 10        1H NMR (400 MHz, DMSO-d 6) 8 7.31 (s, 1H), 7.08 (d, J= 8.0 Hz, 1H), 6.89 (d, J= 8.0 Hz, 1H), 6.77 (s, 1H), 6.32 (s, 1H), 5.99 (d, J= 4.0 Hz, 2H), 5.65 (s, 1H), 4.22-4.20 (m, 1H), 3.88-3.85 (m, 1H), 3.79-3.74 (m, 6H), 3.67-3.60 (m, 1H), 3.28-3.20 (m, 1H), 2.73-2.66 (m, 1H), 2.33-2.26 (m, 1H), 2.15-2.08 (m, 1H). 15 Example 48 Synthesis of compound AB35433 The structure of compound AB35433 was as follows: The synthesis method of compound AB35433 was as follows: Step (1): Cul,Pd(PPh3)4,TEA 60°C,16 h 20 Compound 1 (6.2 g, 28.29 mmol, 1.2 eq) and compound 2 (5.4 g, 23.58 mmol, 1.0 eq) were dissolved in tetrahydrofuran (100 mL), and copper iodide (135 mg, 0.71 mmol, 0.03 eq), bis (triphenylphosphine) palladium dichloride (492 mg, 0.70 mmol, 0.03 eq) and triethylamine (7.2 g, 70.74 mmol, 3 eq) were added. The mixture was reacted at 60 C for 16 h under N2, and the reaction 25 was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was washed with brine once, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (100-200 mesh silica gel, PE / EA=3 / 1) to afford compound 3 (6.5g, yield: 75.6%) as a yellow solid. 30         Step (2): 2026242260   02 Oct 2026 NH4OAc, AgNO3 tBuOH, RT Compound 3 (2.0 g, 5.46 mmol, 1.0 eq) was dissolved in tert-butanol (50 mL), and ammonium acetate (2.1 g, 27.32 mmol, 5.0 eq) and silver nitrate (1.85 g, 10.93 mmol, 0.2 eq) were added. The mixture was reacted at room temperature for 16 h, and the reaction was detected to be performed 5 completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was washed with brine once, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (100-200 mesh silica gel, PE / EA=3 / 1) to afford compound 4 (1.5 g, yield: 75.3%) as a yellow solid. 10         Step (3): 15 Compound 4 (1.5 g, 4.11 mmol, 1.0 eq) was dissolved in tetrahydrofuran (20 mL), and lithium triethylborohydride (16.4 mL, 16.44 mmol, 4 eq) was slowly added dropwise at -78 °C. The mixture was reacted at room temperature for 3 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with saturated sodium chloride aqueous solution and then extracted with ethyl acetate twice, the organic phase was washed with brine once, dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried to afford compound 5 (630 mg, yield: 47.1%) as a yellow solid. Step (4): 20 Compound 5 (100 mg, 0.29 mmol, 1.0 eq) was dissolved in THF (5 mL), and methanesulfonyl chloride (68 mg, 0.58 mmol, 2.0 eq) and triethylamine (117 mg, 1.16 mmol, 4.0 eq) were added at 0 C. The mixture was reacted at room temperature for 2 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was filtered, the solid was 25 purified by reversed phase preparation chromatography (acetonitrile / water+0.01% formic acid) to afford solid compound AB35433. Compound AB35433: MS-ESI: Calculated [M]+: 320.09, Found: 320.06. 1H NMR (400 MHz, DMSO-d 6) 5 9.48 (s, 1H), 8.72 (s, 1H), 7.73 (s, 1H), 7.69 (s, 1H), 7.50 (s, 30    1H), 7.08 (s, 1H), 6.40 (s, 2H), 6.15 (s, 2H), 4.74-4.41 (m, 2H), 3.18-3.14 (m, 2H). Example 49 Synthesis of compound AB35467 The structure of compound AB35467 was as follows: AB35467 The synthesis method of compound AB35467 was as follows: 2026242260   02 Oct 2026 5        Compound 1 (200 mg, 0.56 mmol, 1.0 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and cyclopentylmagnesium bromide (3.4 mL, 3.36 mmol, 6.0 eq, 1M) was added at 0 C. The mixture was reacted at room temperature for 0.5 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with dichloromethane twice, the organic phase was 10 dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.1% formic acid) to afford compound AB35467. Compound AB35467: MS-ESI: Calculated [M+H]+: 390.17, Found: 390.15. 15        1H NMR (400 MHz, DMSO-d 6) 6 7.17 (s, 1H), 6.75 (s, 1H), 6.58 (s, 1H), 6.52 (s, 1H), 5.97 (s, 2H), 5.88 (s, 2H), 5.79 (s, 1H), 4.15 (d, J= 8.0 Hz, 1H), 3.42-3.37 (m, 1H), 2.87-2.82 (m, 1H), 2.652.60 (m, 1H), 2.21-2.15 (m, 1H), 1.60-1.56 (m, 1H), 1.45-1.10 (m, 8H). Example 50 Synthesis of compound AB35468 20       The structure of compound AB35468 was as follows: AB35468 The synthesis method of compound AB35468 was as follows: 25        Compound 1 (200 mg, 0.39 mmol, 1.0 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.6 mL, 1.95 mmol, 5.0 eq, 3M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.1% 5 formic acid, 30%-40% acetonitrile, reverse phase column Green ODS, 21.2 * 250 mm, 10 um, 120 A) to afford compound AB35468. MS-ESI: Calculated [M+H]+: 484.24; Found [M+H]+: 484.25. 1H NMR (400 MHz, DMSO-d6): 5 7.27-7.23 (m, 2H), 7.18-7.12 (m, 3H), 6.85-6.82 (m, 4H), 6.01 (d, J= 4.0Hz, 2H), 4.65-4.60 (m, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 3.18-3.08 (m, 2H), 2.74-2.59 10   (m, 6H), 1.72-1.63 (m, 3H), 1.45-1.40 (m, 1H), 0.93 (d, J= 4.0Hz, 3H). 2026242260   02 Oct 2026 Example 51 Synthesis of compound AB35469 The structure of compound AB35469 was as follows: 15       The synthesis method of compound AB35469 was as follows: Step (1): Compound 1 (10 g, 66.57 mmol, 1 eq) was dissolved in dichloromethane (200 mL), and DessMartin Periodinane (3.4 g, 79.88 mmol, 1.2 eq) was added in batches at 0 °C. The mixture was 20 reacted at room temperature for 2 h, and the reaction was detected to be performed completely using TLC. The reaction mixture was filtered, the filtrate was concentrated. The crude product was purified by fast chromatography (PE / EA= 100 / 1) to afford compound 2 (7.8g, yield: 79.6%) as a yellow liquid. Step (2): 25 Compound 3 (2 g, 5.9 mmol, 1 eq) was dissolved in ethanol / acetic acid (30 mL / 5 mL), and compound 2 (7.8 g, 52.6 mmol, 9 eq) was added. The mixture was reacted at 90oC for 4 h, an appropriate amount of hydrochloric acid was added, and the mixture was concentrated. To crude product was added a small amount of dichloromethane and an appropriate amount of ethyl acetate, 30 the mixture was stewed for 0.5 h and then filtered to remove solid. The filtrate was stewed for overnight to precipitate a solid, the solid was filtered and collected to afford compound 4 (1.2 g, yield: 40.4%) as a yellow solid. 2026242260   02 Oct 2026 Step (3): Compound 4 (200 mg, 0.39 mmol, 1 eq) was dissolved in chloroform (8 mL), and aqueous ammonia (4 mL) was added. The mixture was reacted at 30oC for 48 h under N2. The reaction 5 mixture was diluted with water and then extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH=100 / 1 to 50 / 1) to afford compound AB35469. Compound AB35469: MS-ESI: Calculated [M+H]+: 586.13; Found [M+H]+: 586.10. 10        1H NMR (400 MHz, CDCI3) 5 7.30-7.26 (m, 2H), 7.21-7.17 (m, 3H), 7.07-7.00 (m, 2H), 6.86 (s, 1H), 6.67 (s, 1H), 5.97 (s, 2H), 5.58 (s, 1H), 4.09-4.02 (m, 1H), 3.93 (s, 3H), 3.89 (s, 3H), 3.463.42 (m, 1H), 2.80-2.53 (m, 6H), 1.83-1.75 (m, 3H), 1.54-1.47 (m, 1H). 15 Example 52 Synthesis of compound AB35475 The structure of compound AB35475 was as follows: The synthesis method of compound AB35475 was as follows: Step (1): 20 25 Compound 1 (1.0 g, 2.79 mmol, 1 eq) was dissolved in N, N-dimethylformamide (20 mL), and compound 2 (1.7 g, 11.16 mmol, 4 eq) was added. The mixture was reacted at 75C for 16 h, and the reaction was detected to be performed completely using TLC and LCMS. The solvent was spin dried, and water was added, the mixture was extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM / MeOH=50 / 1 to 20 / 1) to afford compound 3 (400 mg, yield: 25.6%). Step (2): Compound 3 (200 mg, 0.42 mmol, 1 eq) was dissolved in a mixture of chloroform (8 ml) and aqueous ammonia (4 ml). The mixture was reacted at room temperature for overnight, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over 5 anhydrous sodium sulfate, filtered and spin dried. The crude product was purified fast chromatography (dichloromethane / methanol= 100 / 1 to 50 / 1) to afford compound AB35475. Compound AB35475: MS-ESI: Calculated [M+H]+: 558.07, Found: 558.05. 1H NMR (400 MHz, DMSO-d6) 5 7.29 (s, 1H), 7.05 (d, J= 8.0 Hz, 1H), 6.85 (d, J= 8.0 Hz, 10    1H), 6.77 (s, 1H), 6.29 (s, 1H), 5.98 (d, J= 4.0 Hz, 2H), 5.55 (s, 1H), 4.12-4.08 (m, 1H), 3.81-3.78 (m, 1H), 3.77 (s, 3H), 3.74-3.71 (m, 1H), 3.63-3.60 (m, 3H), 3.25-3.19 (m, 1H), 2.72-2.66 (m, 1H), 1.73-1.64 (m, 4H), 1.47-1.41 (m, 4H). 2026242260   02 Oct 2026 15 Example 53 Synthesis of compound AB35476 The structure of compound AB35476 was as follows: The synthesis method of compound AB35476 was as follows: Step (1): 20        Compound 1 (2.0g, 5.59mmol, 1eq) was dissolved in acetonitrile (40mL), and compound 2 (5.1g, 22.36mmol, 4eq) was added. The mixture was reacted at 80C for 16 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast 25 chromatography (DCM / MeOH=50 / 1 to 20 / 1) to afford compound 3 (1.48 g, yield: 48.2 %) as a yellow solid. Step (2): Compound 3 (1.3 g, 2.36 mmol, 1.0 eq) was dissolved in a mixture of chloroform (40 ml) and 30 aqueous ammonia (20 ml). The mixture was reacted at 30C for overnight, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with — 135 — 2026242260   02 Oct 2026 water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified fast chromatography (dichloromethane / methanol= 100 / 1 to 50 / 1) to afford compound AB35476. Compound AB35476: 5        MS-ESI: Calculated [M+H]+: 588.11, Found: 588.10. 1H NMR (400 MHz, DMSO-d6) 5 7.30 (s, 1H), 7.27-7.23 (m, 2H), 7.07 (d, J= 12.0 Hz, 1H), 6.91-6.85 (m, 4H), 6.76 (s, 1H), 6.29 (s, 1H), 5.98 (d, J= 8.0 Hz, 2H), 5.58 (s, 1H), 4.21-4.16 (m, 1H), 4.04-4.01 (m, 2H), 3.91-3.86 (m, 1H), 3.77 (s, 3H), 3.69-3.65 (m, 1H), 3.59-3.53 (m, 1H), 3.223.14 (m, 1H), 2.66-2.62 (m, 1H), 1.90-1.82 (m, 2H), 1.21-1.10 (m, 1H), 0.83-0.71 (m, 1H). 10 Example 54 Synthesis of compound AB35478 The structure of compound AB35478 was as follows: AB35478 The synthesis method of compound AB35478 was as follows: 15         Step (1): Compound 1 (1.5 g, 4.19 mmol, 1 eq) was dissolved in N, N-dimethylformamide (30 mL), and compound 2 (3.1 g, 16.76 mmol, 4 eq) was added. The mixture was reacted at 70 °C for 16 h, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture 20 was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified by fast chromatography (DCM:MeOH=50:1) to afford compound 3 (560 mg, yield: 26.2%) as a yellow solid. Step (2): 25 Compound 3 (160 mg, 0.31 mmol, 1.0 eq) was dissolved in a mixture of chloroform (8 ml) and aqueous ammonia (4 ml). The mixture was reacted at 30C for overnight, and the reaction was detected to be performed completely using TLC and LCMS. The reaction mixture was diluted with water and then extracted with dichloromethane twice, the organic phase was dried over anhydrous 30 sodium sulfate and filtered, the filtrate was spin dried. The crude product was purified fast chromatography (dichloromethane / methanol= 100 / 1 to 50 / 1) to afford compound AB35478. MS-ESI and 1H NMR of compound AB35478 were as follows: 2026242260   02 Oct 2026 10 MS-ESI: Calculated [M+H]+: 500.05, Found: 500.25. 1H NMR (400 MHz, CDCI3) 6 7.15 (s, 1H), 6.97-6.87 (m, 2H), 6.60 (s, 1H), 6.09 (s, 1H), 5.94 (d, J= 4.0 Hz, 2H), 5.61 (s, 1H), 4.98-4.80 (m, 1H), 4.78-4.62 (m, 1H), 4.37-4.33 (m, 1H), 3.96-3.82 (m, 5H), 3.71-3.64 (m, 1H), 3.35-3.28 (m, 1H), 2.74-2.68 (m, 1H), 2.24-2.10 (m, 2H). Example 55 Compound SJ0002 was prepared by conventional method, the structure of compound SJ0002 was as follows: Example 56 Compound SJ0003 was prepared by conventional method, the structure of compound SJ0003 was as follows: 15 I compound SJ0003 Example 57 Compound SJ0005 was prepared by conventional method, the structure of compound SJ0005 was as follows: 20 I compound SJ0005 Example 58 Compound SJ0006 was prepared by conventional method, the structure of compound SJ0006 was as follows: 25 I compound SJ0006 Example 59 Compound SJ0007 was prepared by conventional method, the structure of compound SJ0007 was as follows: 2026242260   02 Oct 2026 compound SJ0007 Example 60 Compound SJ0008 was prepared by conventional method, the structure of compound SJ0008 was as follows: I compound SJ0008 10 Example 61 Compound SJ0010 was prepared by conventional method, the structure of compound SJ0010 was as follows: I compound SJ0010 15 Example 62 Compound SJ0011 was prepared by conventional method, the structure of compound SJ0011 was as follows: 20 Example 63 Compound SJ0013 was as follows: compound SJ0011 was prepared by conventional method, the structure of compound SJ0013 compound SJ0013 2026242260   02 Oct 2026 10 15 Example 64 Compound SJ0014 was prepared by conventional method, the structure of compound SJ0014 was as follows: I compound SJ0014 Example 65 Compound SJ0015 was prepared by conventional method, the structure of compound SJ0015 was as follows: compound SJ0015 Example 66 Compound SJ0017 was prepared by conventional method, the structure of compound SJ0017 was as follows: I compound SJ0017 20 Example 67 Compound SJ0018 was prepared by conventional method, the structure of compound SJ0018 was as follows: I 25 compound SJ0018 Example 68 Compound SJ0019 was prepared by conventional method, the structure of compound SJ0019 was as follows: 2026242260   02 Oct 2026 I compound SJ0019 Example 69 Compound SJ0020 was prepared by conventional method, the structure of compound SJ0020 was as follows: I compound SJ0020 10 Example 70 Compound SJ0021 was prepared by conventional method, the structure of compound SJ0021 was as follows: I compound SJ0021 15 Example 71 Compound SJ0022 was prepared by conventional method, the structure of compound SJ0022 was as follows: 20 compound SJ0022 Example 72 Compound SJ0023 was prepared by conventional method, the structure of compound SJ0023 was as follows: I compound SJ0023 Example 73 2026242260   02 Oct 2026 Compound SJ0025 was prepared by conventional method, the structure of compound SJ0025 was as follows: I compound SJ0025 Example 74 Compound SJ0026 was prepared by conventional method, the structure of compound SJ0026 was as follows: 10 I compound SJ0026 Example 75 Compound SJ0027 was prepared by conventional method, the structure of compound SJ0027 was as follows: I compound SJ0027 15 Example 76 Compound SJ0029 was prepared by conventional method, the structure of compound SJ0029 was as follows: I compound SJ0029 20 Example 77 Compound SJ0030 was prepared by conventional method, the structure of compound SJ0030 was as follows: 2026242260   02 Oct 2026 compound SJ0030 Example 78 Compound SJ0031 was prepared by conventional method, the structure of compound SJ0031 was as follows: I compound SJ0031 Example 79 Compound SJ0032 was prepared by conventional method, the structure of compound SJ0032 was as follows: I compound SJ0032 10 Example 80 Compound SJ0033 was prepared by conventional method, the structure of compound SJ0033 was as follows: 15 I compound SJ0033 Example 81 Compound SJ0034 was prepared by conventional method, the structure of compound SJ0034 was as follows: 20 I compound SJ0034 Example 82 Compound SJ0035 was prepared by conventional method, the structure of compound SJ0035 was as follows: 2026242260   02 Oct 2026 10 15 I compound SJ0035 Example 83 Synthesis of compound AB35484 The structure of compound AB35484 was as follows: compound AB35484 The synthesis method of compound AB35484 was as follows: Step (1): Compound 1 (7.1 g, 16.5 mmol, 1 eq) was dissolved in methanol (50 mL), and potassium carbonate (6.8 g, 49.5 mmol, 3.0 eq) and sodium borohydride (499 mg, 13.2 mmol, 0.8 eq) were added at 0 °C. The mixture was reacted at 0 °C for 1 h. and the reaction was detected to be performed completely using LCMS. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and filtered, the solid was filtered and washed with a small amount of water and methanol to obtain compound 2. Step (2): Compound 2 (1.0 g, 2.84 mmol, 1 eq) was dissolved in ethanol / acetic acid (10 mL / 8 mL), and 20 phenylpropionaldehyde (3.8 g, 28.4 mmol, 10 eq) was added. The mixture was reacted at 90oC for 4 h, an appropriate amount of hydrochloric acid was added, the mixture was concentrated and spin dried, a small amount of dichloromethane and an appropriate amount of ethyl acetate were added, the mixture was stewed for 0.5 h and then filtered to remove impurity solid. The filtrate was stewed for overnight and filtered to afford compound 4. 25         Step (3): 2026242260   02 Oct 2026 Compound 4 (200 mg, 0.39 mmol, 1 eq) was dissolved in a mixture of aqueous ammonia (5 mL) and chloroform (10mL). The mixture was reacted at room temperature for overnight, and the reaction was detected to be performed completely using LCMS. The reaction mixture was diluted 5 with water and then extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate, filtered, and spin dried. The crude product was purified by fast chromatography (dichloromethane / methanol=100 / 1 to 50 / 1) to afford compound AB35484. The MS-ESI and 1H NMR spectra of compound AB35484 were as follows: MS-ESI: Calculated [M+H]+: 586.13, Found: 586.10. 10   1H NMR (400 MHz, DMSO-d6) 6 7.29-7.25 (m, 2H), 7.21-7.17 (m, 3H), 7.06 (d, J= 8.0 Hz, 1H), 6.88 (d, J= 8.0 Hz, 1H), 6.75 (s, 2H), 5.53 (s, 1H), 4.28-4.21 (m, 4H), 3.84-3.79 (m, 7H), 3.56-3.54 (m, 1H), 2.68-2.51 (m, 6H), 1.90-1.70 (m, 2H). 15 Example 84 Synthesis of compound AB35485 The structure of compound AB35485 was as follows: AB35485 The synthesis method of compound AB35485 was as follows: 20        Compound 1 (200 mg, 0.39 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (10 mL), and methylmagnesium bromide (0.7 mL, 1.95 mmol, 5 eq, 3M) was added at 0 °C under N2. The mixture was reacted at room temperature for 0.5 h. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and then extracted with ethyl acetate twice, the organic phase was dried over anhydrous sodium sulfate and filtered, the filtrate was spin dried. The 25 crude product was purified by reversed phase preparation chromatography (acetonitrile / water+0.1% formic acid) to afford compound AB35485. The MS-ESI and 1H NMR spectra of compound AB35485 were as follows: MS-ESI: Calculated [M+H]+: 398.17; Found[M+H]+: 398.15. 1H NMR (400 MHz, DMSO-d6) 6 7.21 (s, 1H), 6.79 (d, J= 8.0 Hz, 1H), 6.74 (s, 1H), 6.65 (d, 30   J= 8.0 Hz, 1H),5.97 (d, J= 4.0 Hz, 2H), 5.90 (s, 1H), 4.73-4.68 (m, 2H), 4.59-4.56 (m, 1H), 4.03 4.00 (m, 2H), 3.72 (s, 3H), 3.24-3.16 (m, 2H), 2.76-2.71 (m, 2H), 2.11-2.01 (m, 2H), 1.02 (d, J= 8.0 Hz, 3H). 2026242260   02 Oct 2026 Example 85 Synthesis of compound AB35486 The structure of compound AB35486 was as follows: The synthesis method was as follows: Step (1): 10 Compound 1 (3.0 g, 5.38 mmol, 1 eq) was dissolved in ethanol (50 mL), and phenylethylamine (652 mg, 53.8 mmol, 10 eq) was added. The mixture was reacted at 110 °C for 48 h under N2, the reaction was completed. The reaction mixture was concentrated, the crude product was purified by fast chromatography (DCM / MeOH=100 / 1 to 50 / 1) to afford compound 3. 15 Step (2): Compound 3 (1.5g, 3.25 mmol, 1 eq) was dissolved in chloroform (20 ml), and aqueous ammonia (10 ml) was added. The mixture was reacted at room temperature for overnight under N2, and the reaction was detected to be performed completely using LCMS. The reaction mixture was 20 diluted with water and then extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate, filtered and spin dried. The crude product was purified by fast chromatography (DCM / MeOH=100 / 1 to 50 / 1) to afford compound AB35486. The MS-ESI and 1H NMR spectra of compound AB35486 were as follows: MS-ESI: Calculated [M+H]+: 543.09, Found: 543.10. 25       1H NMR (400 MHz, DMSO-d6) 5 7.30-7.25 (m, 3H), 7.21-7.17 (m, 3H), 6.92 (d, J= 8.0 Hz, 1H), 6.74 (s, 1H), 6.67 (d, J= 12.0 Hz, 1H), 6.24 (s, 1H), 5.97 (d, J= 8.0 Hz, 2H), 5.68 (s, 1H), 4.384.35 (m, 1H), 3.74 (s, 3H), 3.70-3.44 (m, 2H), 3.28-3.24 (m, 2H), 2.77-2.65 (m, 4H). Example 86 Synthesis of compound AB35487 30       The structure of compound AB35487 was as follows: 2026242260   02 Oct 2026 AB35487 The synthesis method of compound AB35487 was as follows: Step (1): Compound 1 (2.0 g, 5.59 mmol, 1 eq) was dissolved in N, N-dimethylformamide (30 mL), and compound 2 (4.6 g, 27.95 mmol, 5 eq) was added. The mixture was reacted a...

Claims

1. A compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof;Rll R12 R13 n5                                                              Iwherein,R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C16 alkyl, substituted or unsubstituted C3-C16 cycloalkyl, substituted or unsubstituted 3-12 membered heterocycloalkyl, substituted or unsubstituted C1-C16 haloalkyl, substituted or 10 unsubstituted C3-C16 halocycloalkyl, substituted or unsubstituted C6-C16 aryl, substituted or unsubstituted 5-12 membered heteroaryl;R3, R4 and R5 are each independently hydrogen, halogen, R17-O-, R17-S-, (R18R19) N-; or R3 and R4, or R4 and R5 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkane ring;15       R6, R8, R11, R12, R13, R14 and R15 are each independently hydrogen, substituted or unsubstitutedC1-C8 alkyl, halogen;R7 is hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C1-C12 haloalkyl, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted 5-16 membered heteroaryl-substituted or unsubstituted C1-C12 alkyl-;20       R9 and R10 are connected to form a substituted or unsubstituted 3-12 memberedheterocycloalkane ring;I DR17 is hydrogen, substituted or unsubstituted C1-C16 alkyl, D , substituted or unsubstitutedC3-C16 cycloalkyl, substituted or unsubstituted 3-12 membered heterocycloalkyl, substituted or unsubstituted C3-C16 cycloalkyl-substituted or unsubstituted C2-C10 acyl-, substituted or 25 unsubstituted C3-C16 cycloalkyl-C(O)-, substituted or unsubstituted C1-C16 haloalkyl, substituted or unsubstituted C3-C16 halocycloalkyl, substituted or unsubstituted 3-12 membered heterocycloalkyl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-, substituted or 30 unsubstituted 5-16 membered heteroaryl-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted C6-C16 aryl-O-substituted  or  unsubstituted  C1-C12  alkyl-,  substituted  orunsubstituted C6-C16 aryl-S-substituted or unsubstituted C1-C12 alkyl-, substituted or unsubstituted 5-16 membered heteroaryl-O-substituted  or  unsubstituted  C1-C12  alkyl-,  substituted  orunsubstituted 5-16 membered heteroaryl-S-substituted or unsubstituted C1-C12 alkyl-, substituted 35 or unsubstituted C2-C8 alkenyl-substituted or unsubstituted C1-C8 alkyl-substituted or-250-2026242260   02 Oct 202610152025unsubstituted C2-C8 alkenyl-substituted or unsubstituted C1-C8 alkyl-, substituted or unsubstituted C2-C8 alkenyl-substituted or unsubstituted C1-C8 alkyl-, (R20R21) N-substituted or unsubstituted C1-C12 alkyl-;R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C6-C16 aryl-substituted or unsubstituted C1-C12 alkyl-; or R18 and R19 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkane ring;R20 and R21 are each independently hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C3-C12 cycloalkyl, substituted or unsubstituted C2-C10 ester group; or R20 and R21 are connected to form a substituted or unsubstituted 3-12 membered heterocycloalkyl;each "substituted" means that one or more (preferably 1, 2, 3, 4, 5, 6, 7, or 8) hydrogen atoms on the ring or group are independently substituted by substituent selected from the group consisting of C1-C10 alkyl, C2-C6 alkenyl, C3-C12 cycloalkyl, C1-C10 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, carbonyl (=O), hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C8 ester group, C2-C4 amide group, C2-C6 acyl, C1-C10 alkoxyl, C1-C10 alkylthio, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl, (R20R21) N-.

2. The compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of claim 1, wherein R1 and R2 are each independently hydrogen, deuterium, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C1-C6 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted C6-C8 aryl, substituted or unsubstituted 5-8 membered heteroaryl;R3, R4 and R5 are each independently hydrogen, halogen (e.g, Cl, Br), R17-O-, R17-S-, (R18R19)I ^41N-; or R3 and R4, or R4 and R5 are connected to form                   ;30R6, R8, R11, R12, R13, R14 and R15 are each independently hydrogen, substituted or unsubstituted C1-C6 alkyl, halogen (e.g, Br);R7 is hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted 5-8 membered heteroaryl-substituted or unsubstituted C1-C4alkyl-,            R23           ,          K;35R9 and R10 are connected to form a substituted or unsubstituted 3-8 membered heterocycloalkane ring;IdR17 is hydrogen, substituted or unsubstituted C1-C8 alkyl, D , substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl, substituted or unsubstituted C3-C12 cycloalkyl-substituted or unsubstituted C2-C4 acyl-, substituted or unsubstituted C3-C12 cycloalkyl-C(O)-, substituted or unsubstituted C1-C8 haloalkyl, substituted or unsubstituted C3-C8 halocycloalkyl, substituted or unsubstituted 3-10 membered heterocycloalkyl-substituted or unsubstituted C1-C6 alkyl-, substituted or unsubstituted C6-C102026242260   02 Oct 202610aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C6-C10 aryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C6-C10 aryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-10 membered heteroaryl-O-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted 5-12 membered heteroaryl-S-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-, substituted or unsubstituted C2-C4 alkenyl-substituted or unsubstituted C1-C4 alkyl-, (R20R21) N-substituted or unsubstituted C1-C8 alkyl-;R18 and R19 are each independently hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C8 aryl-substitutedor unsubstituted C1-C4 alkyl-; or R18 and R19 are connected to form1520253059      , substituted or unsubstituted azacycloheptane ring, (R2oR2i)N-piperidinering; and / orR20 and R21 are each independently hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C2-C8 ester group; or R20 and R21 are connected to form a substituted or unsubstituted 3-8 membered heterocycloalkyl;wherein, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently hydrogen, C1-C8 alkyl, C3-C12 cycloalkyl, C1-C8 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C6 ester group, C2-C4 amide group, C1-C8 alkoxyl, C1-C8 alkylthio, C1-C8 haloalkoxyl, C1-C8 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkyl;R41 is hydrogen, substituted or unsubstituted C1-C8 alkyl;R42, R43, R44, R45, R46, R47, R48, R49, R50 and R51 are each independently hydrogen, C1-C10 alkyl, C1-C10 haloalkyl, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, halogen;R52, R53, R54, R55, R56, R57, R58, R59 and R60 are each independently hydrogen, C1-C10 alkyl, C1-C10 haloalkyl, C1-C10 haloalkoxyl, C1-C10 haloalkylthio, halogen;W1 and W2 are each independently O or S;Z1 and Z2 are each independently substituted or unsubstituted C1-C8 alkylidene.

3. The compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of claim 1, wherein R1 and R2 are each independently hydrogen, deuterium, trichloromethyl, methyl, cyclobutyl, cyclopentyl, butyl, hexyl, phenyl;R3, R4 and R5 are each independently hydrogen, halogen (e.g, Cl, Br), R17-O-, R17-S-, (R18R19)2026242260   02 Oct 2026N-; or R3 and R4, or R4 and R5 are connected to formmethyl-,,;r31R9 and R10 are connected to form a substituted or unsubstitutedR32r33Wiw2R4|R6, R8, R11, R12, R13, R14 and R15 are each independently hydroge, halogen (e.g, Br);R7 is hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, halohexyl, pyridinyl-R30, substituted orunsubstituted     35R1015202530I DR17 is hydrogen, methyl, D , ethyl, propyl, pentyl, hexyl, phenyl-O-butyl-, haloethyl, halopropyl, halobutyl, halohexyl, phenyl-ethyl-, phenyl-propyl-, phenyl-butyl-, cyclodecyl-acetyl-, butenyl-ethyl-propenyl-methyl-, (R20R21)N-hexyl-, (R20R21)N-butyl-, (R20R21)N-ethyl-, piperidinyl-ethyl-, butyl-piperazinyl-, methyl-piperidinyl-, phenyl-phenyl-methyl-, ethylenyl-methyl-, piperidinyl-propyl-, piperidinyl-ethyl-, dimethylamino-ethyl-;R18 and R19 are each independently hydrogen, phenyl-ethyl-; or R18 and R19 are connected to form a methyl-piperazine ring, butyl-piperazine ring, trifluoromethyl-piperazine ring, trifluoromethoxyl-piperazine ring, halopiperazine ring, methyl-piperidine ring, trifluoromethylpiperidine ring, trifluoromethoxyl-piperidine ring, halopiperidine ring, azacycloheptane ring, (R20R21)N-piperidine ring; and / orR20 and R21 are each independently hydrogen, amyl ester group; or R20 and R21 are connected to form piperidine ring;Wherein, R22, R23, R24, R25, R26, R27, R28, R29 and R30 are each independently hydrogen, trifluoromethoxyl, propyl;R31, R32, R33, R34 and R35 are each independently hydrogen, C1-C8 alkyl, C3-C12 cycloalkyl, C1-C8 haloalkyl, C3-C8 halocycloalkyl, C3-C8 cycloalkoxyl, C3-C8 cycloalkylthio, C3-C8 halocycloalkoxyl, C3-C8 halocycloalkylthio, halogen, nitro, -CN, hydroxyl, sulfhydryl, amino, C1-C4 carboxyl, C2-C4 ester group, C2-C4 amide group, C1-C8 alkoxyl, C1-C8 alkylthio, C1-C8 haloalkoxyl, C1-C8 haloalkylthio, C6-C12 aryl, C6-C12 aryl-O-, 5-10 membered heteroaryl, 5-10 membered heteroaryl-O-, 5-10 membered heterocycloalkylR41 is hydrogen, substituted or unsubstituted C1-C4 alkyl;W1 and W2 are each independently O or S;W3, W4, W5 and W6 are each independently O or S;Z1 and Z2 are each independently methylidene, ethylidene, propylidene, butylidene, pentylidene, hexylidene.

4. The compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of claim 1, wherein the pharmaceutically acceptable salt of the compound of formula I comprises the salt formed-253-2026242260   02 Oct 2026by the compound of formula I and one or more of hydrochloric acid, mucic acid, D-glucuronic acid, hydrobromic acid, hydrofluoric acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, 5 methanesulfonic acid, benzenemethanesulfonic acid, benzenesulfonic acid, aspartic acid andglutamic acid.

5. The compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of claim 1, wherein the compound is selected from the following group:2026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 2026O O                      O'ZxO                         O^O                       o^o O                Q       JU       Jk / r~L                fU             / / ~X— /               tU              )=< / / \ /                             \ — / \.                         ( / (                               ) ( 2                          -O o o o \    /   ■-                               '  \    / \                         >=<                                   —° o                                     ( / \ '                          °\ 9                        —o o o o                              (                                  / —o o    _{          5( 1         1°          t°         > U           U            k            / V to                                                                               ' O^O                         _?                     °\_?                        °J^                       o^o O       O        O       j3 1               fr       r^P       (P / / \ /                             \— /                           \ / \                               / —\ Q                         — o o O>             < / \)—(                            / \ / —\                     >= / \                         -o o £                            ( o       \ / \             oo(\          _ / \_                  /                \ k           k                         7           r\ °<            o^°            M°              $             p ( ZI ZT ( \ $                     __$                         $                           o o—               □ °\ 9 /                         o o o o—                       o o—                          \__ /                    O y^l. °m°’         / v        kw r\-^         ^- / ^                         V- /           r\ / /         \}         O          \ /         W / \                               1 k                               ' '                                   / \                                 z° 0^ / 0                       °x / °                       °\x°                         O O \                               ) O-           K            8 O      12026242260   02 Oct 2026 / \                ozo                                                     0^0 O O                               \__ /                     ----*          O O                           \= /                              \___I 0 / / =(2)        ^Oz           \)\                - / =<) ~d \ b                                 -° / ° o         yy O O (                        (  )                      ( /  \-- /                       /                  \    /  \ \ / \ \__ / \ \= / \ /                                   -o o P               (             °\ / ° \ '                                     /                                  f                                   o                                      / o^o                         ,=.    o^o            °y?             ° / \° I                / =\    /                                           '    --\     / --\                    / =\   /              DO         /   \ I          )= / /                                             / / —A Z—               / \ a                / / \ / o o (                                        ( / \__ /             -o p £              \   /  ( / ^( \ ) \ / \ /                          /                         /                                                       o o <           5 9,°-          Q                         'MTy n o o-           q--^M             e                               r\ / C>= /                   O O    0     0         w 0^0                 °x / °                   0^0 /                         Q                        /                                               / \   / \                 )                 7? o o—                                    \ > °w°       S          M                  L .2026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 2026OX-'X\          0 XX < XX'n .       < XX (J    Li (J ^3^¼   vOX- fT         TV O^X>X^ O.,^                                 /   ||  ^|    | IIYxxcci3           (Y\^ 0^ JO     II III 0 VCC\ rY CCQ n n^j         IY XX      XX । O^XX^      F  O^^XX < I T '        P < 1 Y । Y^Ox^n           o-J-k XX      XJ 1 -264 ,N .CCI3           IJXlL^N 13cci3 XX°\   x^^X'-X^ TT   (J    IT 1             I-Jplx^ccis XI,--0-^ ^Cl               y       o -^- .cc|3          / °Y^TT V^VNyCCI3 T I T ''^o^ o^yy^^, X^°XF ^oXX^N^ 1            lr                                       JT 1 ?     X ^°^F XX^N X - / C1 r n Xl    r) -^-^       ( N XX '0                     ^'X 1                                                                                                                                                                                                                          1 -2026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 202627077616_1 (GHMatters) P124432.AU.12026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 202627077616_1 (GHMatters) P124432.AU.12026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 202627077616_1 (GHMatters) P124432.AU.12026242260   02 Oct 20262026242260   02 Oct 202627077616_1 (GHMatters) P124432.AU.12026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 20262026242260   02 Oct 20266. A pharmaceutical composition, wherein the pharmaceutical composition comprises (a) the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of claim 1; and (b) a pharmaceutically acceptable carrier.5        7. Use of the compound of formula I, or an optical isomer thereof, or a racemate thereof, or asolvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of claim 1 in the preparation of a composition or a preparation for preventing and / or treating tumor;wherein, the tumor comprises tumor with low or no expression of NNMT gene; and / orthe tumor comprises tumor with high expression of DNA methylase; and / or10        the tumor comprises tumor with high expression of UHRFl; and / orthe tumor comprises tumor with high methylation level of nucleotide site of NNMT gene; and / orthe tumor comprises tumor with high methylation level of DNA CpG site of NNMT gene.

8. The use of claim 7, wherein the NNMT gene is human NNMT gene;15        the expression comprises protein expression and / or mRNA expression; and / orthe DNA methylase is selected from the group consisting of DNMT1, DNMT3a, DNMT3b, and combinations thereof.

9. The use of claim 7, wherein the low or no expression of NNMT gene means the ratio (E1 / E0) of the expression E1 of NNMT gene in the tumor cell to the expression E0 of NNMT gene in the20 same type of cell is <1.0;2026242260   02 Oct 2026the tumor with high expression of DNA methylase means the ratio (A1 / A0) of the expression level A1 of DNA methylase in the tumor cell to the expression level A0 of DNA methylase in the same type of cell is > 1.0;the tumor with high expression of UHRF1 means the ratio (F1 / F0) of the expression level F1 5 of UHRF1 in the tumor cell to the expression level F0 of UHRF1 in the same type of cell is > 1.0;the high methylation level of nucleotide site of NNMT gene means the ratio (L1 / L0) of the methylation level L1 of nucleotide site of NNMT gene in the tumor cell to the methylation level L0 of nucleotide site of NNMT gene in the same type of cell is > 1.0; and / orthe high methylation level of DNA CpG site of NNMT gene means the ratio (W1 / W0) of the 10 methylation level W1 of DNA CpG site of NNMT gene in the tumor cell to the methylation level W0 of DNA CpG site of NNMT gene in the same type of cell is > 1.0.

10. The use of claim 9, wherein the same type of cell refers to the same type of tumor cell with normal or high expression of NNMT gene;the same type of cell refers to the same type of tumor cell with normal or low expression of 15 DNA methylase;the same type of cell refers to the same type of tumor cell with normal or low expression of UHRF1;the same type of cell refers to the same type of tumor cell with normal or low methylation level of nucleotide site of NNMT gene; and / or20        the same type of cell refers to the same type of tumor cell with normal or low methylation levelof DNA CpG site of NNMT gene.

11. The use of claim 7, wherein the methylation level of nucleotide site of NNMT gene refers to the ratio of the number of methylated nucleotides to the number of all nucleotides in the NNMT gene;25        the high methylation level of nucleotide site of NNMT gene means the methylation level ofnucleotide site of NNMT gene in the tumor cell is > 1%;the high methylation level of nucleotide site of NNMT gene means the methylation level (M%) of nucleotide site of NNMT gene in the tumor cell is > 3% and < M1%, wherein Ml is any positive integer from 3 to 100;30        the methylation level of nucleotide site of NNMT gene comprises the methylation level ofnucleotide site in promoter region of NNMT gene;the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide sites from 1050 bp before the transcription start site to 499 bp after the transcription start site in NNMT gene;35        the methylation level of nucleotide site of NNMT gene comprises the methylation level ofnucleotide sites from 1050 bp to 193 bp before the transcription start site in NNMT gene;the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide sites from 840 bp to 469 bp before the transcription start site in NNMT gene;the methylation level of nucleotide site of NNMT gene comprises the methylation level of 40 nucleotide site between any two sites selected from group consisting of site 114165695, site 114165730, site 114165769, site 114165804, site 114165938, site 114166050 and site 114166066 on human chromosome 11;the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide sites selected from group consisting of site 114165695 on human chromosome 11, site 45   114165730 on human chromosome 11, site 114165769 on human chromosome 11, site 114165804on human chromosome 11, site 114165938 on human chromosome 11, site 114166050 on human chromosome 11, site 114166066 on human chromosome 11, and combinations thereof;the methylation level of nucleotide site of NNMT gene comprises the methylation level of nucleotide site between any two sites selected from group consisting of site 1161, site 1196, site 50   1235, site 1270, site 1404, site 1516 and site 1532 in nucleotide sequence of SEQ ID NO: 1;the methylation level of nucleotide site of NNMT gene comprises the methylation level of2026242260   02 Oct 2026nucleotide site of one or more of site 1161, site 1196, site 1235, site 1270, site 1404, site 1516 and site 1532 in nucleotide sequence of SEQ ID NO: 1;the methylation level of DNA CpG site of NNMT gene refers to the ratio of the number of methylated CpG nucleotides to the number of all nucleotides in the NNMT gene;5        the methylation level of DNA CpG site of NNMT gene refers to the ratio of the number ofmethylated DNA CpG nucleotides to the number of all CpG nucleotides in the NNMT gene;the high methylation level of DNA CpG site of NNMT gene means the methylation level of DNA CpG site of NNMT gene in the tumor cell is > 1%;the high methylation level of DNA CpG site of NNMT gene means the methylation level (M%) 10 of DNA CpG site of NNMT gene in the tumor cell is > 3% and < M2%, wherein M2 is any positive integer from 3 to 100;the methylation level of DNA CpG site of NNMT gene comprises the methylation level of DNA CpG site in promoter region of NNMT gene;the methylation level of DNA CpG site of NNMT gene comprises the methylation level of 15 DNA CpG sites from 1050 bp before the transcription start site to 499 bp after the transcription start site in NNMT gene;the methylation level of DNA CpG site of NNMT gene comprises the methylation level of the DNA CpG sites from 1050 bp to 193 bp before the transcription start site in NNMT gene;the methylation level of DNA CpG site of NNMT gene comprises the methylation level of 20 DNA CpG sites from 840 bp to 469 bp before the transcription start site in NNMT gene;the methylation level of DNA CpG site of NNMT gene comprises the methylation level of DNA CpG site between any two sites selected from group consisting of site 114165695, site 114165730, site 114165769, site 114165804, site 114165938, site 114166050 and site 114166066 on human chromosome 11;25        the methylation level of DNA CpG site of NNMT gene comprises the methylation level of sitesselected from group consisting of site 114165695 on human chromosome 11, site 114165730 on human chromosome 11, site 114165769 on human chromosome 11, site 114165804 on human chromosome 11, site 114165938 on human chromosome 11, site 114166050 on human chromosome 11, site 114166066 on human chromosome 11, and combinations thereof;30       the methylation level of DNA CpG site of NNMT gene comprises the methylation level ofDNA CpG site between any two sites selected from group consisting of site 1161, site 1196, site 1235, site 1270, site 1404, site 1516 and site 1532 in nucleotide sequence of SEQ ID NO: 1; and / or the methylation level of DNA CpG site of NNMT gene comprises the methylation level of sites selected from group consisting of site 1161 in SEQ ID NO: 1, site 1196 in SEQ ID NO: 1, site 123535 in SEQ ID NO: 1, site 1270 in SEQ ID NO: 1, site 1404 in SEQ ID NO: 1, site 1516 in SEQ ID NO: 1, site 1532 in SEQ ID NO: 1, and combinations thereof.

12. The use of claim 11, wherein M1 is 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95 or 100;M2 is 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95 or 100;40       the nucleotide sequence of the promoter region of NNMT gene is as shown in SEQ ID NO: 1;the sites from 1050 bp before the transcription start site to 499 bp after the transcription start site in NNMT gene is sites 951-2500 of nucleotide sequence as shown in SEQ ID NO: 1;the sites from 1050 bp to 193 bp before the transcription start site in NNMT gene is sites 9511808 of nucleotide sequence as shown in SEQ ID NO: 1; and / or45        the sites from 840 bp to 469 bp before the transcription start site in NNMT gene is sites 11611532 of nucleotide sequence as shown in SEQ ID NO: 1.

13. The use of claim 7, wherein the tumor is human tumor; and / orthe tumor is selected from the group consisting of lung cancer, renal carcinoma, breast cancer, colon cancer, lymphoma, leukemia, pancreatic cancer, brain tumor, liver cancer, prostate cancer, and 50 combinations thereof.

14. The use of claim 13, wherein the lung cancer is selected from the group consisting of non-2026242260   02 Oct 2026small cell lung cancer, small cell lung cancer, and combinations thereof;the colon cancer comprises colon adenocarcinoma;the breast cancer comprises triple negative breast cancer;the lymphoma is selected from the group consisting of B-cell lymphoma, skin T-cell lymphoma, 5 and combinations thereof;the brain tumor is selected from the group consisting of brain glioblastoma, neuroglioma, brain medulloblastoma, brain neuroblastoma, and combination thereof;the renal carcinoma is selected from the group consisting of clear cell renal cell adenocarcinoma, renal carcinoma Wilms, and combination thereof;10        the pancreatic cancer comprises pancreatic ductal carcinoma; and / orthe leukemia is selected from the group consisting of T-lymphocyte leukemia, myeloid leukemia, and combinations thereof.

15. The use of claim 14, wherein the lymphoma comprises diffuse large B-cell lymphoma;the brain medulloblastoma comprises cerebellar medulloblastoma;15        the brain glioblastoma comprises glioblastoma multiforme;the T-lymphocytic leukemia comprises acute T-lymphocytic leukemia;the myeloid leukemia comprises type M4 of acute myeloid leukemia; and / orthe myeloid leukemia comprises FAB type M4 of acute myeloid leukemia.

16. A method for preventing and / or treating tumor, which comprises administering the20 compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of claim 1 to a subject in need.

17. The method of claim 16, wherein the tumor is the tumor of any one of claims 7 to 15.

18. A pharmaceutical composition, wherein the pharmaceutical composition comprises:25        (1) a first active ingredient, the first active ingredient comprises anti-tumor drug, the anti-tumordrug is the compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof of claim 1; and(2) a second active ingredient, the second active ingredient comprises NNMT gene inhibitor, 30 DNA methylase promoter, UHRF1 promoter, methylation promoter of nucleotide site of NNMT gene, and / or methylation promoter of DNA CpG site of NNMT gene.

Images